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ABSTRACT 
 Despite the fact that over the past two decades the total death rate has declined up 
to twenty percent, cancer remains the second leading cause of death in the United States 
and accounts for nearly one in every four deaths.  It is therefore of paramount importance 
that new strategies continue to develop in an effort to curb both incidence and treatment 
of disease.  The current research landscape is focused on developing strategies to disrupt 
molecular signatures of cancer cell types, commonly known as targeted therapy.  Of 
particular importance in the advancement of targeted therapies are matrix 
metalloproteinases (MMPs), a family of endopeptidases whose primary function lies in 
cleaving extracellular matrix (ECM) proteins and are frequently dysregulated in cancer.   
While research regarding MMPs is decades old, their significance in the signal 
transduction of several oncogenic pathways is yet to be fully explored.  In addition, a 
dearth of quantitative data exists describing the action of MMPs in three dimensional 
(3D) networks, a configuration that causes cells to express vastly different behaviors 
compared to traditional two-dimensional (2D) in vitro culture methods.  
 This dissertation aims to further elucidate the intimate relationships between 
MMPs, the ECM, cancer pathway signaling, and cell migration.  First, the behavioral 
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crosstalk between MMPs and the ECM is studied using quantitative methods in 3D 
matrices.  Next, the role of MMPs in both Ras oncogenic and HER2 positive breast 
cancer is probed via extensive protein expression analysis.  Finally, the behavioral 
aspects of MMPs in 3D are assessed marrying both in vitro data with a computational 
model to predict migration response.  The results reveal that MMPs exhibit a 
bidirectional relationship with respect to matrix architecture, and the ability to regulate 
and be regulated by the ECM.  In addition, it is concluded that MMPs play a significant 
role in both active Ras and HER2 upregulated cancer signaling.  Finally, the data 
demonstrates the robustness and accuracy of our methods in manufacturing a model to 
predict migration in 3D matrices.  The work described here promises to further enhance 
the knowledge of MMPs in cancer and potentially inform future drug development 
endeavors.  
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1 
CHAPTER ONE: CANCER 
Despite the fact that over the past two decades the total death rate has declined up 
to twenty percent, cancer remains the second leading cause of death in the United States 
and accounts for nearly one in every four deaths [1]. While the overall drop in cancer 
related deaths is a promising trend, these statistics are heavily influenced by the 
decreased incidences of the lung and bronchus, commonly attributed to societal lifestyle 
changes regarding the use of cigarettes and other tobacco related products. Factoring in 
this information, one realizes that improvements in mortality are much more modest, and 
for some forms of cancer remain unperturbed [1].  These data provide the motivation for 
sustained efforts toward detection and eradication of the disease.  In order to meet these 
demands treatment options must mimic the characteristics of cancer itself: adaptive and 
robust.  This can only be accomplished through a multi-scale comprehension of the 
system, from the molecular underpinnings, to macroscopic crosstalk with the surrounding 
tissues. 
 
1.1 Properties and Development 
 
1.1.1 Incidence of Cancer 
Cancer is the byproduct of changes in the cell or surrounding cells that leads to 
dysregulation of tightly controlled processes such as proliferation, cell growth, apoptosis, 
angiogenesis and many others. The result is unmitigated neoplastic growth, leading to 
disruptions and in the case of death ultimate failure of tissues and organs that harbor the 
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disease [2].  While the physical causes of cancer are enumerative and highly debated, on 
the cellular level, cancer is thought to be the result of genetic mutations as well as 
epigenetic changes to gene expression that either activate specific oncogenes or silence 
what are known as tumor suppressor genes [3]. Further genetic alterations and the 
presentation of multiple cytogenetically different clones lead to the malignant phenotypes 
and properties endowed to cancer cells [3]. The prevailing belief is that the production of 
clonal subtypes confers selective advantage to growth compared to surrounding somatic 
tissues.  Although cells have various mechanisms by which to protect DNA integrity, 
cancer cells develop methods to either bypass these processes or increase their sensitivity 
to mutagenic agents [4,5].  Cancer cells often harbor defects to genes involved in 
detecting and repairing DNA, such as DNA repair protein RAD51 homolog 1 (RAD51), 
cellular tumor antigen p53 (TP53) and breast cancer type 2 susceptibility protein 
(BRCA2), as well as destroying potential harmful DNA damaging agents [4,6,7]. It is 
possible then that the primary step toward the evolution of cancer is random genetic 
mutations that render inactive these DNA control systems, allowing for more widespread 
changes to genomic DNA.  Another possible impetus toward the increased genetic 
instability displayed by cancer is the loss of telomeres as cells age. Telomere shortening, 
discussed in more detail later, can lead to alterations in chromosomal segments [8]. The 
inevitable loss of telomeres could therefore lead to the initial mutations that enable other 
mutagenic cascades and selective cycles leading to stable malignant clones. As DNA 
sequencing technology improves how cancer cells evolve, which genes they 
preferentially target will become clearer. 
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Cancer incidence can also be influenced by inflammation resulting from innate 
immune responses.  In fact, immune cells can be found at the cities of almost all 
neoplastic tissues including lymphocytes, macrophages and mast cells [9]. Although the 
immune system is thought to have anti-tumorigenic properties, it may also exacerbate an 
already compromised neoplastic region by enhancing inflammation. Chronic 
inflammation may lead to the release of cytogenic factors that signal cancer growth, 
angiogenesis, and an invasive phenotype through activation of vascular endothelial 
growth factor (VEGF) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) among other pathways [10,11]. Inflammatory cells such as macrophages have 
been shown to foster tumor initiation and spurn release of reactive oxygen species 
resulting in damage to cell structure and enhancement of mutagenesis [10,12,13]. This 
potential for cancer progression presented by immune response as well as the previously 
mentioned mutations initiated by genomic instabilities provide the impetus for tumor 
formation. Although cancer remains a genetically and phenotypically diverse disease, 
several characteristics are shared amongst most forms.  The emergence of common 
properties shared by many cancer cells has served as basis for devising strategies to 
counteract disease progression. 
 
1.1.2 Proliferative Induction  
 Cancer’s most basic underlying feature is the capacity for unrestricted 
proliferation.  This capability for indefinite self-renewal is wrought through many 
different means.  Primarily, this is achieved by activating growth signals.  In certain cases 
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the cells themselves may produce stimulatory growth factors, or in others they may 
stimulate surrounding cells to do so. In the absence of increased local ligand 
concentration, cells may also increase their sensitivity to certain ligands by increasing 
receptor density on the cell surface or amplifying intracellular signaling responses to 
certain effectors [14–16].  DNA sequence analysis of cancer cells has revealed that 
somatic mutations can lead to changes in important regulators of kinase mediated 
proliferation pathways such as phosphoinositide 3-kinase (PI3K), resulting in 
downstream hyperactivity [17]. The constituent activation of Ras through oncogenic RAS 
mutations can also lead to constant proliferative signaling by disrupting feedback 
mechanisms imparted by Ras GTPases [18]. Other examples of the disruption of negative 
feedback regulators by cancer include phosphatase and tensin homolog (PTEN) 
phosphatase and mammalian target of rapamycin (mTOR) kinase. Loss of PTEN function 
results in the amplification of the previously mentioned PI3K pathway. Similarly, mTOR 
serves as a catch against the protein kinase B (Akt/PKB) pathway and when inhibited 
results in rampant cancer growth [19]. 
 Aside from the upregulation of positive signals toward increased growth, cancer 
cells also adapt their metabolic pathways to enhance proliferation.  Generally, in the 
presence of oxygen, cells undergo aerobic metabolism leading to the mitochondrial 
transport chain and the production of ATP. However, cancer cells have adopted a 
alternative metabolic scheme termed “aerobic glycolysis”, where energy production is 
mostly provided through the glycolytic pathway, the main choice in anaerobic settings 
[20,21]. While this phenomenon has been widely observed, whether it confers a definable 
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survival advantage, or is merely a vestigial byproduct of other genetic changes remains to 
be determined. The preference for aerobic glycolysis is present in cells also harboring 
activated oncogenes such as RAS and MYC [22,23]. As tumors continue to grow they 
develop necrotic deoxygenated cores which lead to the upregulation of glucose 
transporters and transcription factors hypoxia-inducible factor alpha (HIF1α and HIF2α) 
to enhance glycolysis [24,25]. These instances suggest that glycolytic metabolism is 
merely a symptom of rampant proliferation. However, cancer cells have also been shown 
to upregulate glucose transporters such as facilitated glucose transporter member 1 
(GLUT1) to compensate for the less efficient energy production from glycolysis, 
suggesting that tumorigenic cells are not unresponsive to changes in metabolism [26]. 
Glycolysis may provide benefit to rapidly dividing cells through utilization of glycolytic 
intermediates for the synthesis of organelles and cellular material [27]. Some tissues have 
also displayed interplay between cancer cells and local stromal and endothelial cells in 
which the cancerous aerobic glycolytic cells produce lactate to feed surrounding recruited 
cells.  These cells then provide extracellular factors and extracellular matrix (ECM) 
remodeling properties back to the cancer cells, influencing tumor growth [28,29]. 
Metabolic changes to cancer in conjunction with persistent proliferative signaling 
represent powerful pathways to enact tumor growth.  However, overall tumor progression 
must also avoid active suppression of proliferation in the form of feedback mechanisms. 
 
1.1.3 Evasion of compensatory mechanisms 
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 Although the stimulation of positive growth signals is a powerful agent in 
maintaining a highly proliferative state, cancer cells also actively avoid suppression of 
growth as well. Somatic tissues are equipped with mechanisms that serve to halt cell 
growth often called tumor suppressor genes.  Negative regulation of several tumor 
suppressor genes such as those encoding the retinoblastoma-associated (RB) and TP53 
proteins can lead to a loss of senescent signals [30,31].  These proteins generally act as 
gate keepers of the cell-cycle and halt growth in response to damage to the genome, 
reduction in oxygen availability and many other stressors.  The fact that RB null cells and 
TP53 null mice develop normally suggests that the anti-tumorigenic properties availed by 
these genes are part of a larger set of redundant pathways, complicating the 
understanding of senescent avoidance by cancer [32,33]. Another mechanism by which 
cancer cells can circumvent growth suppression is by avoiding senescent signals 
mediated by contact inhibition, the halting of cell growth upon formation of cell-cell 
contacts. Finally cancer cells have displayed an innate insensitivity to anti-proliferative 
effects mediated by transforming growth factor beta (TGF-β) [34,35]. 
 Unbridled proliferation and avoidance of growth suppression do not equate to 
overall growth, unless the rate of replication surpasses that of death.  While certain 
tumors that lie dormant are postulated to succumb to this truth, with total growth equaling 
that of cell death, cancer that does maintain net growth has established methods to resist 
cell death actuated by either the host, or from exogenous therapies. Tumor cells acquire 
various alterations in order to avoid apoptotic signals. First and foremost is the loss of 
TP53 tumor suppression, normally activated upon DNA damage frequently incurred upon 
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rapid proliferation. Cancer cells may also increase expression of anti-apoptotic regulators 
such as apoptosis regulator Bcl-2 (Bcl-2), a protein that inhibits pro-apoptitic signaling 
proteins Bcl-2-associated X protein (BAX) and Bcl-2 homologous antagonist killer 
(BAK) [36,37].  An additional mechanism by which tumor cells avoid apoptosis is by 
increasing the level of autophagy, and important cell-response to stress and nutrient 
deficiency.  This process allows cancer cells to break down cellular organelles for energy, 
a useful trait for cells with infinitely growing nutrient demands [38].  Unsettlingly, 
treatments such as cytotoxic drugs and radiotherapy can actually enhance autophagy and 
induce protective properties to tumors. In fact, imparting necrosis on cells through 
chemotherapy may also spawn detrimental side effects by antagonizing inflammatory 
responses that can be tumor promoting [10,39].  
 In addition to tight control of proliferative signals, growth suppressors, cellular 
senescence and apoptotic signals, somatic cells are also physically imbued with an 
inability to replicate indefinitely.  The shortening of telomeres, DNA ends that buffer 
chromosomal DNA from karyotype scrambling induced by uneven end-to-end fusions 
during replication, acts as a natural barrier to immortality for cells. Cells that do manage 
to avoid senescent signals will eventually experience a crisis phase from DNA damage 
and experience massive death. Cancer cells utilize Telomerase, the specialized DNA 
polymerase that extends telomere sections at the ends of replicated DNA, to avoid this 
fate.  Normally expressed in very low quantities in somatic cells, telomerase enables 
cancer cells to undergo indefinite cellular divisions without risk for DNA damage 
[40,41]. Interestingly, the very shortening of telomeres that cancer cells are often immune 
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to can lead to widespread genetic mutations that can enhance incipient neoplastic cells.  It 
may be that cancer cells initially do undergo telomere shortening before experiencing a 
plethora of genetic changes, including the production of clones capable of halting the 
very telomere shortening that granted them this ability [8,42,43]. 
 One additional method cancer cells utilize to avoid compensatory mechanisms for 
controlling growth is through evasion of the immune system. For decades it was thought 
that a processes termed immuoserveillance acted as a barrier to rampant cancer growth. 
Lymphocytes and other component of the immune system are enacted in response to 
immunogenic cancer cells to eradicate them [44]. Not only have results such as this been 
demonstrated in the clinic but have now spawned the entire field of cancer immunology 
en route to the development of vaccines, antibodies and various other treatment options 
[45–47].  Cancer presents an inherent susceptibility toward innate immune systems 
through the increased rate of cancers observed in immunocompromised individuals.  
Although a significant portion of these incidences are the result of virally induced 
neoplasms [48], mouse models confer that the immune system possesses an innate 
capacity for depressing the development of cancer. Deficiencies in production of both 
natural killer cells and T lymphocytes led to a higher rate of cancer than mice with fully 
functional immune systems [44,49]. The role of T lymphoctyes and natural killer cells in 
the elimination of cancer also happens to be key step in the process of immunoediting. 
This process describes the initial recognition of malignant cells by the immune system, 
massive cell death via natural killer cells, T lymophcytes, and macrophages and the 
ensuing birth of a stable but resistant population of cancer cells that are minimally 
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immunogenic. This model highlights the importance of the immune system for keeping 
cancer cells in check and postulates that many cancers may be the result of a highly 
selective Darwinian process for those cells able to avoid immunogenically derived 
apoptotic signals [50]. Finally, cancer cells may also circumvent immune response by 
producing well known immunosuppressive compounds such as TGF-β [51].  
The ability for cancer cells to continuously proliferate, bypass growth inhibition, 
avoid apoptosis, and induce replicative immortality aids in the formation of what is 
known as a primary tumor.  This is the initial neoplastic tissue, the original spawn of the 
disease.  However, in order to continue to develop and colonize the body, tumor cells also 
hi-jack other processes that enable them to control their surroundings and eventually 
migrate to distant sites. 
  
1.1.4 Angiogenic Control 
 The sprouting of new vasculature, angiogenesis, is a process utilized in wound 
healing and development to provide nutrients to growing tissues.  As tumors increase in 
size, they turn on these pathways to form neovasculature in what is described as an 
“angiogenic switch” [52].  These new vessels help support expanding neoplasms.  The 
switch toward angiogenic neovasculature is maintained via the interplay between 
vascular endothelial growth factors (VEGF) and its inhibitory counterpart 
thrombospondin (TSP). During tumorigenesis, VEGF induced vascularigenesis is 
activated through oncogenic signals, hypoxic conditions, and sequestration in the 
extracellular matrix (ECM) and its consistent activation outweighs the inhibitory signals 
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provided by TSP [53,54].  The imbalance of these factors results in a disorganized, leaky, 
and convoluted vasculature prone to hemorrhaging and endothelial cell apoptosis.  
Nevertheless, this disjointed set of microvasculature is produced relatively early in the 
life of tumors and aids in the initial growth of cells [52,55]. Tumors do however; exhibit 
a stratum of angiogenic activity and sprouting.  The degree of neovasculature that is 
produced is the result of a complex process between VEGF, oncogenes such as RAS and 
MYC, and inhibitors in concert with stromal cells and the ECM [56,57].  In response to 
this, angiogenic inhibitors have been developed to help reduce the increased angiogenic 
signals and represent a wide class of anti-tumorigenic drugs.  In mouse models, 
upregulation of endogenous inhibitors of angiogenesis may lead to reductions in tumor 
size [58].  Other potential targets are cell types that aid in neovascularigenesis such as 
pericytes and bone marrow derived stem cells.  Both cell types have been implicated to 
engage in aiding the activation of the angiogenic switch in quiescent tissue and protect 
against drugs targeting endothelial cells that act to sustain angiogenesis in tumors 
[12,59,60]. 
 
1.2 Microenvironmental Effectors 
 
1.2.1 Cell types 
 While distinct mutagenic and phenotypic differences have been observed between 
cancerous and normal cells, almost equally important to the growth of tumors and their 
ability to metastasize to foreign tissues are the cells that make up the local 
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microenvironment.  It has been increasingly proposed that cancer may initiate in response 
to defects of the organization and processes carried out by the microenvironment [61,62].  
One such cell type that contributes to the role of the microenvironemt in cancer 
progression is the cancer stem cell (CSC).  These cells differ from typical malignant 
cancer cells through their stem cell like expression of proteins.  They are also able to 
induce tumor growth at an extremely efficient rate [63,64].  Normally, a large mass of 
cells is required to successfully induce tumor growth upon mural transplantation.  
However, it is hypothesized that these CSCs are the impetus beyond this action.  Isolation 
of these cells from larger tumor masses confirms that they are able to induce tumor 
development at an extremely efficient rate.  Therefore, in a large tumor mass it is thought 
that only these few CSCs are actually able to adapt to a new host, and form ectopic 
malignancies.  This has led many to believe that CSCs are also responsible for the 
successful “hibernation” periods certain tumors exhibit before reconvening a malignant 
phenotype upon the introduction of new external cues, or as the result of genetic 
mutations or tumor cell differentiation [65–67]. The stem like properties of CSCs may 
also offer an alternative explanation to the genetic variability within tumor masses.  
Instead of increased random mutations followed by Darwinian selection, it is possible 
that clonal differences are derived from a range of partially or fully differentiated cells 
emanating from a CSC source.  While the origins, actions, and prevalence of CSCs in 
developing tumors are a matter of debate, these cells still represent a distinct population 
in the microenvironment that influence tumor fate that merits further study. 
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 Along with CSCs other cells located in the tumor stroma contribute to the 
microenvironmental development of cancer. Endothelial cells are key promoters of the 
“angiogenic switch” and contribute to vessel formation through activation of VEGF and 
fibroblast growth factor (FGF) pathways [68].  Pericytes are also constituents of the 
microenvironment that aid in angiogenesis.  These cells curl around vessels to provide 
paracrine signals to the endothelial layers.  Inhibition of platelet derived growth factor 
(PDGF) is able to disrupt tumor vasculature integrity via reduction of pericyte association 
highlighting their importance in angiogenic growth [59,69]. Tumor angiogenesis is also 
mediated through the presence of inflammatory cells of the immune system such as 
macrophages, neutrophils and T lymphocytes.  Through release of pro-angiogenic factors 
such as VEGF and epidermal growth factor (EGF) along with matrix metalloproteinases 
(MMPs) such as MMP-9 these cells paradoxically do more harm rather than eliminate 
cancerous growths [12,70]. Indeed, inflammation has long been a commonly observed 
theme among tumor tissues [10]. These cells offer not only markers to evaluating the 
stage of cancer, but also serve as targets for future therapy. 
 Final contributors to the microenvironment of cancer are carcinoma associated 
fibroblasts (CAFs).  These cells secrete soluble growth factors such as VEGF, FGF, 
PDGF to promote angiogenesis [71].  They are also active in the suppression of immune 
response toward cancer.  In addition to their growth promoting activities CAFs also 
protect cancer cells. Through production of TGF-β, CAFs are able to inhibit natural killer 
cells, a component of the immune system that has been more commonly linked to the 
destruction of cancer rather than its promotion through inflammatory responses [72]. 
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CAFs also aid in the survival of tumor cells by performing aerobic metabolism, 
producing lactate to feed cancer cells [73]. After preserving these tumor cells, CAFs can 
even help them escape and colonize other organs.  Like other fibroblast cells, CAFs 
extrude a wide variety of matrix components such as collagen and fibronectin to alter 
ECM properties influencing the infiltration and extravasation of migrating tumor cells 
[74,75]. 
 
1.2.2 Extracellular Matrix 
 
1.2.2.1 Structure and Function 
 Although the ECM may seem to function simply as a scaffold for cellular 
organization, this collection of various proteins serves a much more complex and 
integrated role in cell biology.  The composition of the ECM mainly consists of 
glycoproteins, proteoglycans, and polysaccharides along with other proteins such as 
collagen, laminin, fibronectin, and elastin.  The structure generally produces patterns in 
which endothelial or epithelial cells of the parenchyma are separated from stromal cells 
and the interstitial matrix by a basement membrane (BM).  The BM is a dense assortment 
of collagen, laminin and fibronectin as opposed to the highly charged and hydrated 
interstitial matrix which houses stromal cells, and glycoproteins to provide the 
viscoelastic nature of tissues [76–78]. 
 The ECM functions in a variety of ways to direct and maintain cell growth.  
Fibers provide adhesions to anchor cells and also serve as extracellular signaling cues 
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mediated by integrins [79].  Other physical properties offered by the ECM are migration 
and organizational barriers between tissues and connective interstitial matrices.  These 
same barriers can also serve as migration avenues in tissues with aligned fibers [80,81].  
Biochemically, the ECM also informs cells by providing soluble signaling factors 
emanating from degraded fibers and through the dissemination of biomechanical force 
via integrin-actin mechanosensors [82,83].  The formation of focal adhesion complexes 
represents a marriage between many of these ECM properties, in which the cell attaches 
to a matrix ligand, and transduces intracellular biochemical signals dependent on fiber 
stiffness and abundance [84,85]. In response, cells may extrude enzymes such as MMPs 
to further modulate the matrix and enhance or counteract the initial signal [86].  This 
example highlights how ECM characteristics are interdependent, highly dynamic and 
exhibit crosstalk with cells.  Unfortunately, ECM dysregulation has direct consequences 
to cancer development. 
 
1.2.2.2 Dysregulation and Cancer development and progression   
 Not only are changes in the ECM widely expressed among cancerous tissues, 
these alterations are also thought to be a driving force behind cancer inception and 
progression.  ECM integrity can be assailed through loss of proteolytic control and 
upregulation of enzymes such as MMPs and a disintegrin and metalloproteinases 
(ADAMs) [87,88].  Such enzymes are released via microenvironmental cell types such as 
CAFs [89].  The result manifests in cancerous tissues as reduced or accelerated ECM 
turnover of collagens, and indeed increased deposition of such fibers are present during 
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tumor formation [90].  Increased MMP activity is also prominent in ageing, and other 
ECM binding components processed by MMPs such as CD44 that facilitate tumor 
progression are overexpressed in cancer cells [91,92]. This topographical disruption leads 
to losses in cell polarity maintained by tissue architecture.  Indeed, certain ECM fibers 
are necessary for proper planar cell polarity during epithelial morphogenesis [93].  ECM 
remodeling can also lead to changes in cell signaling, and increased invasive potential. 
The restructuring of ligand availabilities and types such as collagen, fibronectin and 
laminin can lead to alterations in TGF-β and epigenetic expression mediated by integrin-
β1 receptors and mothers against decapentaplegic homolog 4 (SMAD4) transcription 
factors [94]. MMP upregulation can also disrupt the basement membrane barrier and 
invite cancer cells to extravasate via thickening and linearization of collagen fibers 
[95,96].    
Dysregulation of the ECM can also lead to structural changes that confer a 
different set of biomechanically derived signals in cancer cells.  Evidence of this potential 
is observed in cancerous breast tissues that commonly present a substantially stiffer 
stroma potentially mediated by highly linearized organization of collagen fibrils [97,98]. 
In such cases ECM stiffening is the product of excess crosslinking enacted by lysyl 
oxidase (LOX).  Increases in LOX expression have been observed in multiple cancer 
types, and its inhibition has been shown to reduce tumor incidence [97,99].  In contrast, 
induction of LOX expression in mouse models promotes tumor invasion. These changes 
in stiffness due to crosslinking also enhance tumor progression via increased integrin 
signaling, highlighting the interdependence of ECM properties [97].  
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The ECM structure and stiffness can also play a prominent role in stem cell 
biology, inducing anchorage to promote paracrine signaling between neighboring cells 
and alignment of mitotic spindles for cell division [100,101].  In fact, ECM stiffness has 
been shown to direct the fate of stem cell lineage and differentiation [102].  Disruption of 
the ECM and these properties therefore provide CSCs accommodating niches leading to 
their self-renewal and progeny into other tumor associated cells [103,104]. Structural 
changes that alter cellular behavior are not exclusive to stiffness alone.  Simple changes 
in the stretching of ECM fibers may alter signaling through the exposure of cryptic 
binding sites.  Extension of such proteins such as fibronectin and collagen reveal binding 
motifs for integrins and growth factor receptors [105,106].  Whether exposure of such 
cryptic sites can influence cancer progression is subject to more research, however, the 
potential for altered signaling remains contingent only upon changes in biomechanical 
ECM structure. Such results infer that simple crosslinking of fibers or changes in tissue 
stiffness due to increased proteolytic processing may be enough to spurn cancer 
development, and that ECM dysregulation should be viewed a driver of disease 
progression rather than an artifact.   
  As discussed earlier, angiogenesis is an important process that leads to tumor 
growth and assists in extravasation and colonization of metastatic sites.  In addition to 
signals produced via mutagenesis and through microenvironmental cell types such as 
immune inflammatory cells, the ECM can also confer the induction of angiogenesis.  
Certain ECM fragments such as endostatin, tumstatin, and canstatin derived from 
collagen types are potent stimulatory markers of angiogenesis [107].  Angiogenic 
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sprouting can also be enhanced by LOX like protein-2 which is produced by tumor cells 
in hypoxic conditions leading to ECM stiffening [108].  Besides angiogenic cues, the 
ECM also provides structural integrity and mechanical signals during vessel formation.  
Several ECM components are vital toward the formation of vessels including basement 
membrane fibers used to provide mechanical support to the vasculature.  The branching 
vascular patterns during angiogenesis are also dependent on matrix elasticity [109–111].     
 Finally, the ECM plays a role in inflammation, and directly influences immune 
responses that lead to cancer progression.  ECM glycoproteins such as SPARC (secreted 
acidic and rice in cysteine) help regulate macrophage populations in tissues, and loss of 
this protein leads to increases in immune cells [112].  Other fibers such as elastin function 
as chemoattractants to specific sites to recruit monocytes [113].  The function of the 
basement membrane barrier is also paramount in the control of immune cells.  
Presentation of binding sites for integrins aid in extravasation into the parenchyma, and 
physical attributes of the matrix such as collagen fibril size can determine migration 
efficiency of immune cells [114,115].  The contributions of the ECM in cell signaling, 
angiogenesis and control of immune response suggest that the matrix plays a direct and 
symbiotic role with microenvironmental cell populations and cancer cells themselves.  It 
stands to reason that improper control of such environmental cues such as tissue stiffness, 
ligand presentation or soluble chemoattractants provided by the matrix play significant 
roles in cancer development.  
 
1.3 Cancer Cell Metastasis 
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 Cancer survival rates and prognosis are markedly improved upon early detection 
of malignant growths.  This result is mainly due to treatments such as resection and 
chemotherapeutics that prevent any metastatic proliferation of the disease.  Metastatic 
propagation not only complicates treatment options, but actually accounts for over ninety 
percent of mortalities [116,117]. The process of metastasis comprises of many steps 
beginning with local invasion of stromal tissue, intravasation into the vasculature, 
survival in the circulatory system, extravasation at external sites, survival in a foreign 
microenvironment, and metastatic colonization and growth.  The ability to overcome 
these widely varied and demanding hurdles speaks to the frighteningly robust and 
adaptable nature of cancer cells.  Indeed, it would seem as if cancer has a mind of its 
own. 
 
1.3.1 Intravasation 
 Metastasis begins with the detachment of cells from epithelial tumorigenic 
growths located in the parenchyma of tissues.  This process can be undertaken by both 
single cells and groups of cells as part of a collective migration.  Tumor cells first disrupt 
the basement membrane barrier described earlier via protease secretion from stromal and 
cancer cells that degrade BM components and release soluble growth factors.  The 
weakening of the BM is not the only barrier to intrastromal inhabitation.  Epithelial 
tissues are tightly packed, organized and often stratified masses with strong intracellular 
connections mediated by E-cadherin.  However, in a process known as epithelial to 
mesenchymal transition (EMT), cancer cells are able to shed their cell-cell contacts via 
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downregulation of this protein and other adherens junctions, enabling them to escape 
epithelial tissue structures [118,119].  This transdifferention is a property utilized mainly 
in wound healing and development but can be induced in cancer cells through mutations, 
changes in epigentic expression, interaction with stromal cells to induce dysregulation of 
N-cadherin expression, transcriptional factors and microRNAs [120,121].  Completion of 
the EMT confers a much more migratory phenotype with potential to also extrude a 
different set of soluble growth factors and proteases [122,123]. Cells that undergo EMT 
are also likely to be imbued with stem-like properties and potentially forming the CSCs 
that are able to initiate tumorigenic growth with high efficiency [124].  Upon entering the 
stroma, cancer cells may be further modulated by microenvironmental cell types through 
heterotypic signaling.  Secretion of soluble factors interleukin 6 (IL-6) and epidermal 
growth factor receptor (EGFR) by apidocytes and tum-associated macrophages (TAMs) 
provide further stimuli for increased invasiveness [125,126].  After inhabiting the stroma, 
cancer cells migrate and ultimately intravasate into the vasculature.  Exposure to the 
circulatory system allows cancer cells to traverse the body and begin the process of 
external metastatic colonization.  This process is facilitated TGF-β and EGF secreted by 
TAMs and mechanical assistance mediated by VEGF [127,128].  Such growth factors can 
spark neoangiogenic growths that support intravasation via cyclooxygenase, and MMPs 
[129]. 
 
1.3.2 Extravasation 
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 Upon entering the circulatory system, cancer cells have an uphill battle consisting 
of survival within vessels, attaching to a distant site and extravasating into the tissue 
stroma.  Cells that have achieved venous dissemination are termed circulating tumor cells 
(CTCs) [130].  These cells must avoid cell death caused by the absence of adhesions 
called anoikis.  Although particular signaling pathways may be altered in cancer cells that 
allow them to avoid this fate, it is also likely that CTCs are quickly arrested in capillary 
beds before the commencement of apoptosis.  CTCs are also able to avoid immune 
detection and resist the shear forces in the circulation by covering themselves in platelets 
via selectins [131].  Where CTCs ultimately settle and why certain cancer types 
metastasize to specific organs is a matter of debate.  While evidence exists that the 
colonization of external sites is simply a function of circulatory pathways and size 
exclusion of tumor cells [117], specific sites may be preferential based on expression of 
adhesion receptors.  For example, lung carcinoma cells can promote inflammatory cells 
to alter the hepatic microvasculature and enhance metastasis to the liver [132].    
 Although specific tissue vasculatures may be more receptive to certain CTC 
populations, this does not aid in the extravasation process of crossing back through the 
vasculature into the stromal compartment of tissues.  At the initial arrival of CTCs, there 
exists no distended vascular network similar to the network established by tumors during 
the intravasation process.  This is supported by the fact that tumors found at metastatic 
sites frequently present different microenvironmental structures [12].  Therefore, the 
majority of attachment sites for CTCs are most likely largely impermeable.  To overcome 
this, cancer cells secrete a wide range of factors including MMPs and growth factors and 
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pleiotropic agents such as EREG COX-2 and angiopoietin-like-4 (Angptl4) to 
permeablize vascular epithelial layers [133].  The efficacy of these factors toward 
inducing extravasation has been shown to vary between organs, suggesting that CTCs 
may have a preferred or even predestined metastatic fate [134]. 
 
1.3.3 Metastatic Establishment 
 After exiting the circulatory system, tumor cells that are able to invade through 
stromal compartments of tissues to arrive at the parenchyma meet a new set of 
challenges.  The ECM and local microenvironment varies widely throughout the body, 
and newly arrived tumor cells must be able to survive and adapt to their new 
surroundings.  In certain cases, however, cancer cells may encounter favorable 
conditions.  This has been thought to occur through the creation of premetastatic niches, 
where primary tumors and their associated surrounding stromal cells can release specific 
enactors such as LOX to induce organ specific changes in ECM composition at distant 
sites [135].  These changes in the ECM, which are generally organ specific, can then 
enact a cascade of cellular events to alter local microenviroments.  At the sites of niche 
formation, changes in fibronectin content can attract hematopoietic progenitor cells from 
bone via interactions with β1 integrins.  These cells can then be recruited to secrete 
various MMPs to remodel the microenvironment, well before any metastasis of the 
primary tumor has taken place.  This represents a potentially powerful mechanism by 
which neoplastic growths can groom external sites for future metastases and challenges 
the linear stepwise paradigm of cancer progression.  Whether targeting this phenomenon 
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to treat cancer will produce clinically relevant options cannot be answered at this time.  
However, the propensity for cell survival in foreign microenvironemts can be altered 
simply by changing the destination of these progenitor cells [136] suggesting potential in 
such an approach. 
 Formation of metastatic niches and restructuring of the microenvironment is 
necessary for migrating tumor cells to survive at distant sites; however, a large majority 
of these colonized cells remain dormant or are unable to proliferate [137].  Cells that lie 
dormant in newly invaded tissue may experience a lack of stimulatory factors that were 
present at the site of the initial growth.  Such examples include breast cancer cells that are 
functionally quiescent in other tissue structures due to lack of focal adhesion kinase 
(FAK) and Src pathway stimulation [138].  Those cells that are capable of self-renewal 
may stagnate in their overall growth due to the inhospitable local environment or lack of 
a tumor vasculature to provide adequate nourishment.  While growth signals are present, 
the rate of cell death is prohibitive for continuous growth, leading to a plateau in tumor 
size [137].  Incompatibility between metastatic cancer cells and the local 
microenvironment seems to follow specific trends as addressed via the “seed and soil” 
hypothesis.  This hypothesis states that certain cancer types tend to migrate to specific 
distant organs due to inherent compatibilities between microenviroments [139].  Indeed, 
melanoma cells that have frequently been shown to form lung metastases have also 
displayed this behavior in vivo, forming metastatic growth preferentially in lung tissue 
over an equally vascularized renal site [140].  This preference for specific tissue types 
may emanate from the expression of certain genes potentially altered during incipient 
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carcinogenic mutagenesis.  For example, in breast cancer, the IL11 and CTGF genes 
promote angiogenesis and osteoclast recruitment to the sites of bone metastases to disrupt 
the normal ECM and release growth factors such as TGF-β [141].  Genetic changes that 
confer organ specific metastatic growth are thought to be shared with those that also 
promote EMT and the capacity for self-renewal such as transcription factors Snail, Twist, 
and ZEB1 [119].  Identification of such metastatic inducing genes holds potential in 
predicting metastatic sites to treat cancer more effectively. 
  With an appreciation to the high degree of complexity that involves the entire 
metastatic process it is not difficult to infer its inherent inefficiency.  Between local 
migration, intravasation, survival in the circulation, extravasation, survival in a new 
microenvironment and overcoming uninviting tissue structures to regain proliferative 
capacity, the large majority of tumor cells are unable to effectively metastasize.  Recent 
work has however, been able to identify the key bottleneck of this process to be the 
growth of tumors after invasion and survival at distant sites.  Extravasation and survival 
in the circulation is not uncommon, and in many patients CTCs are frequently observed 
without any indication of metastatic development.  It is estimated that less than 0.01% of 
these CTCs go on to develop metastases [130,137].  In the cases where CTCs are able to 
evolve into macroscopic metastases, this process can take years to decades.  A study 
involving more than 1000 breast cancer patients displaying micrometastases saw only 
50% develop clinically detectable metastases within a decade.  This prolonged dormancy 
eventually leading to malignant growth is supported by those patients who after resection 
of a primary tumor develop metastatic lesions years after the initial procedure [142,143].   
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 Amidst the understanding that cancer metastases generally hinge upon their 
ability to proliferate at new sites, few prevailing theories have emerged as to the path 
cancer cells take to complete this process. The Darwinian selection model simply states 
that tumor progression is the result of clonal selection arising from oncogenic mutation 
events.  This paradigm suggests that genetic changes occurring at the primary tumor are 
responsible for malignant metastases.  In the cases where metastases do not erupt 
immediately but rather take years to develop, further genetic mutations at the metastatic 
site may account for adaptations for growth in a new microenviorment.  Another 
possibility is that dormant micrometastases await microenviromental changes that finally 
allow for further growth [117,144,145].  In contrast to the Darwinian selection model, the 
model of parallel progression states that cancer may develop in parallel before any clonal 
selection at the primary site.  Instead, dissemination at the early stages of incipient 
neoplastic growth results in several potentially dormant micrometastases that evolve in 
parallel to develop malignant tumors [146].  The early dissemination described by this 
model helps account for the vast genetic differences observed between primary and 
metastatic tumors.  Further genetic testing for the validation of either model or the 
creation of future models to describe tumor metastasis promises to enhance therapies to 
attack this, the most deadly aspect of cancer progression. 
 
1.4 Cancer Subtypes 
 Due to the complexity and individuality expressed by cancer one could argue that 
there exists an infinite number of cancer types and subtypes.  Nevertheless, in an attempt 
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to categorically understand and treat cancer, those diseases that present familiar patterns 
are pooled into designated groupings.  The most course grain of such grouping 
mechanisms is the tissue of origin, however, such classification rarely gives insight to 
treatment options outside of surgical feasibility and likely metastatic patterns.  More 
specific and pragmatic delineations are derived from identification of oncogenes or 
upregulation of proteins.  Here we review two common examples of such groupings in 
oncogenic Ras and Erbb2 upregulated cancer subtypes. 
 
1.4.1 Oncogenic Ras 
 The discovery of Ras oncogenes began in rat models subjected to two 
carcinogenic viruses called the Harvey sarcoma and Kristen sarcoma viruses.  The 
common genetic mutations observed in these models represented the origin of the name 
Ras from Rat Sarcoma and human cellular homologues were eventually identified in 
1981.  Thus H-ras (Harvey) and K-ras (Kristen) oncogenes were born with the discovery 
of N-ras following shortly after [147–149].  Oncogenic potential in these genes stems 
from single point mutations within reading frames, altering the tertiary structure of Ras 
proteins [150,151].  Ras proteins and small single unit GTPases that represent vital way 
points in many signaling pathways such as the mitogen-activated protein kinase 
(MAPK/ERK), PI3K/AKT, and Rho pathways, which reside over such biological 
processes such as migration and proliferation [152–155].  Ras, like other GTPases, 
operate in on and off states depending upon the phosphate content of bound guanosine 
nucleotides.  When activated, Ras is bound to guanosine triphosphate (GTP) and 
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maintains the potential to activate downstream effectors.  Ras is also capable of self 
hydrolyzing GTP to GDP (guanosine diphosphate) releasing an organic phosphate and 
thus rendering the GTPase in the inactive or off state. However, this process is inefficient 
and nucleotide phosphate status is generally controlled by GTPase activating proteins 
(GAPs) and guanine nucleotide exchange factors (GEFs).  GAPs inactive Ras by 
assisting in the hydrolization of GTP to GDP, while GEFs promote Ras activation by 
releasing GDP and allowing a new GTP moiety to take its place [156,157].  Thus, the 
interplay between GAPs and GEFs dictate the state of Ras activity.  The formation of Ras 
oncogenes disrupts the delicate balance between Ras activation and inactivation and 
potentiates the undue activation of signaling transduction pathways leading to unchecked 
proliferative signals.  The most common example of this is of constitutively active Ras, a 
result of mutation at residue 12, preventing GAP from hydrolyzing GTP thus blocking 
the inactivation of Ras [150,151].  Such dysregulation of Ras activity is extremely 
common, with Ras oncogenes comprising 20 to 30 percent of all malignant tumors, 
representing the single most common oncoprotein, and is present in over 50 percent of 
highly untreatable cancers such as those in the digestive tract and the pancreas [158,159].  
Unfortunately, cancers fueled by oncogenic Ras are not as simply acting as one would 
hope.  In fact, Ras oncogenes have been shown to produce paradoxical pathway changes 
such as the inactivation of FAK activity leading to increased migration and invasion and 
the depression of integrin mediated cell signaling [160].  The de-emphasis of these two 
key modulators of migration in Ras oncogenic cancer cells muddles the integrin-FAK 
mediated paradigm of cancer signaling.  Ras activity is also highly dependent on post-
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translational modifications mediating localization to the lipid biliayer and Golgi 
apparatus possibly accounting for the organization of different isoforms of Ras between 
tissue types [159].   Cancers associated with Ras, while commonly expressing the Ras 
oncogene, can also stem from dysregulation of other proteins and processes that directly 
affect Ras functioning.  Upregulated Ras activity can be the product of other upstream 
oncogenes, such as p210BCR-ABL or the tumor suppressor gene NF1 causing increased 
signaling through Ras and decreased inactivation via loss of neurofibromin function 
[161,162].  Despite its discovery approximately 50 years prior, these complexities show 
why Ras oncogenes and their mediators remain highly studied drivers of malignant 
cancers. 
 
1.4.2 HER2 Breast Cancer 
 One in eight United States women will develop invasive breast cancer in their 
lifetime with 85 percent of these cases stemming from the estrogen receptor (ER) or the 
subfamily of epidermal growth factor receptors (EGFRs) called HER receptors [163].  
HER receptors, like all EGFRs, exist as transmembrane tyrosine kinases presenting both 
extracellular domains capable of binding soluble ligands and intracellular domains 
responsible for transmitting signals to docked proteins via enzymatic phosphorylation.  In 
this way HER receptors are capable of signal transduction to the nucleus, eventually 
influencing transcription factor activity and epigenetic status.  These receptors also rely 
on dimerization for full activation which occurs after ligand binding [164].  While all 
four HER receptors (HER1-4) contribute to growth factor signaling, in breast cancer 
28 
HER2 is the dominant signaling mechanism governing MAPK, PI3K and signal 
transducer and activator of transcription (STAT) pathways related to growth and 
apoptosis [165].  Upregulation of HER2 is observed in approximately 15-30 percent of 
breast cancers and is strongly associated with poor prognosis.  Increased expression of 
this protein can influence increased dimerization between HER2 and other HER proteins 
and lead to several increased proliferation, metastatic potential and resistance to 
endocrine therapy [166–168].   
 HER2 upregulation also supports increased integrated efforts between HER2 and 
other transmembrane proteins including CD44.  CD44 is a cell surface glycoprotein 
involved in cell adhesion and acts as a co-receptor for integrin mediated signaling.  Due 
to its large number of isoforms created by post-translation modifications, CD44 is 
involved in a myriad of processes including cell proliferation and differentiation [169–
171].  As such, changes in CD44 expression are common in breast and other cancers.  In 
relation to breast cancer, CD44 has been shown to associate with both EGFR and HER2 
in metastatic mammary carcinoma cells [172].  Not only does this protein become 
physically linked to HER2 but their interaction can enhance tumor development by 
upregulation of CXCR4 via epigenetic silencing of mRNA-139 [173,174].  Often, 
hyaluronan, a CD44 associated ligand, potentiates CD44 to increase tumor malignancy.   
Stromal cells exhibiting high levels of CD44 as well as increased hyaluronan content 
have been associated with poor prognosis in breast cancer [175].  Hyaluronan binding to 
CD44 may also act as a physical barrier to protect HER2 from antibody treatment as well 
as enhance HER2 recycling from the membrane [176,177].  The interaction and comorbid 
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expression of HER2 and CD44 is a striking example into the complexity of receptor 
mediated signaling in cancer.  Through interactions between other EGFRs and CD44, 
HER2 a seemingly benign ligand-less receptor, governs a significant fraction of invasive 
breast carcinomas. 
 
1.5 Current Treatment Strategies  
 The complexity and individual variability expressed by cancer has translated into 
a wide range of therapeutic treatment options.  In the majority of cases, combatinive 
approaches must be undertaken with the addition of adjuvant or neoadjuvent therapies 
augmenting the principal treatment strategy.  The current landscape of conventional 
cancer treatment options includes surgery, radiation therapy, chemotherapy, 
immunotherapy, targeted therapy, hormonal therapy, angiogenic inhibitors, and other less 
common and developing strategies.  The goal of all therapy options is the elimination of 
cancer cells whilst leaving somatic nearby tissues unharmed.  
  
1.5.1 Surgery 
 Tumor resection remains the most straightforward approach to the removal of 
cancer.  Visible tumors are removed commonly from breast, prostate, and lung however; 
surgery is not an option for inaccessible areas such as the brain or cancers of 
hematological origin.  During the procedure, the tumor and a small area surrounding it is 
resected. Invasive surgery can also be important in the process of cancer staging and 
determining prognoses.  Finally, surgery can be a form of palliative or therapeutic care to 
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relieve symptoms stemming from inflammation such as spinal cord compression or 
bowel obstruction [178–180]. 
 
1.5.2 Radiation Therapy 
 Surgery is often paired with ionizing radiation in the form of photons or charged 
particles.  Radiation acts upon cancer cells by causing irreparable DNA damage in either 
single or double stranded form [181,182].  Cancer cells, which possess increased stem-
like properties, express an enhanced ability to reproduce, however lack machinery to 
efficiently repair DNA which propagates in either cell death or diminished replicative 
capacity [183,184].  However, limitations are imposed upon such strategies stemming 
from the indirect ionization technique utilized by common radiation therapies.  Ionization 
of DNA atoms is normally imposed not by the photons themselves, but indirectly through 
the formation of free radicals such as hydroxyl radicals.  In this setting oxygen is vital to 
impose such indirect ionization, however, solid tumors possess a semi-necrotic, hypoxic 
core which is inaccessible through systemic capillaries.  In response, a number of agents 
have been developed to increase local oxygen content near large tumors to enhance 
radiosensitivity [185].  Other enhancements to simple external beam radiation such as 
intensity-modulated radiation therapy (IMRT), particle therapy, and brachytherapy have 
enabled more localized treatments to conform to problematic areas while relieving 
damage to nearby epithelial tissues [186–188]. 
 
1.5.3 Chemotherapy 
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 Similar to radiation therapy, the use of cytotoxic agents to eliminate neoplastic 
growth relies on either damaging DNA, or disrupting the mitotic cycle.  Such insults are 
meant to trigger apoptosis in rapidly diving cells.  There exist several classes of 
chemotherapeutic drugs including alkylating agents, anti-metabolites, anti-microtubules, 
and topoisomerase inhibitors.  Disruption of the cell cycle by these compounds is 
possible via DNA damage, blocking DNA replication through insertion into the genome, 
preventing the formation of microtubules during mitosis, and causing supercoiling 
mediated DNA stress [189–192].  Unfortunately, the ubiquitous nature of such drugs is 
harmful to all cells, albeit more harmful to rapidly diving ones.  As a result, most 
common side effects damage rapidly diving cells such as those of the gastrointestinal 
tract or hair cells [193,194].   Newer classes of such drugs that are continuously being 
developed and utilized are those that target specific oncogenes, proteins and pathways 
that are famously expressed and employed by cancer cells.  This expanding field called 
targeted therapy rests on the ability to identify the oncogenic addictions of cancer cells.  
Classification of tumor types has led to a myriad of newly developed drugs that intend to 
attack specific nodes in several pathways that control migration and apoptosis.  In 
addition to destroying the oncogenic pathways of cancer, other approaches have targeted 
non-oncogenic proteins in an attempt to disrupt machinery that cancer cells heavily rely 
on.  Antibody-mediated inhibition of VEGF binding interferes with angiogenesis, a 
process vital to a growing tumor.  Drugs blocking stromal cell support of cancer also 
share this potential
 
[195–197].  In order for targeted therapy to be effective, however, 
researchers must have intimate knowledge of the pathway system of interest.  In ErbB2 
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expressing breast cancer, competitive inhibitors of the ErbB2 receptor must combat 
resistances brought on by an alternate pathway through the MET receptor.  Drugs 
targeting ATP competitive tyrosine kinase inhibitors (TKIs) also lead to chemoresistance 
via mutation of the gatekeeper residue in the protein kinase domain.  In the case of 
rampamycin, an mTORC1 blocker, secondary tumors begin to form due to the shutdown 
of feedback mechanisms originally in place to regulate proliferation
 
[198–201].  These 
examples of targeted therapies demonstrate how robust cancer signaling can be, with 
resistances deriving from mutation of the original target, alternate parallel pathways, or 
feedback mechanisms [202].  Such treatment options have become possible with new 
technologies in in vitro drug screening.  These include PI3K and MEK inhibitors such as 
trametinib and perifosine.  Targeted therapies have also expanded beyond traditional 
small molecules to include monoclonal antibodies such as the drug trastuzumab used to 
treat HER2 positive breast cancer [203–205]. 
   
1.5.4 Chemoresistance 
Unfortunately traditional and targeted approaches, however, succumb to the same 
drawback of chemoresistance, in which cancer cells are able to avoid apoptosis and more 
robust clones continue to thrive and repopulate tumors.  Several mechanisms have been 
proposed as to how cancer cells develop resistance to certain drugs including alternative 
pathway upregulation, downregulation of the drug target, or amplification of the drug 
target to counterbalance therapeutic action [202].  The phenomenon can perhaps be 
attributed to the fairly recent discovery of cancer stem cells (CSCs).  A pervading 
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hypothesis is that these cells are mutated variants of adult hematopoietic stem cells.  
However, only a small portion of these cells exist in tumors, highlighted by the fact that 
most explants from patients fail to recreate tumors when re-administered to the body.  
When these cells differentiate into a progenitor cell then the malignant, invasive cancer is 
born.  CSCs are also thought to be responsible for chemoresistance, surviving 
chemotherapy treatment and developing new colonies with similar resistances
 
[206].  
Some small tumors are also postulated to survive treatments due to the hypoxic effect 
rendering them in a quiescent state
 
[207].  This is a functional change from a malignant 
phenotype, essentially a hibernating version of a cancer cell that avoids cell death.  These 
challenges in treating cancer have led to a new generation of drugs using a strategy called 
targeted therapy. 
  As drug development evolves, a great emphasis is being placed on understanding 
complete pathway mechanisms.  Feedback mechanisms and alternate pathways require 
that we understand the inner complexities of these networks, and also that orthogonal 
therapies be manufactured.  Growing evidence suggests that a single drug or point of 
attack will not be sufficient to eradicate cancer, therefore, the greatest potential lies in a 
cocktail of drugs that debilitate not only primary pathways governed by oncogenes, but 
also supporting avenues which provide outlets for chemoresistance.   
 
1.5.5 Immunotherapy 
 In creative and intriguing fashion, many scientists and oncologists have worked to 
develop methods to tap into ones innate immune system to help fend off cancer.  As 
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stated previously, the immune system acts as a double edged sword in relation to cancer 
development.  While certain cell types such as natural killer cells have been shown to 
induce tumor death and prevent proliferation, other immune cell types such as 
macrophages are commonly found in malignant tissues.  From this one may postulate that 
the over activity of the innate immune system may be detrimental to cancer development 
supported through the high degree of chronic inflammation in the nearby tumor 
microenviroment.  Over activity of such processes may also contribute to decreased 
function of the innate immune system via T cell exhaustion, cytokinetic signaling to 
downregulate immunogenic response, and the development of immunoresistant clones 
during the process of immunoediting [13,49,50].   
 Current immuno-based strategies for treatment of cancer include cell based 
approaches, antibodies, and cytokines.  Cell based approaches including the FDA 
approved sipuleucel-T operates by capturing a patients monocytes and incubating with 
the cytokine GM-CSF, which allows activation and maturation of these cells.  This 
activated cell population is then reintroduced to the patient, to enhance T cell 
development and anti-tumor action [208]. Adoptive T cell therapies utilize a similar 
methodology to enhance sluggish function and activity of the adaptive immune system 
specifically against cancer cells [209].  Antibody treatment can aid in treatment of cancer 
in several ways.  Anti-body mediated cell death can be used to co-localize tumor cells 
with natural killer cells and causing death through the process of complement-dependent 
cytotoxicity [210].  Anti-cancer small molecules can also be attached to antibodies that 
target specific exterior cancer expressing proteins such as ErbB2 or CD20 [211].  Finally 
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antibodies may simply function to block cellular pathways such as VEGF or KRAS 
[212,213]. 
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CHAPTER TWO: CELL MIGRATION 
Despite the fact that most cells remain stationary throughout their existence, 
cellular migration is vital to many processes in the body including development, wound 
healing and angiogenesis
 
[214].  After appreciating how vital cell migration is, it is of no 
surprise that deregulation of this behavior is manifested in disease states such as cancer.  
While oftentimes treatable, cancer is most deadly when it reaches a metastatic state, 
traveling to and establishing satellite colonies distinct from its origin
 
[215].  In an effort 
to control migratory processes and prevent malignancies, much research has been 
undertaken to understand migration at its most fundamental level.  Dozens of proteins 
involved in signaling cascades have been identified with the most prominent players 
targeted for various drug development endeavors.  These same proteins and cascades also 
correlate with other major cellular behaviors such as proliferation and survival
 
[216,217].  
Cancer motility is also related to malignancy and matrix degradation, which implies that 
cellular systems are most efficiently studied in their entirety rather than focusing on one 
specific aspect.  Included in this is the interaction of cells and their extracellular matrix 
(ECM).  As a consequence of the interconnected nature of cell processes, the basic 
patterns by which cells evolve into malignant phenotypes and the mechanisms by which 
they accomplish this is an active area of research.  Major discoveries have added to the 
existing knowledge base, however, some of these findings are contradictory and much of 
the process is still a mystery
 
[218,219].  Unfortunately, it seems, migration and its 
partnering characteristics are cell type dependent, causing great distress to researchers 
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striving to find a dominant universal effector.   It is therefore of paramount importance 
that studies continue to probe the difficult questions that underlie this complex problem. 
 
2.1 Process and subtypes 
 The complexity of the migratory process stems initially from the fact that all cell 
types do not migrate in the same fashion.  The most obvious example of this is 
erythrocytes and leukocytes.  These have adopted adhesion independent mechanisms of 
migration and in the case of white blood cells tend to roll along the endothelial layer of 
blood vessels until adhering and extravasating the vasculature [220].  This represents a 
unique method of motility with the large majority of cells choosing mesenchymal or 
amoeboid migration. While each of these migration methods rely on different cellular 
components and are present in different cellular populations, they both proceed in a 
similar step wise process. 
   
2.1.1 Cell polarization 
 Polarity of cells can be derived from a myriad of external factors including 
paracrine and autocrine signaling, chemotactic agents, and haptotactic matrix derived 
stimuli [221].  Derived from this is asymmetric activation of certain receptors that enable 
to cell to form a “front” and “rear”.  Such effectors include G proteins as well as PI3K, 
protein kinase C (PKC), and cell division control protein 42 homolog (Cdc42).  These 
proteins enact specific signals that engage cytoplasmic reorganization [222,223].  Cdc42 
along with Wiskott-Aldrich syndrome protein (WASP) and Rac are involved in actin 
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polymerization at the leading front of cells.  The contracture of cortical actin allows the 
beginning of the following step of migration, protrusion.  Rac is also important as it 
pertains to its interplay to the Rho cascade.  Rac is thought to suppress the Rho pathway, 
which regulated the contractility of the cell via actomyosin bundles.  Localization of Rac 
to the leading edge may create an asymmetric action in Rho which later allows 
propulsion of the cell in a more directed fashion [224,225].  
 
2.1.2 Protrusion 
 Cell protrusions are formed via the polymerization of actin monomers that cause 
membrane expansion is any given direction.  Membrane extensions and protrusions 
generally consist of both filopodia and lamellipodia.  Filopodia are protrusions that act as 
sensors of the local environment regulated by Rho GTPases and Cdc42 [226,227].  They 
are also part of the larger lamellipodial protrusion which constitutes the motile edge of 
the cell.  Similar proteins that encourage cell polarity also influence the formation of 
lamellipods.  Rac and Cdc42 are able to interact with WASP to eventually cause binding 
of the Arp2/3 complex to actin filaments to create actin nucleation cores.  In this way 
Arp2/3 is capable of controlling actin polymerization through the branching and capping 
of filaments [228].  Permanent formation of lamellipodial protrusions depends on 
adhesion, however.  In the absence of such adhesions the cell merely undergoes 
membrane ruffling [229].   
 
2.1.3 Adhesion 
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 Attachment to ECM moieties is necessary for establishment of protrusions in the 
process of migration.  Adhesion structures exist as a spectrum of increasingly complex 
and robust forms.  Nascent adhesions are highly transient and rarely mature and are 
indicative of highly migratory cells.  While they do not possess the mechanical strength 
to pull cells along migratory tracks, they are postulated to regulate force transmissions in 
response to tissue rigidity and begin the sequestration process for other adhesion related 
proteins such as FAK and talin [230,231].  Those nascent adhesions that do begin to 
mature evolve into focal complexes housing constitutively forms of Rac.  These 
complexes require myosin II for formation at the leading edge of lamellipodia [232,233].  
The final matured form of adhesions is called focal adhesions that are expressed as large 
actomyosin bundles and are indicative of stationary, non-migratory cells [234].  Focal 
adhesions are mediated by cell surface adhesion molecules, integrins, that physically link 
the ECM with the actin cytoskeleton.  Other proteins such as zyxin, vinculin and tensin 
are uniquely present at focal adhesions [235].  As discussed later, these complexes are 
also the main driving force for outside-in signaling events, linking extracellular cues to 
intracellular responses in the form of protein expression and transcription factor mediated 
genetic regulation.  The final form of adhesions present at the cell surface is expressed 
mainly by highly migratory cells such as macrophages.  These radial structures called 
podosomes contain actin polymerization proteins such as Arp2/3 and WASP on the 
interior whilst expressing adhesion receptors on the outer region [236].  Cancer cells that 
have hijacked this machinery create podosomes called invadopodia that also highly 
express matrix degrading proteins such as MMPs to aid invasive behaviors [237]. 
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2.1.4 Signal Integration 
 Most cells in the body require an adhesive interaction with the extracellular 
matrix or will otherwise undergo adhesion-deprived death in a process termed anoikis.  In 
the context of cell migration, the main mediators of such function are integrins.  Families 
of dimeric transmembrane proteins, integrins, of which there exist 18 alpha and 8 beta 
chains, mediate this adhesion.  Each integrin set is comprised of an alpha and a beta 
subunit and this combination determines its affinity to extracellular ligands.  Integrins are 
receptors for a wide variety of matrix proteins including collagen, fibronectin, laminin, 
and vitronectin
 
[238,239].  The simple act of adhesion represents only part of integrin 
function, however.  The intracellular region of these proteins is responsible for 
transmitting the signals from the exterior of the cell.  This is primarily accomplished via 
protein signaling cascades, mediated by a plethora of kinases.  Focal adhesions, a 
congregation of kinase enzymes and scaffolding proteins, are formed on these adhesion 
fronts where integrins interact with the ECM and oftentimes aggregate to form integrin 
clusters
 
[240].  Other transmembrane proteins such as caveolin-1, glycoprotein 
hyaluronan receptors and growth factor receptors also co-localize at points of integrin-
ECM connections
 
[241,242].  The result is ultimately genetic regulation, leading to a 
phenotypic response appropriate for the cell.  Integrins support this activity by acting as a 
scaffold for various kinase and GTPases.  The sequestration of other protein types such as 
growth factors allows integration of signals from integrins, growth factor receptors and 
other nearby membrane channels [240].  Due to the wide range of affinities for different 
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ECM ligands produced via varying combinations of alpha and beta chains, integrins can 
mediate a plethora of different reactions depending on matrix architecture and 
microenviroment [240].  A final and relatively recent discovery regarding integrin 
function is that of mechanosensing.  The cytoskeletal network is functionally attached to 
integrins through vinculin, talin, and alpha-actinin proteins.  In this way mechanical force 
induced on integrins is transmitted through the network of fibers, eliciting a cellular 
response
 
[243].  This has led to increasing research to study the biomechanical properties 
of integrins.  Interestingly, not only do integrins pass signals into the cell via mechanical 
pulling, but their active and inactive states rely on the amount of tension they experience 
[244]. 
 
2.1.5 Translocation and Retraction 
    Cell movement is finally conducted during the process of translocation, a 
myosin dependent process of coordinated contraction.  However, such contractile forces 
cannot result in a positive displacement unless there exists an asymmetry in cell adhesion.  
At the cell rear, adhesions are quickly dissolved in order to create a bias for attachment at 
the migrating front of cells.  Contraction then results in directed motility.  This adhesion 
disassembly, which is partially under the realm of cell polarity, is enacted via actomyosin 
contraction, microtubule-induced adhesion relaxation, and proteolytic cleavage of 
adhesions [245–247].  Actomyosin contraction, mediated via the Rho pathway, is 
responsible for pulling the lagging rear of the cell forward.  Besides activation of myosin-
mediated contractility, the Rho/ROCK pathway is responsible for the inhibition of 
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integrin adhesions at the rear of cells [245]. Further relaxation of adhesions is enacted by 
microtubules that enhance shuttling of Dynamin and FAK to attachment sites to regulate 
their disassembly [246].  One final method of adhesion destruction is via calpain 
cleavage.  This family of proteases works to cleave both talin and FAK to release 
adhesion strength [248].  In addition to the deletion of existing adhesions, the cell may 
also express an asymmetry in integrin expression upon the surface, more preferentially 
expressing integrins toward the migratory front via endocytosis and recycling of these 
proteins.  Adhesion turnover, mediated by a wide range of proteins including clathrin and 
3-phosphoinositide-dependent kinase-1 (PDK1) is extremely prevalent in highly 
migratory cells.  During this process, old adhesions are quickly stripped and their 
integrins are shuttled to the sites of new adhesions at cell protrusions [249,250].  Upon 
successful translocation and rear body retraction, the cell has completed what is known as 
one migration cycle.  This process is iterated indefinitely in the case of highly migratory 
cells.  While these basic steps are common amongst almost all migrating cells, there still 
remain two main modes of migration used by cells that differ in some very fundamental 
processes.  The divergence between these two modes is thought to underlie the difficulty 
in controlling the migration process, especially in disease states.  However, before 
exploring these migration modes in detail it is important to understand the cellular and 
extracellular influences on migration. 
 
2.2 Matrix Metalloproteases 
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 In addition to receiving signals from their surroundings, cells also harness the 
capability to adjust the local ECM to better suit their needs.  Cells are able to extrude 
various forms of extracellular matrix proteins and deposit them to enhance their exterior 
network.  Much of the extracellular modulations are performed by matrix 
metalloproteinases (MMPs), zinc dependent endopeptidases whose primary function is to 
cleave matrix proteins.  There are 24 known varieties of MMPs, each belonging to a 
subset responsible for cleaving different targets.  Despite the wide variety of MMP types, 
they all share three common regions, the pro-peptide, catalytic domain and hemopexin 
like C-terminus linked to the catalytic domain via a hinge region.  MMPs are produced 
initially as inactive zymogens that necessitate activation through cleavage via Furin, or 
other MMP subtypes.  While the majority of these enzymes are soluble and extruded 
from cells in a localized fashion, several of them remain bound to the lipid bilayer with 
little intracellular domain or binding sites available.  This has led most to believe that 
membrane anchoring of MMPs is strictly for purposes of co-localization with other 
membrane effectors and for vesicle induced recycling.  Normal function of MMPs is tied 
to wound repair, angiogenesis, and migration [251–253].  In all of these cases MMPs are 
utilized to break down tissue to remodel and create space for additional processing.  
MMPs are also implicated in the process of matrix remodeling, which encompasses the 
aligning of nascent and extruded ECM fibers [88]. 
In order to regulate these powerful effectors, there exist naturally occurring tissue 
inhibitor metalloproteinases (TIMPs)
 
[254].  Unfortunately, there are cases in which the 
delicate balance between MMPs and their TIMP counterparts is disrupted leading to 
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dysregulation of many processes including migration.   In cancer, MMPs are often 
upregulated, and this is directly tied to cancer invasiveness.  The addition of MMPs not 
only allows for cells to migrate in denser environments, but also increases their capacity 
to remodel the surrounding matrix thus creating an ECM more favorable to cell survival
 
[255,256].  Aside from cleaving matrix proteins, MMPs have also been shown to target 
other, non-ECM moieties including growth-factor receptors, cell adhesion molecules, 
chemokines, cytokines, apoptotic ligands, and angiogenic factors
 
[257–259].  Cleavage of 
such receptors or ECM fibers contributes significantly to outward cellular signaling and 
behavior.  MMPs have been shown to cleave the ectodomain of ErbB2 proteins that are 
upregulated in breast cancer, rendering them constitutively active and leading to greater 
malignant potential [260]. Cleavage products from the matrix such as endostatin have 
also been shown to regulate angiogenesis which provides migration avenues for 
metastatic cells to infiltrate the vasculature [261].  Such secondary mediated effects via 
extracellular domain cleavage are propagated via changes in receptor binding or 
activation.  This ultimately changes signaling pathways within the cell that result in 
behavioral changes in cell motility.  The many different ways MMP cleavage can 
contribute to cellular signaling through its large list of proteolytic targets has naturally led 
to several efforts to control rampant MMP activity through small molecule inhibitors.  
However, attempts to produce anti-cancer drugs targeting MMPs have failed almost 
ubiquitously.  It seems that there exist too many alternate pathways and mechanisms by 
which cells can overcome treatment with MMP inhibitors.  Further understanding of 
these pathways promises to aid in educating drug treatment plans to disrupt those 
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mechanisms by which cells circumvent the changes caused by action inhibition.  An 
interesting by product of the MMP drug revolution has been studies showing that MMP 
inhibition can alter cell morphology and signaling to change how cells migrate.  When 
cultured with a protease cocktail, cells take on a rounded morphology and begin to adopt 
an amoeboid like state of migration as opposed to the classic tug and pull mechanism
 
[262].  This fascinating work highlights the robust nature of cancer cells, and also 
indicates that MMP blocking produces cellular cues, suggesting that MMPs have a 
broader utility in migration than simply cleaving matrix proteins. Evidence of such 
contribution to signaling is provided by the co-localization of MMPs to the migratory 
front, interacting with protein signaling mediators integrins, growth factors, and other 
cell-ECM interacting proteins such as glycoproteins [263–265].   
   While no direct link between MMP and integrin signaling has been established, 
the two protein families are commonly linked when it comes to migration.  
Unfortunately, due to the large number of proteins that comprise both the integrin and 
MMP families, there remains more to discover regarding their interaction with other 
pathway modulators.  This is possibly potentiated by the fact that the majority of research 
on integrins in this and other areas of research has been of those isoforms most 
commonly expressed, or those that contribute to adhesion of the model system in use. A 
similar pattern has emerged in research regarding MMPs; nevertheless there has been an 
established link between integrin function and MMPs.  Several targets have been 
identified through research and account for the majority of the current knowledge base.  
Integrin v3 activation has been shown to cooperate with MMP-9 in breast cancer 
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metastasis [266].  Alpha integrin binding can also influence the activation of MMPs to 
remodel fibronectin.  Generally, integrin activation has been shown to correlate with 
MMP protein levels, indicating a positive correlation between both integrin-ligand 
interaction and MMP activity leading to an increase in cancer cell invasiveness and 
malignancy
 
[267,268].  MMPs are extruded into the matrix upon integrin-ligand 
interactions, which are oftentimes increased in disease states due to microenvironment 
changes and integrin upregulation
 
[269].  In a more specific case of integrin MMP 
interaction, MMP-14, a transmembrane member of the MMP family has been shown to 
co-localize on the lead edges of migrating cells with β1 integrins [262].  How this 
connection is established is unknown, but evidence suggests a possible interplay between 
the two proteins.  The current dogma pins integrin as the effector, controlling MMP 
release
 
[270,271].  However, evidence exists that links MMP as an integrin pathway 
modulator.   Deletion of the cytoplasmic tail of MMP-14, while leaving the proteolytic 
segment intact, is enough to halt migration suggesting that MMP-14 plays a role in the 
signaling cascade
 
[272].  MMP-14 also associates with caveolin-1 via Src mediated 
phosphorylation, suggesting that this all occurs at sites of focal adhesions
 
[273].  A 
further link connecting MMP-14 to integrin function is established through its necessary 
cleaving of CD44 at the cell surface in order for efficient migration to occur.  CD44 is 
often localized with integrin β1 on the surface and serves as a secondary adhesion 
molecule.  Another study established a link between MMP-2 knockdown and the 
frequency of the integrin-FAK connection, a staple of focal adhesion formation
 
[274,275].  The proximity to integrin β1 may indicate that there exists a link between 
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itself and MMPs, and that the connection may be bi-directional in nature.  Establishing a 
connection between MMP activity and integrin function would alter the paradigm into 
which MMPs are currently being studied and expand their role in migration in relation to 
signaling pathway modulation.  Locating the locus at which MMP ultimately intersects 
and interplays within the integrin pathway could unleash new potential for combinatorial 
targeted migration therapies. 
In addition to integrins, MMPs have also been shown to interact explicitly with 
growth factors in a bidirectional manner to influence migration.  While MMPs have yet 
to be implicated in direct signaling changes to alter growth factor expression and 
activation, their proteolytic capacity secondarily influences growth factor mediated 
responses.  Secretion of MMPs by cells results in matrix processing releasing soluble 
factors VEGF and bFGF, two powerful angiogenic stimulators.  MMPs can also cleave 
VEGF, modulating its activity [261].  Combined with degradation of the basement 
membrane, MMP mediated angiogenesis represents a key process in the migration of 
cells, especially malignant metastatic cancer cells.  This process is subject to positive 
feedback stimulation as well, with growth factors such as TNF-α able to stimulate MMP-
1 production via EGF signaling.  VEGF has also been shown to upregulate MMPs in 
vascular smooth muscle cells [276,277].  This intimate relationship between MMPs and 
growth factor signaling highlights the delicate balance that is reached in order to stabilize 
and control migration. 
   
2.3 ECM 
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2.3.1 Contract Guidance 
 Cell migration is heavily influenced not only by the surrounding cells that 
comprise the microenvironment but also from outside-in signals stemming from the 
ECM.  Although it may seem that the structure of the ECM is important to cells only as a 
scaffold for tissue structure, there are several cues that it imparts on cells to influence 
motility.  The first of which is contact guidance, or the propensity for cells to migrate 
along ECM fibers.  The phenomenon is demonstrated when cells direct their migration 
paths along segments of oriented or aligned fibers.  In situations where the fibers are 
randomly aligned this directed migration no longer occurs [278].  This process is also 
dependent upon the distance between aligned fibers that allow cells to accurately sense 
the mean directional angle [279,280].  Contact guidance may also be replicated and 
studied using biomaterials of different textures and grooved substrata.  Such ECM 
mediated effects can be transmitted on a nano-scale between cells in a monolayer, and is 
also affected by population pressure [281,282].  In 3D matrices, contract guidance of 
breast cancer cells is regulated by matrix remodeling via the Rho/ROCK pathway [283].  
Understanding how cells are influenced by topographic organization and what pathways 
are used in such processes may aid in halting metastasis from tumors.  Not only have 
prostate cancer cells been shown to migrate along organized fibers, but the ECM 
surrounding tumors is often highly aligned and dense serving as a potential cue for 
tumorigenic cells to break away from tightly packed cell masses and infiltrate the 
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surrounding stroma [95,284].  Fiber alignment, while representing a powerful migration 
effector, is not the only means by which the ECM controls directed movement of cells. 
 
2.3.2 Haptotaxis 
 Surface bound ligands oriented in a gradient also have the capability to provide 
migration signals in a process termed haptotaxis.  Migration due to haptotaxis can be 
initiated via a gradient of protein types such as laminin or fibronectin and the speed of 
migration is directly related to the strength of the gradient [285,286].  Several platforms 
have been engineered such as the Boyden chamber to utilize the principle of haptotaxis in 
identifying cellular cues to migration.  Tumorigenic cells have been shown to migrate 
toward matrix bound thrombospondin, establishing a link between inflammatory response 
and metastasis [287].  The signaling pathways that initiate integrin mediated haptotaxis 
have also been shown to be unique to other chemoattractant gradient sensing 
mechanisms, utilizing tyrosine phosphorylyzation of paxillin rather than G protein 
mediated signaling [288].  Integrin mediated signaling via the α1β1 and α2β1 subtypes 
have also been shown to be necessary for haptotactic cell invasion in response to EGF 
and bFGF and play a significant role in angiogenic sprouting [289]. 
 
2.3.3 Chemotaxis 
 In a similar fashion gradients of soluble factors may also induce migration via 
chemotaxis.  This process is mediated by membrane receptors on cells that are able to 
detect even minute asymmetries in concentration gradients.  Chemotaxis is at the 
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forefront of wound healing, development, and the immune response.  In fibroblasts, 
PDGF signaling coordinates with cytoskeletal reorganization to direct movement during 
wound healing [290].  Signaling through the Cdc42 and Rho pathways are common 
among macrophages in response to CSF-1 activation, a key cog in hematopoietic stem 
cell differentiation [291].  Finally, several proteins that are released upon pathogen 
detection such as defensins and cathelicidin serve as chemoattractants to stimulate both 
the innate and adaptive immune system [292].  While it may seem that the ECM does not 
play a role in chemotaxis, it has been shown to influence such processes through its 
degradation products.  Protease induced cleavage of both fibronectin and porcine urinary 
bladder ECM both have been shown to possess chemotactic potential in vitro [293,294].  
Due to the wide spread use of this technique in recruiting cell types, chemotaxis is 
currently the most widely studied migration function mediated by the ECM. 
 
2.3.4  Galvanotaxis 
 While not as celebrated as chemotaxis, galvanotaxis has also been shown to direct 
eukaryotic cell migration.  In this process, cells are influenced by electric field potential 
with the majority of cells preferring the cathode of any given circuitry.  The ECM plays a 
role in galvanotaxis by acting as a scaffold for epithelial layering and bundling.  In most 
organs a transepithelial potential is present in the range of hundreds of mV/mm and play 
significant roles in tissue regeneration and embryogenesis [295].  Current theories pin the 
migration response of cells on the electrochemical potential for calcium flux toward the 
anode.  This relative increase in calcium concentration would prove detrimental to 
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cellular movement, which necessitates an adequate calcium gradient between the extra 
and intracellular regions [296]. The dependence of cell migration due to galvanotaxis on 
calcium is highlighted by the lack of migratory potential across electric field gradients in 
the presence of calcium blockers [297].  Theory notwithstanding, this mode of migration 
mediated by ECM structure remains an important mechanism in disease and cancer.  
Studies have shown that cell transformation can alter the response of cells to electric 
fields.  Similarly, highly invasive breast cancer cells have shown an opposing preference 
for the anode versus weakly metastatic cells [295].  While these findings point to a 
significant role of galvanotaxis in metastatic migration, more must be uncovered 
regarding specific mechanisms to rule out this phenomenon as merely an artifact of other 
more powerful migration forces. 
 
2.3.5 Durotaxis 
 Perhaps a somewhat less intuitive mechanism for ECM driven cell migration is 
that of durotaxis, or the propensity for cells to migrate toward stiffer substrates.  Tissue 
stiffness varies widely through the body between several hundred Pascal to an upper 
range in the MPa region, and is measured by the cell via its link through the integrin-actin 
connection [85].  As discussed earlier, ECM stiffness can play a large role in the fate of 
cells and alter their signaling pathways.  Dysregulation of this behavior is commonly seen 
in disease states and may represent a positive feedback mechanism in which the 
malignant cells increase the substrate stiffness by depositing ECM proteins.  Aside from 
disease progression, the stiffness of the ECM has been shown to direct stem cell fate as 
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well as proliferative capacity and apoptotic signaling [298,299].  In relation to migration, 
the tendency for cells to move toward stiffer substrates may be the result of asymmetry in 
cell signaling arising from focal adhesion formation due to the ability for stiffer 
substrates to promote greater focal adhesion sizes.   These focal adhesions have been 
shown to tug on matrix adhesions to sample the rigidity and through the FAK/paxillin 
pathway direct cell movement toward stiffer surfaces [300].    Migration toward stiffer 
substrates is also dependent on both the stiffness gradient and the local confinement of 
cells.  Mesenchymal stem cells migrate comparatively faster in regions of high stiffness 
gradients [301].  Local cell confinement also contributes to faster migration across 
changes in substrate stiffness [302,303].  Despite these and other recent discoveries 
presenting cells migrating toward stiffer substrates, caution must be taken in treating 
durotaxis as an absolute.  Indeed, a biphasic dependence on stiffness has been reported on 
multiple occasions suggesting that there remain substances too stiff for efficient motility.  
In this scenario, integrin-ligand adhesions are either too rigid or plentiful in order for the 
cell to polarize and translocate properly [85].  Nevertheless, such findings may provide 
rationalizations to the branching out of individual cancer cells from a tumor which 
represents a very confined space with a potentially lower elastic modulus than the 
surrounding reformed tissue.    
 In order to govern migration properly matrix rigidity is tightly controlled through 
the composition of the matrix, fiber alignment, and crosslinking. As a result alterations 
through each of these facets of ECM stiffness through injury or remodeling effects cell 
migration.  Reductionist approaches have done outstanding work in identifying the 
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specific properties of the ECM that influence migration.  Unfortunately, changes in the 
ECM due to remodeling most likely effect multiple properties simultaneously creating 
highly interdependent systems of cell signals.  Increasing research must therefore be 
undertaken in a systems level approach to fully appreciate how the ECM drives 
migration.  
 
2.4 Mesenchymal Versus Amoeboid Migration 
 Single cell migration is currently classified under one of two migration modes.  
Mesenchymal migration is characterized by spindle like morphology with a clear leading 
edge.  These cells follow the migration patterns described earlier starting with 
polarization/protrusion and ending with rear detachment of the cell and translocation.  
This mode of migration has also been identified as both integrin and MMP dependent.  
Cells migrating mesenchymally depend heavily on integrin-ECM contacts that allow 
them to produce traction forces via actinomysin machinery.  Due to this dependence on 
adhesion, MMPs are necessary to degrade and remodel fibers in order to create both 
adequate space for the migrating cell and provide sufficient directional fiber alignment to 
continue the pulling mechanisms utilized for cell translocation [304,305].   
 In contrast, amoeboid like movement follows a cycle of expansion and retraction 
of the cell body by cortical actin and myosin.  Phenotypically, these cells do not resemble 
those of mesenchymal type, adopting a rounded morphology.  Utilizing the Rho/ROCK 
pathway, cells utilizing the amoeboid migration mode achieve motility via membrane 
blebbing and squeezing.  In this case protrusion of lamellipodia is not from actin 
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polymerization of the leading edge as described earlier, but instead due to expansion of 
the leading edge due to actin-myosin contraction at the rear deflating the posterior of the 
cell and pushing intracellular contents forward much like the action when squeezing a 
water balloon.  Instead of increased actin deposition at the leading edge, bleb formation is 
in fact aided by the loss of attachment of cortical actin with the membrane allowing it to 
swell outward.  Unlike mesenchymal migration, these cells can move independent of 
matrix adhesions and even prefer to express only nascent integrin-ECM attachments.  
MMP activity is also not necessary as these cells are capable of navigating dense matrices 
by squeezing through small pores or expanding the matrix itself through contractile force 
[304,305]. 
 Although these two migration modes seem diametrically opposite to one another, 
they can both be expressed by the same cell depending on extracellular cues.  This is 
known as the plasticity of cell migration, either describing the transition from amoeboid 
to mesenchymal migration (AMT) or mesenchymal to amoeboid (MAT).  Several key 
pathways are necessary for either amoeboid or mesenchymal migration, and inhibition 
causes cells to switch from one migration mechanism to another.  In melanoma cells, 
amoeboid migration is transformed to a more mesenchymal like movement scheme 
through the silencing of the Rho/ROCK pathway [155].  These same cells are also guided 
toward mesenchymal migration by inhibition of PDK1, a stabilizer of myosin light chain 
proteins at the cell cortex through activation of ROCK1 [306].  The Rho pathway has also 
been shown to reduce the activity of the Rac pathway, which is a key component of actin 
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polymerization and cell polarization in mesenchymal migration.  High expression of Rho 
pathway proteins is able to direct cells toward amoeboid migration [307]. 
 In contrast, the pathways that stimulate mesenchymal migration or a MAT, stem 
mainly from the Rac pathway.  Inactivation of Rac in mesenchymally migrating 
melanoma cells leads to a rounded morphology, indicative of amoeboid migration [307].  
This effect is potentiated via the role of Rac and its upstream and downstream effectors in 
polarization, actin polymerization at the leading edge, and focal adhesion turnover [308].  
Other proteins such as Smurf1 that inhibit Rho/ROCK at the leading edge promote 
mesenchymal migration by allowing the Rac pathway to dominate cell signaling [309].  
Finally, Cdc42, through its regulation of microtubules is necessary for mesenchymal 
migration by structuring cell polarization.  In contrast, amoeboid migration benefits from 
disruption of microtubule organization by inducing ROCK activation [223]. 
  Just as the ECM is able to direct migration directionality, its specific 
characteristics can also influence cells to use mesenchymal or amoeboid movement.  
Studies in 3D collagen gels have shown that proteolytic blockers can transform migrating 
cancer cells from a mesenchymal to amoeboid migration scheme.  The inhibition of 
proteolysis, a mechanism which mesenchymal migration depends upon, caused 
downregulation of integrins on the cell surface, reduced FAK phosphorylation and 
amoeboid like blebbing through pores [127,262].  Fiber alignment to tumors has also 
been shown to direct MAT or AMT transitions through the activation or inactivation of 
the ROCK pathway.  When fibers are aligned perpendicularly to the tumor, ROCK 
independent migration can occur, however in the case of randomly aligned fibers, ROCK 
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activation is necessary for protease independent amoeboid migration [283].  While these 
results are intriguing one must consider the lack of in vivo evidence regarding any MAT 
or AMT processes.  Other researchers have also questioned the validity of migration 
plasticity by claiming that non-native 3D collagen networks lack the crosslinks to 
sufficiently remodel in vivo like tissues.  They contend that cells may only migrate in an 
amoeboid, protease independent fashion in absence of these crosslinks, an unlikely 
scenario under more realistic conditions [310].  Despite any skepticism regarding specific 
results garnered from in vitro settings, the potential for cells to transform their mode of 
migration in response to local inhibition is a phenomenon that should and does greatly 
interest those determined to quell unbridled migration in disease states. 
 
2.5 Drug Development 
Cell migration has been shown to influence some of the most important in vivo 
processes such as development, immunogenic response, and cancer progression.  It is 
therefore unsurprising that constant endeavors to manufacture drugs to oppose harmful 
migratory events have been undertaken.  Unfortunately, despite decades of research the 
field to this point has relatively little to currently offer patients [311].  The death of 
successful drugs to target cell migration has, however, begun to build upon the constant 
stream of knowledge regarding the migration pathway.  Several strategies are currently 
being implemented to target various nodes in the migration pathway with respect to 
inflammatory diseases.  Such ailments are derived from inappropriate or chronic 
immunogenic responses.  Therefore, drug development efforts have focused on 
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controlling the series of events that lead to leukocyte recruitment to tissues, particularly 
during the process of extravasation.  Current drug strategies have been to target this 
process in three separate but related ways: selection inhibition, integrin inhibition, and 
chemoattractant receptor inhibitors [311].   
Selectins are weakly adherent cell surface adhesion glycoproteins that participate 
in leukocyte rolling along the vascular wall.  These proteins are upregulated in response 
to inflammatory factors such as thrombin and allow leukocytes to gently probe the vessel 
wall for other binding carbohydrate groups [312].  Selectin adhesion events are, however, 
simply precursors to other events that facilitate leukocyte invasion.  Rolling immune cells 
utilizing selectin mediated adhesion are able to sense further chemoattractant molecules 
at sites of injury or inflammation which increases their affinity via GPCR receptor 
mediated contacts.  Finally, firm adhesion is then brought on by integrin connections 
where traditional chemotactic migration can occur as the leukocyte extravasates the 
vasculature [313,314].  Inhibition at each of these nodes in the migration process has 
been the target of the migration drug development scheme.   
Due to the wide variety of chemoattractants in comparison to selectins and 
integrins, these receptors currently garner most of the attention from researchers. To date, 
most drugs in this pipeline of research are either being testing on animal models, or have 
not successfully made the transition to humans [311].  Success in this field may simply be 
contingent on more knowledge regarding the relationships between chemokine pathways.  
Given the prospect of new discoveries, chemokine inhibitors promise to represent tools 
for tissue specific immunologic control.   
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Another avenue by which scientists have attempted to control migration is 
through the inhibition of MMPs.  These inhibitors of proteolytic activity were first 
developed to treat invasive and metastatic cancers.  Unfortunately, close to no significant 
positive results were extracted through over a decade of clinical trials.  It has been 
postulated that perhaps the highly mutable nature of cancer is not a suitable target for 
MMP inhibitors, however, they may serve other purposes in the realm of inflammatory 
disease [315].  Current studies are testing the viability of MMP inhibitors in such 
malignancies with greater optimism due to the comparative genetic stability of these 
diseases.  Encouragingly, the necessitation for oral use and high selectivity required for 
the development of anti-cancer drugs may not hold true for inflammatory treatments.  
Still, research continues to probe the use of increasingly specific MMP inhibitors both 
endogenous and artificial [316].  Despite the fact that there currently exists a dearth of 
effective anti-migratory drugs, a platform for further understanding how migration can be 
controlled in the form of inflammatory disease may serve as a stepping stone to tackle 
more complex malignancies involving migration such as cancer. 
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CHAPTER THREE: CELL MIGRATION ASSAYS 
 The study of cells and their characteristics is a decades old endeavor, beginning in 
the 19
th
 century with several attempts to culture explanted tissues [317].  The concept of 
tissue culture was born soon thereafter through the efforts of Ross Granville Harrison 
establishing the growth of frog neuroblasts in lymph medium in the early 20
th
 century 
[318].  Advanced culturing techniques however would not develop until the mid 20
th
 
century as a result of virology experiments with the task of purifying viruses for vaccine 
production [319].  This marked the humble beginnings of what is commonly known as 
cell culture and today thousands of different cell lines exist via isolation from tissues.  
Culture of such cells is performed in controlled environments on tissue culture plastic; 
polystyrene plastic modified for the generation of highly energetic oxygen ions, rendering 
the surface hydrophilic upon the inclusion of cell culture media.  A second common 
modification on tissue culture plastic is the attachment of poly-D-lysine residues for the 
generation of a negative net charge allowing enhanced attachment of cells.  This general 
mode of cell culture remains the standard for the majority of cell related assays, including 
migration assays [320].  However, specific questions regarding migration cannot be 
probed due to the limitations of this system.  In response, the field has adopted a wide 
range of substrates and culture techniques to broaden the versatility and functional 
relevance of scaffolds. 
 
3.1 2D assays 
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 Most assays for the study of cell migration probe motility on 2D surfaces.  The 
most straightforward of such assays is the scratch wound assay, used to test the ability of 
cells to close gaps between confluent layers of cells.  Cells are allowed to grow to a 
confluent monolayer in culture, and using a small device such as a pipette tip, a small 
linear wound is inflicted leaving a gap between now two intact confluent layers.  Since 
cells can either migrate as single entities or sheets, this assay can probe either single or 
collective cell migration characteristics [321].  Ease of use and setup along with low cost 
also makes this approach appealing.  Such an assay is influenced however, by the relative 
strength of contact inhibition between cell lines and whether they tend to form 
monolayers to begin with.  Inconsistencies in the wound size may also influence results 
in many cases.  Finally, wounds inflicted to cells in this manner cause damage to the 
remaining cells. Not only does this affect the ability of injured cells to migrate but also 
brings into question the role of any necrotic or apoptotic paracrine signaling.  This 
approach is perhaps more efficiently demonstrated using cell exclusion.  The setup of this 
assay is similar to the scratch wound, however, a small inert silicone stopper is placed 
upon the culture surface, restricting cells from growing in a specific region.  After 
confluence is reached, the stopper is removed and cells are allowed to populate the 
restricted region [322].  This small change in assay setup removes the variability in 
scratch wound length as well as the problems caused through cellular stress in addition to 
allowing the researcher to design and manipulate the size and shape of the restricted 
region. 
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 A second popular 2D approach to studying migration is the Boyden Chamber.  
Although technically an assay developed in 2D, the Boyden Chamber is capable of 
studying cell invasion.  The setup of this assay consists of cells cultured in a well the 
bottom of which is littered with microdiamter sized holes.  This well is encased within a 
larger well of a plate resulting in an upper and lower chamber.  The upper chamber 
consists of the cells and the lower chamber, empty.  Both chambers can be filled with 
media, with the lower commonly containing a chemoattractant molecule.  Cells are then 
assessed for their proclivity to transmigrate across the porous barrier either via 
visualization with a cytological dye, or detachment and quantification through other 
methods such as fluorescent staining.  The Boyden Chamber, also commonly referred to 
as the transwell assay, is capable of testing the relative strength of chemotactic agents, as 
well as other impositions that effect transmigration [323,324].   
 More advanced strategies to assess migration in two dimensions utilize 
specifically designed platforms or substances.  Microfluidic environments can be used to 
study leukocyte migration via the formation of two distinct chambers separated by a 
channel.  While cells are cultured in one channel a chemoattractant is introduced to the 
other, allowing for migration to occur.  The advantage of this approach, as is the case 
with most biology based microfluidic devices, is the small volume that is necessary for 
assay performance.  Controlled flow rates also make these platforms ideal for assessing 
migration in the face of resistant current, such as those in blood capillaries [325].  Finally, 
the use of synthetic substrates allows for the study of migration in relationship to matrix 
architecture, stiffness and binding affinities.  Perhaps the most commonly used synthetic 
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substrates for cell culture and migration are polyacrylamide (PLA) and polyethylene 
glycol (PEG).   Both of these gel systems provide substrates that can be engineered to 
achieve different stiffness and can also be dressed with any desired ECM protein 
[303,326].  Despite the fact that 2D assays offer significant benefits toward studying cell 
migration, they are undoubtedly far from in vivo like in nature.  The desire to observe 
cells in biologically relevant environments has influenced the development of several 
platforms that boast the culture of cells in three dimensions.   
 
3.2 Importance of 3D culture systems  
Before delving into the variety of 3D assays for migration, it is first important to 
appreciate the motivation behind the growing number of such approaches.  As detailed in 
the previous chapters, cell behavior is greatly influenced by the microenviroment, taking 
cues from both cells and the ECM itself.  The protein composition, stiffness, and fiber 
patterning have all shown to direct migration, differentiation, and adhesion.  
Interestingly, research now indicates that dimensionality can also dictate cell behavior.  
In vivo, cells rarely encounter scenarios that mimic the 2D monolayer that develops as a 
result of culture on treated plastic.  Most cells are embedded in a 3D network, motivating 
the need for more biologically relevant scaffolds for the study of cultures.  A further look 
into how 3D culture influences cell behavior reveals that this phenomenon is prevalent in 
almost all ECM mediated processes. 
     
3.2.1 In Cell-ECM adhesion 
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In search of investigating cell-ECM interactions, the dimensionality in which the 
study is performed cannot be overlooked.  Traditionally, in vitro assays are done on two-
dimensional tissue culture flasks, a vast simplification of how cells normally interact with 
their environment.  While outstanding accomplishments have been conducted in a 2D 
environment highlighting the importance of substrate stiffness, ECM components, and 
integrin activity with regards to cancer aggressiveness; assays performed in 2D may 
undersell other vital cues involved in cellular behavior [327–329].  A major topic of both 
study and debate is one of focal adhesion sites, where integrin-ECM connections evolve 
into large multi-protein structures thought to enhance cell-ECM interactions and play a 
major role in migratory processes [330,331].  Whereas in 2D these structures are well 
defined, they have what seems to be a less prominent role when cells are cultured in 3D 
lattices, differing in which proteins are present at the adhesion site. 
This suggests that 2D focal adhesions may represent an exaggerated case of what 
is actually visualized in 3D [332,333].  This is most likely due in part to the lack of dorsal 
cell-ECM interactions, forcing the cell to adopt an elongated structure rarely seen in 3D 
matrices.  In addition, the disparity in spatial integrin-ligand binding may cause cells in 
2D to differ genotypically and offer different signaling networks [334,335]. 
  
3.2.2 In Angiogenesis 
Another often overlooked factor when making the transition between 2D and 3D 
culture is the effect of dimensionality on the efficacy of angiogenesis in a growing tumor.  
Angiogenesis is the formation of new blood vessels, a process that is vital for growing 
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tumors.  As tumors grow in size they require an enhanced system of vascularity in order 
to efficiently deliver oxygen to the regions on the tumor that are unable to absorb oxygen 
via simple diffusion through the tissue [117].  Study of cells in monolayers in 2D ignores 
the spherical nature of tumorigenic growth, and therefore do not fully recapitulate the 
hypoxic dilemma that normal cell masses encounter after a specified growth period [336–
338].  Culture in 3D has also shown to enhance the onset of angiogenesis through an 
increase in integrin engagement with the substrate as a result of spherical versus planar 
architecture [339,340].  This planar format of 2D cells also fails to capture angiogenic 
signals that are presented in the form of mechanical stresses due to flow or cell pulling 
[341].  Finally, metastatic signals that enhance angiogenesis are often conveyed through 
simple cell density measures felt by a growing tumor, a characteristic that is not 
reproducible in 2D culture [342].  
  
 3.2.3 In Cell Migration and Metastasis 
 A discussion regarding cancer and its progression would be egregiously 
incomplete without mention of what is highly regarded as the crux of the ongoing 
struggle to treat cancer, cell movement and metastasis.  While treating localized cancer 
legions has become a somewhat manageable process, after metastasis of the primary 
tumor the disease becomes inordinately more difficult to contain.  Metastasis is a 
multistep process in where cells from the primary tumor first distance themselves, either 
genetically, phenotypically or both from the overall cell mass.  Reacting to either ECM or 
chemokine signals, these cells break away from the tumor mass and extravasate into the 
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blood stream, intravasate back through the vasculature at a new tissue site and either 
undergo necrosis, lay in a quiescent state, or begin to proliferate into a new tumor [343].  
Much of this relies upon the underlying state of the cell, and the framework of the ECM 
where the cell relocates [137].   
 Metastatic cells that release from the primary tumor oftentimes present a slightly 
different pheno- and or genotype from the original cell mass [117,344].  Making matters 
worse, those cancer cells that do survive travel through the blood stream or lymphatic 
system and begin to divide in another organ of the body are altered from their parent cells 
due to the new environment that they have adopted [137,345].  As a result, these new 
growth sites are often much more resistant to chemotherapy and complicate overall 
cancer treatment [346–348].   
 As highlighted through the enigmatic process of metastasis, a thorough 
understanding of cell migration at its basic level is critical toward capturing the entire 
picture of cancer progression.  The migration of individual cells is a multistep process in 
which the cell polarizes, extends pseudopodia out from the leading edge, creates a 
traction force via actin and myosin contraction within the cell body, and retracts its rear 
end to release the previous adhesions and propel the cell forward [349].  Including this 
dogma of cell movement, much has been revealed through analyzing cell migration on 
2D surfaces [214,350,351].  However, there are few, if any, physiologically relevant 
situations in which cells encounter a two-dimensional migration space.   
 Cells migrating in 3D matrices have been reported to exhibit smaller lamellipodia 
and reduced Rac activity, leading to less aggressive, but more directed cellular 
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movements [352,353].  In addition to these phenomenological changes in migration 
characteristics, 3D matrices tend to offer different ECM cues such as a more pliable, 
heterogeneous matrix leading to directed movement via durotaxis, and changes in 
integrin-ECM interactions [333,354].  3D environments also introduce physical barriers 
not seen in 2D environments.  As a result, many cells exhibit proteolytic dependent 
migration requiring MMP degradation in order to fit through matrix pores, while also 
adapting to an amoeboid form, a method of migration completely absent in 2D  
[262,355]. 
 
3.3 3D Assays 
 With an appropriate appreciation for the role of dimensionality in cell behavioral 
processes including migration, it is of no surprise that 3D assays have garnered 
significant attention.  There currently exists several methodologies to assay migration in 
3D; however, the increase in biomimicry is met with raised cost and complexity.  All of 
these assays utilize one of the many methods to culture cells in 3D.  Cell suspensions can 
be grown in 3D in animal derived or synthetic matrices.  Matrigel, a decellularized 
reconstituted basement membrane derived from mouse, provides a porous gel like 
solution by which cells can be embedded.  The nascent protein expression in the gel 
promotes cell survival and growth, however, the exact protein content is unknown and 
can vary from batch to batch [356].  Similarly to Matrigel, purified collagen is often used 
to create gels for 3D culture.  While not providing the extensive protein variety of 
Matrigel, collagen matrices are better defined and represent a large portion of 3D culture 
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techniques [357].  Synthetic hydrogels formulated via polystyrene and PEG are extremely 
versatile for their customizability [358].  These scaffolds can be well characterized and 
tuned to achieve desired matrix stiffness and ligand density.    
When embedded in a 3D matrix, cells can either be cultured as a single cell 
solution similar to 2D, or formed into a spheroid to further advance the in vivo-like nature 
of the culture system.  Cell spheroids are commonly formed through culture in low 
adhering well plates or the hanging drop method.  Low adhering well plates are similar to 
other small well plates for the exception of a rounded bottom that fails to react with 
adhesion proteins on the cell surface.  This lack of cell-substrate adhesion enhances the 
cell-cell contacts, influencing the cells to form a spheroid shape [359].  The hanging drop 
method consists of culturing a small population of cells within a drop of liquid and 
inverting the solution such that the cells are suspended within the drop, hanging from the 
bottom of a plastic contact [360].  While this method seems rather crude, several 
commercial systems have been developed to standardize the process reducing variability 
between batches and avoiding unstable drop formation.  Spheroids can also be formed via 
culture in other low adhesive settings such as agarose gels [361].  These cell spheres can 
then be studied, or transplanted into traditional 3D culture matrices such as collagen.  
Although 3D cell culture represents a much more biologically relevant scenario for cells, 
drawbacks of such approaches stem from both monetary cost and time.  Collagen gel and 
similar derivatives are significantly more expensive than simple tissue culture plastic.  
Culturing efforts using these techniques are also more time intensive with seeding and 
gelation times ranging from hours up to overnight.  There also does not exist a 
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standardized subculturing method for cells that are harbored in gels.  These shortcomings 
while substantial may be alleviated with increasing attention toward 3D culture. 
Successful 3D culture techniques serve as the host for several migration assays.  
The most basic of such approaches is the vertical gel invasion assay.  In order to assess 
invasive potential, cells are plated either on top or underneath a layer of matrix.  Ensuing 
invasion is quantified by sectioning the matrix and staining the cells.  The setup of this 
method is rather simple, however gathering results can be labor intensive and one can 
only assay the cells at a single time point.   This model can be extended to observe cell 
spheroids as well.  Clusters cultured within 3D matrices can be allowed to grow and those 
cells that leave the mass can be examined via staining [362–364].  This assay is 
particularly relevant in the study of cancer.  Spheroids can be produced to mimic those of 
incipient neoplastic growths, and conditions varied to assay cluster disaggregation and 
extracellular tissue invasion.  Both single cell invasion and spheroid methods can be 
improved via a process also widely used in the study of 2D migration, real time cell 
tracking.  This is accomplished via whole cell stains and time lapse microscope 
visualization.  Stained cells in 2D, existing as single cells or branching out of a cluster in 
3D are visualized through sequential image acquisition lasting on the order of minutes to 
hours.  Image analysis then allows for the construction of cell tracks as a function of 
acquisition time.   Cell tracking captures more sophisticated data than simple end point 
displacement including instantaneous speed, cell persistence, patterns of leader cell 
behavior in collective migration, and cell-cell interactions [365,366].  Of particular 
interest is the persistence time of cells.  This unit of measurement is derived from the 
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worm like chain model that describes the persistence length of polymers to be the 
distance at which correlations in the direction of the tangent are lost.  Quantification of 
the persistence length is related to the persistence time in cells through derivation of the 
persistence length in the time domain, thus solving for persistence time rather than 
persistent length.  Persistence time is therefore the time span through which a traveling 
cell no longer exhibits correlated movement with its past movements.  For a traveling 
cell, the velocity of successive movements can be expressed as an autocorrelation: 
𝑅(𝜏) ≡ ⟨𝑣(𝑡 + 𝜏) ⋅𝑣(𝑡)⟩  Equation 3.1 
Where 𝑅(𝜏) is the autocorrelation of the cell velocity 𝑣 at a given time 𝑡 as a function of 
time step 𝜏.  It can be shown that the autocorrelation of the velocity follows an 
exponential decay: 
𝑅(𝜏) = 𝑆2𝑒−𝑡/𝑃 Equation 3.2 
Where 𝑆 is the cell speed and 𝑃 is the persistence time.  To relate the persistence time and 
speed to cell tracks, one can derive the equation for the mean square displacement for a 
migration cell to be: 
⟨𝑑2(𝑡)⟩ = 2 ∫ 𝑑𝑡 ∫ 𝑅(𝜏) 𝑑𝑡
𝑡
0
𝑡
0
   Equation 3.3 
Where ⟨𝑑2(𝑡)⟩ is the mean square displacement of a cell track with respect to time.  
Integration leads to the relationship: 
𝑀𝑆𝐷 = 2𝑆2𝑃(𝑡 − 𝑃 (1 − 𝑒−
𝑡
𝑃))  Equation 3.4 
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Where 𝑀𝑆𝐷 is the mean square displacement of a given cell track.  Using curve fitting 
techniques to a known cell mean square displacement track, the speed and persistent time 
can then be derived using this method [365,367–369]. 
  This enhanced view of cells in 3D does however come with a cost.  For accurate 
visualization in 3D, fluorescent probes are common, necessitating the use of confocal 
microscopy to accurately portray signal in the z-direction.  Acquiring data using this 
method also requires much more time than other simpler assays to probe migration in 3D.  
Despite these fairly common methods to probe migration in 3D, there remain no widely 
used standard methods such as the scratch wound assay for 2D migration.  As a result, 
migration assays generally are constructed by the user for a specific application.  
Currently, the same remains true for culture methods in 3D as well.  There exists no 
standard, commercially available method for 3D culture just as there is no standard 
method for the study of migration.  The increasing trend for more 3D culture to better 
mimic in vivo settings will perhaps in the future demand a standard technique by which 
researchers can normalize their studies. 
 
3.4 Computational Models 
A perhaps underappreciated and overlooked aspect of studying cell-matrix 
interactions in 3D is computational modeling.  Migration models represent a wide array 
of computational techniques to describe specific processes such as cell protrusion, up to 
the movement of entire cell sheets. One may also include under the umbrella of migration 
models works that study signaling pathways known to govern the process of migration. 
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Although frequently oversimplified, these computational approaches present methods to 
understand how cells behave in 3D as a function of many interdependent variables.  They 
also provide a means by which to predict cellular behavior under specific conditions on 
both a single and multi-scale level.  Given the complex nature of cell migration and the 
multitude of reactions and forces occurring simultaneously during this process, 
computational models often differ greatly in how they approach the problem of 
reconstructing a framework to accurately portray systems in vivo.   
Currently, many models have focused on the physical process of migration, 
studying the actin network, cell protrusions, and adhesion characteristics [370–372]. 
While models of molecular signaling pathways have been widely implemented, their 
introduction into the realm of migration has been less frequent or concentrated on a 
specific sub-process of migration such as adhesion or protrusion [373–377]. This can 
potentially be attributed to the lack of established techniques to monitor cell signaling in 
the spatial and temporal scales of most migration models. As imaging techniques 
advance, more migration models may incorporate protein signaling to accompany 
physical characteristics of migration such as adhesion, matrix viscosity, and cell stiffness.  
Despite such difficulties to assimilate protein transduction into the computation realm, 
the marriage between real-time protein signaling and migration is being implemented in 
models [280,378]. Models have also incorporated signaling into the process of migration 
using decision trees or Bayesian networks [379–381]. These models translate observed 
signaling patterns to distinct migration behaviors using a priori knowledge. 
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Other model systems are used to recreate cell migration and interaction with ECM 
fibers.  Treating the system as a force based model, cell migration speed and direction 
can be simulated.  In this type of approach integrin-ligand reactions are translated into 
traction forces.  The asymmetry of focal adhesions between the front and rear of the cell 
account for directional movement, counteracted by a viscous ECM [382].  Stochastic 
models base cell movement on random speed samples from a Gaussian distribution and 
can predict how persistent cells will migrate based on population [383].  Implementing 
Monte Carlo methods allow for recreation of cell migration on a larger scale, and present 
a more bulk analysis [384].  Models can also be used to predict how cells will grow and 
interact with the ECM based on several cues such as nutrient composition.  Visualizing 
the cell as a spheroid capable of shape change, a model has been created to simulate cell-
cell interaction forces, and forces present between cells and the ECM to depict a cell 
mass growing [385].  This has implications in tumor growth and also addresses how cells 
depend on metabolic factors diffusing in 3D.  On the molecular scale, models have been 
able to quantitatively describe integrin clustering on the cell surface and describe their 
attachment to collagen fibers, providing insight into a system that is incredibly 
challenging to probe in vitro [386].  Finally, using experimental kinetic parameters, ECM 
degradation can be quantitatively modeled [387].  While modeling cancer and its many 
effectors is still a field in its infancy, the potential for simulations to predict how cells 
react to specific cues on either a cellular or tumor basis is enticing.  As models continue 
to develop and become more complex, they stand to play a larger role in clinical 
applications.  
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CHAPTER FOUR: CANCER CELLS EXHIBIT A BIDIRECTIONAL 
RELATIONSHIP WITH ECM STRUCTURE 
 
4.1 Introduction 
 Current strategies to treat or manage cancer revolve around understanding and 
controlling metastasis.  While primary malignancies still require great care and advanced 
treatment options the overwhelming majority of cancer deaths are related to the spread of 
the primary tumor to distant sites.  Metastasis is a multi-step process that begins in the 
primary tumor where individual or a small collective of cells separate themselves 
physically and in many times genotypically from the original cell mass.  After escaping 
from the parenchyma through the basement membrane and connective tissue, cells 
intravasate the vasculature and attach at distant sites.  If the cell is able to survive this 
passage and the ECM conditions at the external site are favorable, extravasation out of 
the vasculature will occur with a newly populated tumorigenic site being established 
[344].  As one may expect, in order to accomplish this feat a myriad of biological 
processes must be coordinated, including adhesion arrest, ECM degradation and 
remodeling, resistance to immunogenic response mechanisms and a proclivity for 
hypersensitivity toward chemokines or ability to self polarize and direct migration 
[345,346].   While all of these underlying processes have been studied in an effort to 
uncover the underworking of metastasis, most discoveries have taken place in a 2D 
planar geometry.  Unfortunately, several studies have uncovered that while 2D cell based 
assays are extremely valuable they may ignore the role of dimensionality in cellular 
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behavior [332,333,335].  As such, a recent influx of work based in 3D networks, most 
commonly collagen gels, have been undertaken.  
 Of particular interest in 3D matrices is the action of matrix metalloproteinases 
(MMPs).  This family of cell secreted soluble zinc dependent endopeptidases cleaves 
both matrix fibers and extracellular domains of transmembrane proteins.  MMPs are 
important in several cellular processes including development, wound healing, and 
migration.  Their capacity to degrade ECM proteins has also made them indispensable for 
highly motile cells including malignant cancer [118,254].  Indeed, many cancers have 
displayed uncharacteristic upregulation of MMPs that have been postulated to influence 
the microenvironment of tumors and break down basement membrane to allow for 
metastasis to progress [255,256].  Two sub forms of MMP, MT1-MMP and MMP-2, are 
extremely pertinent to each other and cancer cell behavior and remodeling in 3D collagen 
gels.  MT1-MMP, a transmembrane MMP is directly responsible for the activation of 
itself and MMP-2 as well as harnessing the ability to cleave extracellular matrix domains 
of growth factor receptors and glycoproteins [274,388].  MT1-MMP has also been shown 
to localize at the leading front of migrating cells as is in many cases necessary for cell 
migration and invasion [328].  The target of MT1-MMP, MMP-2 is mainly responsible 
for degradation of collagen byproducts and has been shown to be upregulated in cancer 
[255].   While these and many other MMPs have been widely studied, their interaction 
with the ECM in 3D matrices is less certain.  In particular, a quantitative measure of how 
MMPs influence matrix architecture is lacking.   
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 In addition to understanding how MMPs influence the ECM in a quantitative 
manner, one must consider that biological processes rarely operate in a unidirectional 
manner.  Feedback loops and alternative pathways continuously influence cellular 
behavior and the interaction between MMPs and their microenvironment is no different.  
Indeed, several reports have documented the role of substrate stiffness and matrix 
composition on the secretion of MMPs by cells, indicating that the ECM may directly 
influence MMP activity [389–391].  The properties of the ECM that could potentially 
affect MMP output can be altered in several ways outside of direct action by MMPs 
themselves.  Tissue transglutaminase (tTG), an enzyme responsible for crosslinking 
proteins between lysine and glutamine residues, may be introduced to the ECM from 
foreign cell types and plays a role in cell adhesion and ECM stabilization [392,393].  
Increased action of tTG is often associated with stiffer tissues and deregulation of this 
enzyme is commonly seen in inflammatory diseases such as cancer and celiac disease 
[394,395].  tTG mediated crosslinking has also been shown to aid in cancer progression 
via integrin mediated adhesion [97].  The interplay between both MMP function and 
ECM architecture suggests that a bidirectional relationship may exist between the two.  
Unfortunately, no previous work has detailed how MMPs and specific ECM properties 
can quantitatively form a bidirectional relationship in 3D. 
 In this chapter we aim to uncover the bidirectional relationship between MMP 
activity and matrix architecture in 3D.  In order to accomplish this feat we have 
developed an assay based on confocal reflectance microscopy (CRM) to quantify matrix 
remodeling as a function of MMP activity.  In doing so we are able to determine in what 
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manner and to what extent MMPs influence specific properties of 3D collagen gels.  To 
address how the ECM may control MMP related behavior we have utilized the tTG 
enzyme to crosslink collagen gels and observe the role of 3D substrate stiffness and 
integrin engagement on MMP expression and activity. From our data we are able to 
conclude that a significant self-regulatory bidirectional relationship exists between the 
ECM and MMPs in a quantitative manner when cultured in 3D collagen gels.  Our results 
enhance the knowledge base of the growing field of 3D collagen cell culture as well as 
provide a phenomenological framework for the feedback mechanisms cells utilize in a 
quantitative fashion.  
   
4.2 Materials and methods 
 
4.2.1 Cell Culture  
Prostate cancer cell lines PC-3, DU-145 and LNCaP (American Cell Type Culture 
Collection, ATCC).  PC-3 and DU-145 cells were cultured in F12K media and LNCaPs 
in RPMI-1640 (ATCC).  All media were supplemented with 10% v/v fetal bovine serum 
(FBS, ATCC) and 1% v/v penicillin/streptomycin (10,000 IU/mL penicillin, 10,000 
µg/mL streptomycin, ATCC) and maintained at 37°C and 5% CO2. 
 
4.2.2 Collagen Gel Preparation and tTG Crosslinking 
Gels were prepared by mixing the appropriate volumes of collagen type I, from 
rat tail tendon (BDBiosciences), media, and neutralizing solution (100mM HEPES, pH 
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7.3 in 2X PBS).  For samples in which crosslinking was not used, cells were embedded 
directly into the gel during polymerization for 30 minutes at 37°C, 5% CO2 at 200,000 
cells/mL.  Due to the toxic nature of tTG exposure, for all cross-linked gels (and those 
gels used as comparative controls to cross-linked samples) cells were placed on top of 
pre-polymerized gels as follows. Cross-linking was induced by tissue transglutaminase 
from guinea pig liver (Sigma), dissolved in 2mM DTT and 5mM CaCl2 in 10mM Tris, 
pH 7.4. The tTG enzyme solution was added to the collagen gel mixture immediately 
before gels were poured. Samples were prepared using collagen:enzyme (w/w) ratios of 
5,000:1 (0.00084 Units of enzyme) or 500:1 (0.0084 Units). The gels were plated in 
35mm polystyrene culture dishes and polymerized for 30 minutes (37°C, 5% CO2).  At 
this juncture cells were introduced to the apical surface of cross-linked gels at 250,000 
cells/mL gel. For gels used in cell migration experiments 2.0 μm carboxylated, yellow-
green fluorescent polystyrene tracer beads (Molecular Probes) were added to the gel 
solution prior to plating the gel solution in glass bottom 35mm dishes.  
Matrix stiffness was quantified in terms of bulk elastic modulus, G’, of the 
collagen gel. Gel stiffness was measured with a Physica MCR 300 rheometer operating in 
cone & plate mode, stressed at 0.5 μN·m oscillatory torque over a frequency (ω) range of 
0.1 – 10 Hz. Measurements of elastic modulus for each gel concentration were averaged 
and then fit to a power-law equation of the form, 
𝐺′ = 𝛼𝜔𝛽 + 𝛿 at 𝜔 = 1 𝐻𝑧   Equation 4.1 
 
4.2.3 Scanning Electron Microscopy 
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Polymerized gels were fixed and stained using tannic acid, gluteraldehyde, and 
osmium tetroxide (TAGO) fixation. Samples were dehydrated using ethanol exchange 
and dried via critical point drying (CPD). Samples were sputter coated with a 15nm layer 
of Pt/Pd and visualized using a Zeiss Supra 40 VP Scanning Electron Microscope. Three 
gels from each condition were imaged. A total of three images were taken from three 
different tilt angles. To determine pore size, images were skeletonized and converted to 
binary images using ImageJ software and calculated as an average cross-sectional 
diameter of pores as displayed from SEM images, as previously described.  A total of 90 
pores were measured from images of each condition. SEM images were also utilized to 
visually assess the formation of crosslinks after tTG treatment. 
 
4.2.4 Confocal Reflectance Microscopy 
To assess the microstructure of the gels, CRM was performed using a scanning 
confocal microscope (Olympus FV1000) with a 60× 1.2 N.A. water immersion lens for 
empty gels and those seeded with either DU-145 or LNCaP cells.  The basis by which 
CRM allows for the visualization of collagen fibers is as follows.  Collagen plated in 
glass-bottom dishes is excited with a low intensity 488 nm laser and the reflected light 
between 485-495 nm light was collected.  Reflected laser light produces an image of the 
collagen fibers similar to more traditional fluorescent microscopic techniques, instead of 
collecting light from excited fluorophores, the intensity of incident reflected light is 
measured. Images were acquired at least 100 μm into the gel to avoid edge effects. For 
the control gels that were not seeded with cells, three 30 μm stacks with 0.5 μm-thick 
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slices were obtained from randomly selected regions in the gel 1, 3, 5, and 7 days after 
plating. At each time point, for each gel that was seeded with cells, three stacks were 
taken in regions containing cells and three stacks were taken in regions that did not 
contain cells (i.e. had no cells within 10 μm above, below, or laterally). Regions with and 
without cells were identified by performing confocal fluorescence microscopy (CFM) 
simultaneously with CRM. For CFM, a 543 nm laser was used with the settings for the 
excitation/emission spectra of Alexa Fluor 546. In cellular regions, a CFM image of the 
cells was obtained in parallel with the CRM image of the collagen structure. The same 
microscope settings were used for each acquisition to ensure that results were 
comparable. 
To assess the influence of MMP activity on CRM quantified collagen properties, 
after 2 hours gelation all gels were treated with 50 µM Marimastat in complete media and 
supplemented with 100 µM Mariamstat every 24 hours thereafter for 3 days.  During this 
time CRM images were obtained. 
 
4.2.5 Quantitative Gelatin Zymography 
Gelatin zymography was utilized to compare MMP activity between cells lines 
and conditions. LNCaP, DU-145, and PC-3 cells were plated and grown to near 
confluency before incubation with serum-free media for 24 hours. Media was extracted 
from cultures, and concentrated via ultracentrifugation for 30 min (10kDa cutoff). 
Samples were then mixed with Laemmli loading buffer without a reducing agent and 
subjected to gelatin zymography as previously described [396]. Briefly, samples were 
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loaded into a polyacrylamide gel co-polymerized with 0.1% gelatin and subjected to 
electrophoresis. Gels were then transferred to an aqueous solution containing 2.5% 
Triton-X100 to renature the proteins, followed by equilibration in a developing buffer 
(50mM Tris, pH 7.8, 200mM NaCl, 5mM CaCl2, 0.02% Brij-35) and subsequent 
incubation at 37°C for 20 hrs. Gels were finally stained and destained with Coomassie 
blue. After destaining, gels were dried overnight using a gel drying kit (Promega). Areas 
of proteolytic activity are expressed as clear bands against a stained background. Gel 
images were processed with ImageJ and thresholded to acquire appropriate pixel values 
for both MMP-2 and MMP-9 followed by normalization by original cell concentrations. 
The experiment was performed in triplicate.  
 
4.2.6 Pore Size and Fiber Diameter Quantification 
Raw CRM data was analyzed to obtain collagen structural parameters. The same 
processing settings were used from image to image to ensure consistency. Fibril fraction 
and pore size were obtained with ImageJ. Briefly, 2D images from 74 each stack were 
binarized, with collagen fibers indicated by black pixels. The binarized images were then 
used to calculate the fraction occupied by collagen, similar to what has been previously 
reported [397]. Pore size was measured by drawing three lines (horizontal, vertical, and 
diagonal, avoiding cells when they were present) across the binarized image in the center 
of each stack, and using the plot profile function in ImageJ. A script was written in 
MATLAB (MathWorks) to calculate the distance between collagen fibers from this 
profile data. This again is similar to what has been performed before [398].  
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Fiber diameter and length was determined using Imaris (Bitplane). A rough 
surface mask was initially made from the raw CRM data, from which a smooth surface 
was generated. The objects created with the resulting smooth surface each represented a 
collagen fibril and statistics on the radius and half length of each fibril were output. 
 
4.2.7 Cell Migration and Invasion 
All experiments probing motility were performed using the PC-3 cell line. Cell 
invasion was quantified using a transwell assay modified to include collagen gel inserts.  
tTG cross-linked gels were plated in 6.5 mm transwell, 8μm pore polycarbonate inserts 
(Corning) and allowed to polymerize for 1 hour at 37°C, 5% CO2. Gels were then rinsed 
with PBS to remove unreacted tTG and cells plated on top of the gels.  In order to 
influence transmigration through the chamber, serum free media was placed on the apical 
side of the gels, while media containing FBS was used blow in the insert in the chamber 
housed by the bottom of the well and the well insert.  Cells were allowed to migrate 
across the porous barrier for 72 hours at which point gels were removed from the well 
leaving only those cells that had successfully migrated across the porous barrier. 1x 
Calcien AM dye (Sigma) solution was used to stain the cells and absorbance 
measurements were obtained to quantify relative invasiveness.   
To assess cell migration speed, adherent monolayers were stained with 
fluorescent cell tracker Red CMPTX (Molecular Probes) cell stain per manufacturer’s 
directions and subsequently trypsinized using 0.25% Trypsin/0.53mM EDTA. Cells were 
imaged 12 hours after initial plating atop collagen type-I matrices. Time-lapse image z-
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stacks were collected at 15-minute intervals for a total of 12 hours using an EC Plan 
NEOFLUAR 20x/0.5 objective on a LSM5 Live Duoscan (Carl Zeiss, Thornwood, NY). 
Z-stack images were collected at a total thickness varying between 120-140 μm at 
intervals ranging between 1.50-1.70 μm. During imaging, culture environments were 
maintained at 37°C, 5% CO2 within a microscope-mounted incubation chamber. Cell and 
bead trajectories were generated using the spot detection and position tracking options of 
Imaris analysis software (Bitplane). Extracellular tracing beads were included in analysis 
to account for overall sample drift during imaging acquisition. To calculate cell migration 
speed, autoregressive cell tracks were constructed and used to calculate cell speeds and 
displacements from raw position data; total track length was divided by the total time 
each cell was detected within the image field of view. The sample drift was accounted for 
at each time interval such that sample drift is not reported for in overall population cell 
speed. 
 
4.2.8 Flow Cytometry 
Live cell staining of serum-starved PC-3 cells cultured atop 3D gels was 
performed as follows. Following 3 days of culture, cells that had invaded the gels were 
harvested for flow cytometry analysis. Briefly, gels were digested with 10 Units of 
Collagenase I (Gibco) per 1.0 mg/mL of collagen suspended in Cell Dissociation 
Solution for 30 minutes at 37°C. For direct staining, cells were resuspended in ice cold 
staining buffer (10% dialyzed FBS in DPBS) and stained for integrin β1 or integrin α3 
using 1μg/million cells of FITC or PE conjugated primary antibodies (SCBT). Cells were 
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rinsed and resuspended in ice-cold DPBS prior to analysis. For indirect staining, primary 
antibodies (mouse MT1-MMP or rabbit FAK (C20) (SCBT)) were diluted in staining 
buffer using 1μg/million cells. Cells assayed for intracellular proteins were permeabilized 
and fixed. Secondary antibody staining was performed with 1μg/million cells of goat 
anti-Ms IgG AlexaFluor 647 (Invitrogen) or goat anti-Rb IgG PerCP (SCBT) conjugated 
antibodies. Cells were resuspended in ice-cold DPBS prior to analysis.  Stained cells 
were analyzed using a BD FACS Calibur Flow Cytometer. 
 
4.2.9 Blocking of Integrin β1 
Integrin β1 expression was inhibited in PC-3 cells using the anti-CD29 antibody, 
mAB 4B4 (Beckman Coulter) at a concentration of 10μg/mL, a concentration shown to 
block ~95% of available integrin β1 receptors [399]. The 4B4 antibody was added to the 
3D cell culture collagen matrix mixture prior to plating. 
 
4.3 Results 
 
4.3.1 Collagen gel pore size, fiber density, and stiffness are influenced by collagen 
concentration and tTG enzyme activity 
In order to properly gauge the bidirectional relationship between MMP activity 
and collagen gel ECM properties, empty gels were first characterized as a result of 
protein concentration in the gel mixture and in response to tTG crosslinking.  CRM 
images show that increasing the concentration of collagen within the gel mixture results 
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in a denser configuration with individual fibers much less overtly visible at higher 
concentration matrices (Figure 4.1).  Resulting image analysis confirms visual inspection 
of the data, showing decreasing pore sizes and an increasing fibril fraction as the 
concentration of collagen gels is increased.  The relationship between pore size and fibril 
fraction with collagen concentration is maintained throughout the time span of the study, 
up to 7 days (Figure 4.2). 
 Similar results are observed for those gels treated with tTG crosslinker.  SEM 
images of collagen gels displayed a decrease in pore size as tTG concentration is 
increased in the gel mixture.  At high doses of tTG crosslinker, 2 mg/ml gels more 
closely mimicked a higher concentration 3 mg/ml gel than those 2 mg/ml gels without 
tTG treatment (Figure 4.3).  Quantification of SEM images confirmed these qualitative 
observations.  Crosslinking at 0.0084 and 0.0084 Units of tTG resulted in a decreased 
pore size in comparison to untreated 2 mg/ml gels.  In fact, high concentration of tTG 
was able to induce significantly smaller pore sizes than their 3 mg/ml counterparts 
(Figure 4.4B). Increasing crosslinks in 2 mg/ml gels also had an effect on the stiffness of 
gels.  Rheometry measurements showed that tTG treatment was able to increase the 
elastic modulus of 2 mg/ml gels in a dose dependent manner up to and slightly surpassing 
that of 3 mg/ml gels (Figure 4.4A). 
 
4.3.2 MMPs directly govern differential matrix remodeling effects of DU-145 and 
LNCaP cells 
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 The bidirectional relationship shared between MMP activity of cells and ECM 
properties was first probed in 3D by studying the effect of cancer cell MMP extrusion on 
the quantified measures of matrix pore size and fibril fraction.  Interestingly, DU-145 and 
LNCaP cells altered matrix pore size and fibril fraction differentially.  DU-145 cells 
increased the fibril fraction as well as decreased the pore size of 2 mg/ml gels.  However, 
at concentrations of 3 mg/ml and 4 mg/ml DU-145 cells did very little to alter the gels in 
any way with the least amount of matrix recomposition occurring in the 3 mg/ml samples 
(Figure 4.5).   
LNCaP cells displayed the opposite preference for collagen gels.  In contrast to 
the DU-145 cells, the least amount of matrix recomposition was done at 2 mg/ml.  In this 
scenario, LNCaP cells altered fibril fraction minutely; they did however, decrease the 
pore size of gels at 2 mg/ml.  Despite this fact, the 2 mg/ml collagen density was easily 
the least remodeled gel of the LNCaP group, with 3 and 4 mg/ml gels showing greater 
changes in both fibril fraction and pore size in comparison to control gels.  Unlike DU-
145 cells which, in their most active state (2 mg/ml gels) increased fibril fraction and 
decreased pore size, LNCaP cells proved to do the opposite, decreasing fibril fraction and 
increasing pore size in their most active states (3 and 4 mg/ml gels) (Figure 4.5).  Overall, 
DU-145 cells seemed to alter collagen gels to more closely mimic the properties of 3 
mg/ml gels, while LNCaP cells seemed to remodel gels to achieve a pore size and fibril 
fraction closer to that of 2 mg/ml gels.  Time dependent quantification of pore size and 
fibril fraction showed that initial seeding of cells produced an equilibrium in matrix 
remodeling after approximately 3 days in culture.  Therefore, while these trends are 
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initially time dependent, they indeed stabilize and can be measured after an appropriate 
time lag (Figure 4.6-8). 
 
4.3.3 Matrix remodeling by DU-145 and LNCaP cells is a MMP dependent process 
The extent by which MMPs contribute to the observed changes in pore size and 
fibril fraction in collagen gels was tested using the broad based MMP inhibitor 
Marimastat and quantitative gelatin zymography.  Zymograms performed on conditioned 
media displayed several differences between MMP expression between DU-145 and 
LNCaP cell lines (Figure 4.9A).  Quantified and normalized values of expression showed 
that DU-145 cells possessed a significantly higher amount of active MMP of both MMP-
2 and MMP-9 subspecies.  Observation of latent, non-active form of MMP-2 showed that 
DU-145 cells more preferentially expressed the active versus inactive MMP-2 while a 
large portion of MMP-2 in LNCaP cells was of the inactive form (Figure 4.9B). 
Administration of Marimastat at 3 and 4 mg/ml densities for both DU-145 and 
LNCaP cell lines indicated that the ability for both lines to effectively remodel collagen 
gel fibril fraction is disrupted when MMPs are blocked.  At 4 mg/ml, cells cultured with 
the inhibitor Marimastat displayed a decrease in the fibril fraction of gels compared to 
gels seeded with cells alone.  Paradoxically, Mariamstat at 4 mg/ml in both DU-145 and 
LNCaP samples decreased the fibril fraction to a value lower than that of gels seeded 
without any cells.  These effects, however, were not seen at 3 mg/ml for either cell line 
(Figure 4.10). 
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4.3.4 tTG mediated collagen gel crosslinking induces expression of MMPs and cell 
migration in a biphasic manner 
While the effects of MMPs on ECM remodeling firmly showed that MMP activity 
can influence ECM structure, in order to establish a quantified bidirectional relationship 
between the two in 3D, changes in the ECM structure must have the ability to alter MMP 
activity as well.  To test if ECM properties can have an effect on MMPs, alterations in 
ECM crosslinking were induced and subsequent MMP activity was measured.  As 
reported previously and depicted in Figure 4.4, tTG concentration was able to increase 
collagen stiffness and decrease pore size of 2 mg/ml gels in a dose dependent manner 
(Figure 4.4).  In fact, at both low (0.00084 Units) and high (0.0084 Units) levels of tTG, 
2 mg/ml gels shared a similar range of stiffness with that of 3 mg/ml gels.   
Increased gel crosslinks induced by tTG increased MMP-2 levels in concentrated 
conditioned media of PC-3 cells in a biphasic manner.  While 2 mg/ml gels showed a low 
level of MMP-2 expression, tTG at 0.00084 Units increased both inactive and active 
forms of MMP-2 to levels greater than 3 mg/ml gels.  However, increased tTG 
concentration at 0.0084 Units did not further augment this effect but rather decreased the 
amount of MMP-2 in conditioned media to a value lower than both 2 mg/ml with 0.00084 
tTG and 3 mg/ml gels.  Therefore, while increased crosslinking was initially able to 
greatly induce MMP-2 activity, too many gel crosslinks negated this effect (Figure 4.11, 
4.12).  This biphasic effect on MMP-2 levels mediated by tTG crosslinking was also 
observed for another MMP subspecies, MMP-14.  The pattern of expression as measured 
by FACS analysis was identical to that of MMP-2 (Figure 4.13A). 
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The biphasic increase in MMP activity as mediated by tTG crosslinking also 
translated to cell migration.  Cells invading through a transwell membrane coated with a 
collagen layer saw the greatest number of cells pass through in the 2 mg/ml, 0.0084 Unit 
tTG condition.  The pattern of invasion closely mimicked that of MMP induction (Figure 
4.14A).  This effect was seen to a lesser extent when probing instantaneous migration 
speeds (Figure 4.14B). 
 
4.3.5 Effects of collagen crosslinking on protein expression and cellular behavior is 
dependent on integrin β1 adhesion 
 Due to the fact that signals from the ECM are in many cases transmitted from 
mechanical to chemical signals via integrin receptors, the hypothesis that integrins may 
mediate the effects of tTG crosslinks on PC-3 cells was tested using an anti-integrin-β1 
antibody.  Culture of cells with 10 µg/mL anti-integrin-β1 4B4 clone was able to reduce 
MT1-MMP expression on cell membranes as measured via FACS (Figure 4.13B).  
Integrin inhibition was also able to completely ablate instantaneous speed of cells 
migrating on gels (Figure 4.14B).  Finally, relative measures of integrins on the surface 
of PC-3 cells were measured to ensure that integrin-β1 was indeed highly expressed by 
this cell line.  FACS analysis concluded that the β1 form of integrin was expressed as 
well as α1 and α2 forms, comprising the main integrin subunits that when paired provide 
the most common means for cells to bind collagen fibers (Figure 4.15). 
  
4.4 Discussion 
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As current technologies advance with an eye toward closing the gap between in 
vitro culture techniques and in vivo cellular environments it is imperative to develop an 
understanding as to how new biomimetic culturing techniques influence cellular 
behavior.  At the center of the growing trend toward more in vivo-like tissue culture 
settings are gelatinous 3D matrices, represented most notably by collagen gels.  Drawing 
upon previous research that pins MMPs as a main effector of cell-ECM crosstalk we have 
in this chapter revealed several ways in which there exists a bidirectional relationship 
between ECM properties of 3D collagen gels and MMP activity.  We have also 
developed methods to quantify these effects that MMPs have on the ECM and vice versa. 
   
4.4.1 MMPs influence matrix remodeling by altering fibril fraction and pore size of 
collagen gels 
The first half of the bidirectional relationship between ECM properties and MMP 
activity is displayed through matrix remodeling of collagen gels.  Initial analysis of 
collagen gels at 2, 3 and 4 mg/ml visually confirmed that increasing the concentration of 
collagen within the gel mixture results in a more densely packed gel.  Indeed, at the 
highest concentration of 4 mg/ml, gels are so tightly packed that individual fibers are 
difficult to make out as opposed to the 2 and 3 mg/ml conditions.  Our data showed that 
using CRM techniques we are able to quantify these visual results in terms of pore size 
and fibril fraction and utilize this strategy as a means by which to assay changes in matrix 
composition.   
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Upon embedment into gels, both cell lines were able to manipulate pore size and 
fibril fraction, however, their remodeling patterns were very different.  DU-145 cells 
displayed a tendency to increase fibril fraction and decrease pore size within softer, less 
dense gels (2 mg/ml).  However, in stiffer environments (3 and 4 mg/ml) this was not the 
case with DU-145 cells doing little to alter ECM structure.  This suggests that DU-145 
cells prefer stiffer rather than softer collagen gels, actively remodeling the gels on the 
softer end of the spectrum to mimic those of stiffer gels.  In fact, the resulting fibril 
fraction and pore size of 2 mg/ml gels that were remodeled by DU-145 cells were nearly 
identical to those of the 3 mg/ml condition.  It would seem then that DU-145 cells prefer 
to inhabit matrix densities and stiffnesses offered by 3 mg/ml gels.  However, at 4 mg/ml 
which represents a greater stiffness and density of 3 mg/ml, DU-145 cells do not soften 
their environment by decreasing fibril fraction and increasing pore size but rather accept 
the matrix architecture of the stiffer gels.  Therefore, there may exist a stiffness or density 
threshold of gels that must be met for DU-145s in culture.  If any particular gel is below 
this threshold, DU-145 cells will actively remodel the matrix to meet it; at stiffnesses 
above the threshold no action is necessary.   
The pattern of remodeling displayed by LNCaP cells was in direct opposition to 
the DU-145 line.  These cells tend to more actively remodel the stiffer 3 and 4 mg/ml 
matrices as opposed to the softer 2 mg/ml condition.  Whereas DU-145 cells seemed to 
alter the 2 mg/ml condition to potentially create a stiffer environment by increasing fibril 
fraction and decreasing pore size, LNCaP cells exhibit the opposite response, decreasing 
fibril fraction and increasing pore size in order to soften matrices that are too stiff.  It is 
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also possible to envision a stiffness or density threshold that governs the action of 
proteolytic matrix remodeling in LNCaP cells as well, however, its action is the inverse 
of the DU-145 condition.  Above a certain density threshold, LNCaP cells may work to 
soften the matrix.  Our data suggests this stiffness barrier is between the values 
maintained by 2 and 3 mg/ml gels with an approximate elastic modulus between 20 and 
60 Pa.  For both DU-145 and LNCaP cells, time lapse data of matrix remodeling revealed 
that most if not all of the remodeling occurs between 24 and 72 hours of culture.  After 3 
days, the patterns of pore size and fibril fraction remain relatively unchanged.  This 
indicates further that there is a desired set point at which both cell lines strive to maintain.  
If proteolytic activity was not regulated in this sense, stabilization of such parameters 
would not exist and fibril fraction and pore sizes would continue to be altered almost 
indefinitely.   
Data presented here in the form of zymographic analysis and MMP inhibitors 
finally connect the role of MMPs in matrix remodeling.  Initial screening of MMPs in 
both cell lines displays an expected result.  DU-145 cells exhibit greater expression of 
both active MMP-2 and -9 correlating with the fact that they have been shown to have a 
greater invasive potential than LNCaP cells [400].  Indeed, among malignant prostate 
cancer lesions, high levels of MMPs have been observed, presumably as a means to 
pierce through the highly dense basement membrane [255].  A somewhat curious result, 
however, is the decrease in fibril fraction seen in DU-145 and LNCaP samples upon 
Marimastat treatment.  Clearly, the inhibition of MMPs plays a direct role in matrix 
remodeling, however the blocking of these matrix protein cleaving proteins actually 
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decreases fibril fraction.  This suggests that both cell lines actively utilize MMPs as a 
means to maintain fibril fraction in gels, perhaps through fiber orientation and alignment.  
Due to the fact that CRM is incapable of visualizing fibers oriented in the direction of the 
light [401], it is possible that through the use of MMPs, cells preferentially orient fibers 
perpendicularly to incident light from our system, which also corresponds to an 
orientation that is perpendicular to gravity.   
While this hypothesis holds weight while comparing samples of gels seeded with 
cells treated with or without Marimastat it does not resolve the fact that Mariamstat 
treated samples resulted in a lower fibril fraction than that of empty gel controls.  
However, it is possible that upon MMP inhibition cells alter their preference from a dense 
matrix with fibers aligned perpendicular to gravity to a sparser one with less fiber 
alignment.  Indeed, MMP inhibition has been shown to affect cell-mediated matrix 
contraction as well as collagen deposition [402].  It is by these and perhaps other 
mechanisms that cells abandon dense matrices for sparser ones in the absence of MMP 
activity.  In this sense, our results suggest that MMPs may facilitate the maintenance of a 
dense, fiber aligned matrix and that the absence of such MMP activity can also serve to 
direct cellular behavior by promoting a less dense matrix.  This is supported by data 
indicating that while cancer cells may induce higher MMP expression, cancerous tissue is 
also commonly stiffer and denser than normal parenchyma [403,404].  It can therefore by 
hypothesized that DU-145 cells and to a lesser extent the less invasive LNCaP cells 
utilize MMPs to remodel matrices via collagen deposition and fiber alignment rather than 
degradation of the surrounding collagen as implied by the primary role of MMPs.  
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Conversely, a lack of MMP activity may actually serve as a signal to the cells to promote 
decreased fibril fraction and density within gels.  From this data we have shown how 
MMPs can directly influence the ECM.  However, our data suggests that a bidirectional 
relationship between the two exists. 
 
4.4.2 tTG induced crosslinking influences the expression of MMPs in 3D collagen 
matrices 
 Just as we have shown that MMP activity and expression can affect characteristics 
of the surrounding matrix, our data also suggests that matrix crosslinking can in turn 
influence MMPs.  Adding tTG to collagen matrices during polymerization was able to 
decrease pore size and increase the stiffness up to and surpassing that of 3 mg/ml gels.  
We note here that measurements for pore size using SEM images are different than those 
acquired using CRM image analysis.  We hypothesize that this is due to the alteration of 
collagen gels prior to SEM imaging and the limitations of CRM collagen imaging.  CRM 
imaging, while resulting in quantitation suitable for comparative studies, may lack 
absolute quantitative value due to the fact that only fibers perpendicular to the incident 
light produce reflected light capable of being captured and visualized.   
The change in MMP activity as a result of altered collagen characteristics via tTG 
treatment is apparent upon inspection of active proteases via zymography.  tTG was able 
to influence the activation of MMP-2 in a biphasic manner. Zymography, which is not a 
standardized method for examining protein expression, still allows us to informally 
observe that the total amount of MMP-2 (as indicated by the sum of both the active and 
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inactive states) also follows a biphasic pattern.  Initial increases in activity were met with 
concomitant decreases after crosslinking was induced such that the stiffness and pore size 
of the gels was greater than 3 mg/ml gels.  A nearly identical pattern was observed from 
FACS analysis of MT1-MMP on the cell surface.  The similar pattern seen in MT1-MMP 
corroborates well to the changes in MMP-2 activity due to the fact that MT1-MMP is 
directly responsible for activating MMP-2.  These data indicate that tTG is able to 
increase both expression of MT1-MMP and activation of MMP-2, most likely through 
altering the mechanical properties of the collagen gel.  Due to the fact that crosslinking 
does not influence the abundance of integrin binding sites in collagen, we are left with 
both pore size and stiffness as the imposed mechanical properties altered by tTG that may 
influence MMP activity.   
While one may wish to also isolate stiffness and pore size to fully characterize the 
aspect or aspects of ECM gels that influence MMP activity, this may not be feasible 
given the intimate relationship between pore size and stiffness in this environment.  
Envisioning the matrix as a set of spring-like fibers, any decrease in pore size mediated 
by network connections will always lead to increased stiffness.  Therefore, in our system 
pore size may not be treated as an independent variable, but only as a proxy for stiffness 
or a measure of tTG crosslinking activity.  Pore size has been shown, however, to have 
direct influence on cellular behaviors such as migration and invasion [405,406].  
Unfortunately, efforts to manipulate pore size of gels via polymerization temperature to 
study the impact of MMPs on migration have also shown to influence the inherent elastic 
modulus [406].  Controlling pore size independent of stiffness has been accomplished via 
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a two-temperature polymerization process; however the role of pore size outside of 
migratory capacity alone has yet to be observed [407].  In addition, altering pore size in 
this fashion is based on controlling the nucleation time of collagen fibers during initial 
polymerization and does not address the effect of a crosslinking enzyme such as tTG.  
Indeed, since the mechanisms of temperature controlled pore size manipulation and tTG 
are inherently different (collagen fiber thickening versus collagen fiber crosslinking) in 
regard to crosslinking the action of pore size and stiffness may be inseparable.  Still, by 
studying the action of integrins and the difference in behavior between 2 mg/ml + 0.0084 
Units tTG and 3 mg/ml samples, which ostensibly have identical pore sizes but different 
stiffness, we can observe that stiffness due to crosslinking may be the main modulator of 
MMP induction. 
The leading role of stiffness as the characteristic modulator of MMP activity due 
to tTG crosslinking is revealed through integrin β1 blocking.  Pretreatment of cells with 
an anti-integrin antibody clone (4B4) was sufficient to decrease cell surface MT1-MMP 
expression in tTG treated samples as observed via FACS.  This indicates that integrin β1 
is a key component in the increase of MMP activation in tTG crosslinked gels.  Beta-1 
integrins represent the overwhelming adhesion protein for cells to collagen and are also 
sensitive to ECM stiffness [243].  They therefore also offer insight into how stiffness 
influences cellular behavior.  The loss of MT1-MMP expression upon integrin β1 
adhesion blocking indicates that the attachment of these proteins is necessary for 
modulation of MMP activity. This fact coupled with the knowledge that tTG crosslinking 
increases stiffness but not ligand density allows one to conclude that integrins govern the 
96 
cellular response to MMP activity, and this is likely mediated by the stiffness of the 
environment.  Further evidence of integrin mediated stiffness sensing is portrayed though 
migration and invasion of cells in our system.  Both invasion and migration show a 
biphasic relationship with substrate stiffness. Initial increases in stiffness allow for 
enhances migration and invasion, however as stiffness continues to climb this effect is 
reversed.  We must note, however, that while stiffness likely governs these motile events 
at some threshold decreasing pore size must also be considered to play a role in the loss 
of speed for stiff ECMs.  Regardless of the strength that pore size has influencing these 
events, our experiments show that integrin blocking drastically decreases speed in all 
cases, suggesting that integrin β1 is highly involved during the migration process.   
While stiffness seems to be the leading candidate for changes in MMP induced 
activity, it is important to note that stiffness may not be the end point marker for integrin 
induced changes in MMP activity.  Our final observation of integrins showed that the β1 
subtype is expressed differentially in the presence of tTG.  The expression pattern of β1 
integrins also seems to qualitatively match the invasion and migration patterns as a 
function of ECM stiffness.  Although tTG induced changes in stiffness do not directly 
translate to increased binding sites on the collagen gel itself, it is possible that this 
stiffness sensing induces an upregulation of integrins and that integrin-collagen adhesion 
and subsequent signaling mechanisms may provide the main impetus for changes in 
migration and MMP activation.  Indeed, the β1 subtype has been frequently implicated to 
positively govern MMP activity and the two protein families are often co-expressed 
[266].  Recent work studying the role of matrix crosslinking in tumor progression has 
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also concluded that integrin signaling is enhanced upon crosslinking to produce changes 
in the PI3K pathway [97].  Another study has also shown that tTG mediated crosslinking 
may influence integrin clustering and adhesion [408]. While adhesion may seem like an 
obvious candidate to potentiate the entirety of our data we must remember that tTG 
mediated changes in stiffness were apparent in naked collagen gels, and that the 
crosslinking activity of tTG predated the addition of cells to the system suggesting that 
stiffness was the first identifiable modulator of both integrin expression and MMP 
activity. 
Finally, one may correctly observe that comparisons between 2 mg/ml crosslinked 
gels and 3 mg/ml gels suffer due to the potential increase in binding sites in 3 mg/ml gels.  
This may lead one to reevaluate whether any differences seen between these two cohorts 
are a function of stiffness or a combination of stiffness and integrin binding.  However, 
we note here that all of our conclusions remain valid without considering data from 3 
mg/ml gels as the trends we notice and are drawn to are still held within 2 mg/ml gel 
samples and those cultured with tTG.  Inclusion of the 3 mg/ml samples does provide us 
with a measurable alternative to the stiffness produced in tTG gels in comparison to 
untreated 2 mg/ml gels.  Interestingly, all behavioral data including invasion, migration, 
and MMP activity follow the exact trend as outlined through the stiffness of gels 
suggesting that in this platform the amount of binding sites may not influence cellular 
behavior.  It is possible that at these collagen densities integrin binding sites have reached 
a saturation limit and further binding is mediated only by the abundance of integrin 
receptors themselves.  This hypothesis is supported by the relative expression of integrin 
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β1 in all samples. Higher MMP activity, invasion, and migration are associated with 
integrin β1 expression which is highest at medium stiffness.  The overall trend displayed 
by the data is a biphasic relationship between integrin expression and stiffness in which 
samples with greater integrin expression produce more MMP activity and motility.  This 
pattern governed ultimately by stiffness is not broken by the inclusion of 3 mg/ml 
samples despite their increased density compared to 2 mg/ml gels. 
 When observing the system as a whole it is easy to see how both ECM and 
cellular components participate in bidirectional crosstalk.  We have shown that both 
nascent MMP expression levels and MMP blocking influence the pore size of the matrix.  
In turn, this change in pore size may then alter the stiffness of the matrix, potentiating a 
change in integrin β1 expression and therefore adhesion.  Finally, a differential 
expression of integrins leads to an altered MMP activity prolife and the cycle continues.  
Our data show that other factors such as tTG excretion from cells can also play a vital 
role in the balance of MMPs, matrix stiffness, pore size, and ultimately migration.  By 
establishing the action of a bidirectional relationship between MMP and ECM in 3D our 
research highlights the need for systems level analysis of cells and their processes.  We 
also provide distinct methodologies by which to observe such behaviors and how they 
may contribute to cellular behaviors.  Finally, our data and conclusions add significant 
knowledge to the field of cellular biology and cancer research by directly establishing a 
bidirectional relationship between ECM and MMP activity that may inform future studies 
and help uncover the mechanism behind aberrant behavior in disease states. 
  
99 
4.5 Figures 
  
100 
Figure 4.1: Qualitative analysis of collagen gels of different concentration using 
CRM.  Increasing collagen gel concentration from 2 mg/ml (A), to 3 
mg/ml (B), to 4 mg/ml (C) showed a qualitative decrease in unoccupied 
space within collagen gels (collagen fibers are represented in white as 
reflected light while all empty space remains dark).  Scale bar is 30 µm.  
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Figure 4.2: Quantitative measurements of pore size (A) and fibril fraction (B) from 
CRM images.  In agreement with qualitative observation, pore size 
decreased and fibril fraction increased as collagen concentration was 
raised.  Time scale analysis of pore size and fibril fraction showed that 
over a 7 day period empty gels did not significantly alter their measures of 
pore size or fibril fraction.  
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Figure 4.3: Changes in matrix composition due to addition of tissue transglutaminase 
(tTG) during collagen gel polymerization.  SEM images of collagen gels at 
2 mg/ml (A), 2 mg/ml + 0.00084 Units tTG (B), 2 mg/ml + 0.0084 Units 
tTG (C), and 3 mg/ml (D).  Red arrows indicate crosslinks mediated by 
tTG.  Scale bar is 2 µm.  tTG is able to potentiate crosslinking in collagen 
gels as well as qualitatively decrease the pore size similar to that of 3 
mg/ml gels.  
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Figure 4.4: Quantitative influence of tTG treatment on collagen gel stiffness and pore 
size.  Stiffness comparison of nascent collagen gels and those treated with 
tTG (A).  Culture with tTG at 0.00084 Units and 0.0084 Units was able to 
increase the stiffness of 2 mg/ml gels up to and beyond the stiffness of 3 
mg/ml gels.  Pore size as a function of collagen concentration and culture 
with tTG enzyme (B).  Untreated 2 mg/ml gels represent the greatest pore 
size, decreased by tTG in a dose dependent manner.  At a higher dose of 
tTG (0.0084 Units) the pore size drops below that of 3 mg/ml gels 
corroborating the previously seen increase in stiffness above that of 3 
mg/ml gels for 2 mg/ml gels treated with 0.0084 Units of tTG.  
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Figure 4.5: Changes in fibril fraction (A) and pore size (B) due to matrix remodeling 
by LNCaP and DU-145 cells for a range of collagen concentrations.  
LNCaP cells more actively remodeled 3 and 4 mg/ml gels by decreasing 
the fibril fraction and increasing pore size to values more closely 
resembling softer environments such as 2 mg/ml gels.  Conversely, DU-
145 cells more actively remodeled softer 2 mg/ml gels by increasing the 
fibril fraction and decreasing the pore size to mimic 3 mg/ml 
environments.  
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Figure 4.6: Time dependent changes in pore size (A) and fibril fraction (B) by LNCaP 
and DU-145 cells at 2 mg/ml.  All changes to pore size and fibril fraction 
reached relative equilibrium after the third day in collagen gel culture.  
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Figure 4.7: Time dependent changes in pore size (A) and fibril fraction (B) by LNCaP 
and DU-145 cells at 3 mg/ml.  All changes to pore size and fibril fraction 
reached relative equilibrium after the third day in collagen gel culture.  
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Figure 4.8: Time dependent changes in pore size (A) and fibril fraction (B) by LNCaP 
and DU-145 cells at 4 mg/ml.  All changes to pore size and fibril fraction 
reached relative equilibrium after the third day in collagen gel culture. 
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Figure 4.9: MMP activity of LNCaP and DU-145 cells drives matrix remodeling 3D 
collagen gels.  Qualitative (A) and Quantitative (B) zymographic analysis 
of MMPs in LNCaP and DU-145 cells.  Both cell lines expressed MMP-2 
and MMP-9, however, DU-145 cells expressed more of both and increased 
levels of the active forms.  
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Figure 4.10: Quantitative changes in cell mediated matrix remodeling in response to 
MMP inhibition.  Changes in fibril fraction content in 3 and 4 mg/ml gels 
as a result of Marimastat induced MMP blocking in DU-145 (A) and 
LNCaP (B) cells.  In both cell lines, Marimastat was able to decrease the 
fibril fraction of gels at 4 mg/ml in comparison to control gels and gels 
with cells cultured without drug, decreasing the potential for cells to 
remodel the matrix.  
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Figure 4.11: Qualitative zymographic measure of MMP-2 pro and active forms for cells 
cultured within 2 mg/ml, 2 mg/ml + 0.00084 units tTG, 2 mg/ml + 0.0084 
units tTG or 3 mg/ml gels.  
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Figure 4.12: Quantification of zymography results for cells cultured within 2 mg/ml, 2 
mg/ml + 0.00084 units tTG, 2 mg/ml + 0.0084 units tTG or 3 mg/ml gels.  
tTG was able to increase the expression of MMP-2 pro and active form at 
concentrations of both 0.00084 and 0.0084 units.  However, the increase 
in MMP activity was not linear, but instead followed a biphasic pattern 
with higher concentrations of tTG (0.0084 units) resulting in lower MMP 
activity than more modest tTG concentrations (0.00084 units).  
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Figure 4.13: Changes in MT1-MMP activity in response to tTG culture and integrn-β1 
blocking antibody.  Mean fluorescent intensity via FACS of MT1-MMP 
expressed on the cell surface of cells cultured within 2 mg/ml, 2 mg/ml + 
0.00084 units tTG, 2 mg/ml + 0.0084 units tTG or 3 mg/ml gels in gels 
(A).  Similar to the result seen from zymographic analysis of MMP-2, tTG 
was able to increase the expression of MT1-MMP at concentrations of 
both 0.00084 and 0.0084 units.  However, the increase in MMP activity 
was not linear, but instead followed a biphasic pattern with higher 
concentrations of tTG (0.0084 units) resulting in lower MMP activity than 
more modest tTG concentrations (0.00084 units).  Differential expression 
of cell surface MT1-MMP in the presence of integrin inhibition (B).  
Inhibition of β1 integrins with antibody clone 4B4 decreased MT1-MMP 
content of cells.  
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Figure 4.14: Influence of matrix stiffness on cell invasion (A) and speed (B).  When 
markers of motility are tested against the stiffness of the matrix a similar 
pattern to MMP activity and expression is observed with the emergence of 
a biphasic response.  Peak invasion and speed is observed at intermediate 
stiffness with low and high stiffness resulting in a drop in motility.  Cell 
speed is also heavily impacted by integrin engagement, with speeds 
precipitously decreasing in the presence of 4B4 integrin blocking antibody  
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Figure 4.15: Expression of integrin β1 as observed through FACS analysis.  While β1 
integrins seem to follow a pattern in which the highest concentration is 
reached at intermediate stiffness mediated by tTG, other integrin subunits 
that are less firmly associated as collagen binding moieties do not 
experience this behavior.  
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CHAPTER FIVE: MT1-MMP EXPRESSION IS REQUIRED FOR PROTEASE 
INHIBITOR AND TRASTUZUMAB INDUCED ACTIVATION OF HER2 
MEDIATED PI3K AND ERK PATHWAYS IN HER2
+
/CD44
+
 BREAST CANCER 
CELLS 
 
5.1 Introduction 
 Breast cancer represents the most common cancer in women world-wide 
accounting for 25% of all cancers in women and 12% of all new cancer occurrences.  
Roughly a quarter of breast cancers fall under the subsect of HER2 positive cancers in 
which the HER2 transmembrane growth factor is over-expressed leading to upregulation 
of growth factor signaling, increased invasiveness, and ultimately a poor prognosis 
[409,410].  Fortunately, current treatment methods including the monoclonal antibody 
Trastuzumab (commonly referred to as Herceptin) have shown significant initial efficacy 
as both a neo-adjuvant and adjuvant therapy in increasing both the survival of patients as 
well as suppressing the recurrence of disease [411].  Trastuzumab works on HER2 
positive breast cancer cells by binding to the extracellular domain of the HER2 protein 
and preventing the ligand-indepdendent dimerization of HER2 to other HER family 
receptors.  Binding of Trastuzumab to HER2 also results in decreased ectodomain 
cleavage of HER2, thereby preventing the formation of the hyperactive truncated 
p95HER2 variant.  This inhibition reduces the previously upregulated PI3K pathway 
allowing for control of proliferation by arresting the cell cycle in the G1 phase.  
Unfortunately, up to 70% of patients see no benefit from this treatment due to either de 
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novo or acquired resistance [412].  In the quest to understand why certain patients are 
unresponsive to Trastuzumab treatment and how other cancers are able to avoid and resist 
this drug, research has progressed toward studying tumor explants and established breast 
cancer cell lines.  To date, several mechanisms have been proposed as to how cells may 
acquire resistance to Trastuzumab including amplification of alternate signaling 
pathways, increased signaling from other HER2 family receptors, truncation of the HER2 
receptor preventing the initial binding of Trastuzumab, and steric hindrance of 
Trastuzumab-HER2 binding sites [412].   
Involved in the action of HER2 downregulation, the steric hindrance of 
Trastzumab, and potentially other resistance mechanisms is the presence of the 
glycoprotein CD44 [413].  CD44 has been shown to co-localize with HER2 on the cell 
surface and their interaction can influence the metastasis and progression of cancer via 
upregulation of CXCR4 [173].  Additionally, the CD44-HER2 linkage results in 
phosphorylation and activation of HER2 and the co-expression of these proteins is a 
marker for tumor progression and correlates with poor prognosis [174,175]. Fortunately, 
cancers positive for both HER2 (HER2
+
) and CD44 (CD44
+
) tend to be less common 
than other cell types with the majority of lines that over-express HER2 displaying very 
low amounts of CD44 (HER2
+
/CD44
-
) [414].  However, recent work has established that 
resistance to radiotherapy in HER2 negative breast cancer stem cells (BCSCs) promotes 
the formation of a highly invasive and resistant subpopulation expressing both HER2 and 
CD44 [415].  Other work has proposed that expression of HER2 in cancer increases the 
formation of BCSCs and the CD44
+
 phenotype [416].  Taken together, these works 
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suggest that HER2
+
/CD44
+
 cells potentially harness the chemoresistant and highly 
tumorigenic stem like properties of BSCSs in addition to increasing the likelihood for the 
production of more BCSCs.  Due to the fact that BCSCs are implicated in the formation 
as well as maintenance and survival of dormant and extant micrometastases, developing a 
more thorough understanding of the HER2
+
/CD44
+
 cell type is paramount.   
As CD44 and HER2 share an intimate relationship, it stands to reason that any 
third party effector that influences the action or expression of CD44 may also indirectly 
alter HER2 signaling by disrupting the balance between CD44 and HER2.  Of particular 
interest are matrix metalloproteinases (MMPs), zinc dependent proteases that are most 
formally responsible for degrading matrix proteins such as collagen and fibronectin.  
However, their expression and activity has also been shown to alter signaling pathways 
suggesting that their action extends beyond simple matrix fiber remodeling [388].  
Pathway modification mediated by MMPs is postulated to revolve around cleavage of 
extracellular domains of receptors and other cell surface associated proteins.  Indeed 
ADAM10, a disintegrin and metalloproteinase that is not a member of the MMP family 
but shares proteolytic duties similar to MMPs is directly responsible for cleavage and 
activation of the HER2 ectodomain [417].  In addition, the cell surface transmembrane 
MMP, MT1-MMP, has been shown to interact and cleave CD44 at the rear edge of cells 
to induce detachment and aid in migration [418].  CD44 cleavage has also been shown to 
induce signaling changes via the internalization of the endodomain, and the soluble 
cleaved portion of CD44 (sCD44) is thought to compete with the CD44 ligand 
hyaluronan (HA) to act as a feedback loop in HER2 signaling and MT1-MMP expression 
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[419,420]. These data provide significant evidence to a potential interdependent link 
between HER2, CD44 and MMPs, and in particular MT1-MMP, that may exist in 
HER2
+
/CD44
+
 breast cancer cells.  Unfortunately, to our knowledge there exist no 
studies that probe how HER2
+
/CD44
+
 breast cancer cells depend upon the action or 
efficacy of MMPs or MT1-MMP and whether disruption of this and other similar 
proteases may lead to differences in the response to Trastuzumab. 
In order to probe the relationship between HER2, CD44, MMP activity and MT1-
MMP expression in HER2
+
/CD44
+
 cancer we have developed a cell line that expresses 
HER2, CD44 as well as a high level of MMPs.  In this study we document the action of 
Marimastat, a broad base MMP inhibitor, and Trastuzumab on this cell line in 
comparison to both HER2
+
/CD44
-
 and HER2
-
/CD44
+ 
cells.  Finally, we show that the 
unique responses displayed by the HER2
+
/CD44
+
 cells to Marimastat and Trastzumab are 
dependent on MT1-MMP expression, establishing a concrete connection between MMP 
activity and HER2 mediated signaling.  This work represents the first observation that the 
highly invasive HER2
+
/CD44
+
 cell type may be sensitive to changes in MMP activity, 
specifically in the way of MT1-MMP expression. 
 
5.2 Methods 
 
5.2.1 Cell Culture and Materials 
 BT-549 and ZR-75-30 breast cancer cells were obtained through American Type 
Cell Culture (ATCC) and maintained in RPMI media supplemented with 10% Fetal 
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Bovine Serum (FBS) and 1% Penicillin/Streptomycin at 37°C, 5% CO2 and 75% 
humidity according to vendor instructions.  When appropriate, cells were incubated with 
either 10 µM Marimastat (Tocris) or 25 µg/mL Trastuzumab (commonly referred to as 
Herceptin, Genentech). 
   
5.2.2 Immunoblotting 
 Cell lysates were added to 5x Laemmli buffer and subjected to western blotting 
procedure as described [421].  Total protein was transferred to PVDF membranes and 
probed with anti-HER2, anti-CD44, anti-p-Akt-S308, anti-p-Akt-T473, anti-Akt, anti-p-
ERK-T202/Y204, anti-ERK (Cell Signaling), anti-MT1-MMP (AbCam) and anti-
GAPDH (Santa Cruz Biotechnology) antibodies.  Secondary HRP-conjugated anti-rabbit 
and anti-mouse (AbCam) antibodies were used to visualize protein expression via 
incubation with ECL substrate (Thermo Pierce). 
   
5.2.3 Stable Transfection of HER2 
 BT-549 cells were transfected with either a control plasmid pcDNA3.1
(+)
 
(Invitrogen) or plasmid with a pcDNA3 vector backbone containing  gene insert for full 
length wild type HER2 (Addgene plasmid 16257) using Lipofectamine 2000 (Invitrogen) 
and following manufacturer protocols.  After transfection, clonal selection was mediated 
via inclusion of 0.4 mg/mL Geneticin (G418, Invitrogen) to complete media for 2 weeks.  
Cell colonies were then selected and grown up to assess changes in HER2 protein 
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expression.  Subsequent stable transfectants (termed EV for empty vector or BTHER for 
HER2 positive) were cultured in complete media supplemented with 0.2 mg/mL G418.  
 
5.2.4 siRNA transfection 
The siRNA sequence targeting the RNA sense strands for MT1-MMP was as 
follows: 5’-UCCAGGGUCUCAAAUGGCAACAUAA-3’ targeting nts 571-599. The 
nucleotide sequence was scrambled to generate a control sequence for MT1-MMP: 5’- 
GGCGGGUGAGGAAUAACCAAGUGAU-3’.  Cells were transfected using 
Lipofectamine 2000 according to manufacturer protocol. 
 
5.2.5 Proliferation Assay 
Cells were seeded at 2000 c/well (BT-549) or 5000 c/well (ZR-75-0) in 100 µL 
total volume in 96 well plates overnight before media was changed to contain either 10 
µM Marimastat, 25 µg/mL Trastuzumab, or a combination of both.  For those samples 
that required siRNA transfection, cells were first transfected after initial overnight plating 
for 24 hours after which media was changed once again to contain the appropriate drug 
cocktail.  Cells were then incubated for 72 hours after which 10 µL WST-1 reagent 
(Roche) was added to each well.  After incubation at 37°C for 4 hours, plates were mixed 
and absorbance was measured at 450 nm.  Proliferative capacity was measured as the 
percent absorbance of any given sample with respect to the corresponding control 
condition. 
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5.2.6 CD44 Cleavage Assay 
 Concentration of soluble, cleaved CD44 (sCD44) was measured in conditioned 
media of samples.  Cells were plated at 75,000 c/well and allowed to incubate with 
appropriate drug conditions for 48 hours before collection and concentration of media via 
ultracentrifugation in 10 kDa cutoff filter units (Amicon Ultra-4, Millipore).  
Concentrated media was then tested for the presence of CD44 using an ELISA assay 
(CD44 human ELISA Kit, AbCam), and quantified against a standard curve following 
manufacturer protocols. 
 
5.2.7 Statistical Analysis 
Statistical analysis of data was performed with a student’s two-tailed t-test for 
three independent experiments. 
 
5.3 Results and Conclusions 
 
5.3.1 BT-549 and ZR-75-30 cells behave differently in response to MMP inhibition and 
Trastuzumab treatment 
 Culture of BT-549 cells with Marimastat (10 µM) for 72 hours, while not 
enacting changes in the Akt or ERK pathways was able to modestly increase the level of 
active full length MT1-MMP.  This effect was also noticeable in ZR-75-30 cells, 
however the nascent expression of MT1-MMP was almost undetectable, detracting the 
relative importance of this pattern.  In response to Trastuzumab (25 µg/mL) treatment for 
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72 hours, BT-549 cells observed almost no change in any signaling component, however, 
there was a modest noticeable and reproducible increase in p-ERK expression.  The 
opposite was true for ZR-75-30 cells when cultured with Trastuzumab.  After 72 hours, 
p-ERK as well as p-AKT S473 expression was significantly downregulated (Figure 5.2).  
In addition to offering differential changes in expression, BT-549 and ZR-75-30 cells 
also possessed unique proliferative capacities in response to Marimastat and 
Trastuzumab.  Trastuzumab treatment at 25 µg/mL for 72 hours was enough to decrease 
proliferation in ZR-75-30 cells to nearly half the control sample while BT-549 cells saw 
no change in their proliferative capacity (Figure 5.3A).  In response to Marimastat, BT-
549 cells were much more sensitive at higher concentrations, while ZR-75-30 cells were 
more sensitive at lower concentrations.  Around the concentration of 10 µM, the level 
used to evaluate changes in expression, their proliferative response to Marimastat is 
nearly equal (Figure 5.3B).  This suggests that any observed differential expressional 
level change between the two cell lines due to Marimastat treatment was not caused by a 
disproportional amount of cell death.  
The differential changes in proliferative capacity and protein expression in 
response to Marimastat and Trastuzumab highlights the inherent functional difference 
between both cell lines.  BT-549 cells belong to the common family of “triple negative” 
breast cancer cells which frequently adopt a HER2
-
/CD44
+
 phenotype.  Their low 
expression of HER2 renders then unresponsive to Trastuzumab treatment.  In contrast 
ZR-75-30 cells represent a sect of HER2 positive breast cancer with a HER2
+
/CD44
-
 
phenotype.  These cells express a heightened susceptibility to Trastuzumab treatment 
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presumably due to their reliance on the HER2 pathway for proliferation and survival.  
While examination of both BT-549 and ZR-75-30 cells provides a baseline as to how 
HER2 positive and Triple negative cancer cells react to protease inhibition and 
Trastuzumab, neither gives insight to the more insidious and highly invasive albeit less 
common HER2
+
/CD44
+
 cell type 
. 
5.3.2 BTHER cells display enhanced PI3K and ERK pathway reactivity to Trastuzumab 
and Marimastat treatment 
 In order to study the characteristics of HER2
+
/CD44
+ 
breast cancer cells the triple 
negative BT-549 cell line was transfected with a plasmid coding for the full length wild 
type HER2 protein and Geneticin (G418) resistance.  After transfection and clonal 
selection in G418 supplemented media multiple established clones expressed upregulated 
HER2 expression compared to those cells transfected with an empty vector (EV), and 
untransfected BT-549 cells.  Expression of HER2 in BT-549 transfected clones (now 
referred to as BTHER cells) did not, however, reach that of ZR-75-30 cells (Figure 5.1B). 
BTHER cells were then subjected to Marimastat, Trastuzumab and the 
combination of both drugs as discussed earlier.  The addition of HER2 to the BT-549 
cells in the way of BTHER clones significantly altered the response to both drugs.  
Marimastat was able to increase expression of HER2, MT1-MMP and p-Akt S308.  The 
increase in MT1-MMP was also observed in BT-549 cells, however, the presence of 
HER2 in this cell line influenced the increase in both HER2 and the PI3K signaling node 
p-Akt S308.  Although not readily expressed in ZR-75-30, p-Akt S308 is a direct 
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signaling target of PI3K through PDK1 and becomes active upon HER2 phosphorylation 
via EGF stimulation.  It is possible that expression of PTEN in ZR-75-30 cells (data not 
shown), the main negative modulator of PI3K induced p-Akt activation, is the reason 
behind the absence of p-Akt S308 expression despite high expression of HER2.  Our 
results indicate that protease inhibition can lead to increased expression of the full length 
HER2 and subsequently PI3K activation in cells lacking PTEN.  The mechanism by 
which MT1-MMP and HER2 full length expression is increased via proteolytic blocking 
may be as simple as reduced ectodomain cleavage of both proteins resulting in a greater 
proportion of total protein to exist in the full length form.  Marimastat does indeed inhibit 
MT1-MMP which has been shown to participate in auto-catalysis [422].  Although no 
MMP has specifically been implicated in HER2 cleavage, (it has been suggested that the 
protease responsible is not MT1-MMP) ADAM10 has been found to directly influence 
this event and is also weakly and non-specifically inhibited by Marimastat [417]. 
 BTHER cells also displayed a differential reaction to Trastuzumab compared to 
BT-549 cells.  After 72 hours, full length HER2 was significantly reduced upon 
Trastuzumab treatment and p-ERK activity was increased (Figure 5.4).  The decrease in 
HER2 in response to Trastuzumab is a matter of debate with several studies confirming 
this result and defining the decrease in HER2 as a mechanism of Trastuzumab’s 
effectiveness, while others disagree with both the result and the conclusion [423].  In our 
work here we identify a cell line whose HER2 expression is unaffected by Trastuzumab 
(ZR-75-30) and another in which HER2 is significantly downregulated (BTHER).  
Observation of proliferative potential and protein expression in BTHER cells in the 
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presence of Trastuzumab shows that downregulation of HER2 in this cell line does not 
lead to a decrease in PI3K pathway signaling or proliferation. Proliferation in response to 
Marimastat, Trastuzumab and the combination of both drugs was essentially unchanged 
between BT-549 and BTHER cell lines (Figure 5.6A, columns 1-3 and 7-9).  This 
suggests that Trastuzumab induced HER2 downregulation is not a mechanism by which 
Trastuzumab abrogates hyperproliferation in BTHER cells.  This may due to the fact that 
the BTHER cell line displays a possible mechanism of resistance to Trastuzumab via 
upregulation of an alternative pathway (ERK pathway) upon Trastuzumab treatment.  It 
remains possible; therefore, that HER2 downregulation due to Trastuzumab treatment 
may result in a decrease in proliferation in other cancer cell lines.   
Our results indicate a possible mechanism for resistance in BTHER cells in the 
form of upregulated p-ERK.  Upregulation of p-ERK in response to Trastuzumab was a 
result also observed in HER2 negative BT-549 cells (Figure 5.2), however, in BTHER 
cells the degree of activation is much more dramatic and was consistently observed.  This 
result suggests that the increase in p-ERK expression upon Trastuzumab treatment 
coordinates with HER2 expression in BT-549 and BTHER cells and implies further that 
the increase in p-ERK expression is dependent on the interaction between HER2 and 
Trastuzumab.  It may then be hypothesized (at least in this instance) that a greater 
reliance or utilization of the HER2 pathway leads to a more dramatic increase in alternate 
pathway activation upon Trastuzumab treatment and HER2 downregulation.  Previous 
reports have shown that Trastuzumab has a discordant effect on p-ERK expression 
suggesting that the response is cell line dependent [424].  Our results corroborate this 
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hypothesis with the HER2
+
/CD44
-
 ZR-75-30 cells showing sensitivity to Trastuzumab 
and decrease in p-ERK activity and HER2
+
/CD44
+
 BTHER cells displaying the opposite.  
These patterns suggest that the action of Trastuzumab may be dependent on the status of 
another protein other than HER2. 
  
5.3.3 MT1-MMP expression is necessary for HER2 mediated PI3K and ERK activation 
in response to Marimastat and Trastuzumab 
Expression of MT1-MMP in BT-549 cells was significantly downregulated via 
transfection of siRNA against the target compared to control cells and those transfected 
with a scramble RNA (Figure 5.1A).  Upon siRNA mediated transfection of BTHER 
cells, many of the previously observed changes in HER2, p-Akt S308, and p-ERK in 
response to Marimastat and Trastuzumab were no longer present.  While Trastuzumab 
was still able to decrease expression of HER2, culture with Marimastat no longer 
increased MT1-MMP, HER2, or p-Akt S308 expressions.  Trastuzumab also lost its 
potential to increase p-ERK (Figure 5.4).  These results suggest that MT1-MMP plays an 
integral role in HER2 mediated PI3K and ERK pathway responses to protease inhibition 
as well as treatment with Trastuzumab in BTHER cells.  Serving as a model for 
HER2
+
/CD44
+
 breast cancer, these results also indicate that MT1-MMP may influence 
other cell lines of similar expression profiles. 
In order to uncover potential avenues by which MT1-MMP knockdown 
contributed to the loss of efficacy in Marimastat and Trastuzumab treatment in altering 
the PI3K and ERK pathways, protein expression was examined in the case of low MT1-
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MMP expression.  Upon siRNA transfection, both EV and BTHER cell lines experienced 
a decrease in HER2 and CD44 expression.  MT1-MMP knockdown was also able to 
increase p-ERK expression in both cell lines as well as decrease total Akt protein (Figure 
5.5).  While downregulation of MT1-MMP was been demonstrated to decrease CD44 
expression in osteoclasts [420], there have to our knowledge been no reports of this affect 
in breast cancer cells, nor has MT1-MMP been shown to govern HER2 expression. It is 
possible that siRNA against MT1-MMP is able to decrease HER2 via downregulation of 
CD44, however, a similar report in which CD44 was downregulated in breast cancer cells 
did not result in a decrease in HER2 expression [173].  In fact, it is postulated that 
expression of CD44 and HER2 are inversely related due to the ability of CD44 to 
enhance endocytotic internalization of HER2 [176].  This suggests that knockdown of 
MT1-MMP imparts a separate reaction outside of CD44 downregulation that induces a 
decrease in HER2 expression.  It of course is also very possible that CD44 expression is 
maintained by HER2 expression.  In this case siRNA against MT1-MMP may 
downregulate HER2 and as a consequence CD44 through the initial loss of HER2 
expression.  HER2 has been shown to functionally couple to CD44 and influence its 
shedding and internalization and one study has reported that HER2 downregulation 
influences total CD44 expression in MCF-7 cells [425].  Therefore, the downregulation 
of CD44 may be a consequence from loss of HER2 expression through some other 
mechanism mediated by MT1-MMP.  While MT1-MMP has been shown to influence 
signaling cascades, the intracellular region is both small and does not contain any 
homologous binding regions to common focal adhesion proteins [426].  Therefore, the 
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action by which downregulation of MT1-MMP inhibits CD44 and HER2 expression most 
likely lies in either its capacity for proteolytic processing of transmembrane receptors or 
through physical disruption of focal adhesion formation. 
Although the data clearly shows that MT1-MMP knockdown inhibits the action of 
Marimastat in upregulating the full form HER2 and PI3K signaling in the way of p-Akt 
S308, the mechanism behind this action needs to be further probed.  The lack of p-Akt 
S308 upregulation upon Marimastat treatment in MT1-MMP siRNA transfected cells 
may, however, simply be due to the failure of the drug to increase full length HER2 
expression.  In BTHER cells with ample MT1-MMP expression Marimastat was able to 
increase HER2 expression (Figure 5.4).  It is perhaps this action of Marimastat that was 
able to concurrently increase p-Akt due to the influence of HER2 in the PI3K signaling 
pathway.  We therefore hypothesize that Marimastat was able to increase PI3K signaling 
due to upregulation of the full form of HER2 in BTHER cells.  Loss of MT1-MMP 
expression then disrupted this interplay by no longer allowing Marimastat to increase 
HER2.  How MT1-MMP knockdown influences the ability of Marimastat to increase 
HER2 expression needs to be explored further in order to be fully understood.  Although 
one may postulate that the increase in HER2 full length form due to Marimastat is from 
reduced ectodomain cleavage, the loss of MT1-MMP expression would hypothetically 
only serve to synergize this action, not oppose it as our data describes, suggesting that 
some other action besides HER2 cleavage plays a role in this result.   
Another interesting observation that was made upon siRNA transfection was the 
relative increase in p-ERK activity.  The increase in p-ERK upon MT1-MMP knockdown 
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corresponds well to previous data showing that Trastuzumab treatment in BTHER cells 
also increases p-ERK [427,428].  In both cases, an increase in the ERK pathway is 
observed as HER2 is downregulated further implicating that the upregulation of this 
pathway may serve as an escape mechanism for cells no longer capable of utilizing the 
PI3K growth factor pathway.  Indeed, our data shows that BT-549 and BTHER cells did 
not experience any decrease in proliferative potential even after MT1-MMP knockdown 
and Trastuzumab treatment (Figure 5.6A, columns 4-6 and 10-12).  Due to the fact that 
CD44 has been shown to protect HER2 positive cells from Trastuzumab treatment via 
enhanced internalization, one would also assume in our system that the decrease in CD44 
due to MT1-MMP knockdown would result in increased sensitivity to drug.  The null 
result observed here coupled with the concurrent increase in p-ERK signaling suggests 
that this alternate pathway activation may play a role in the sustained resistance to 
Trastuzumab even after CD44 expression is compromised in these cells.   
Due to the fact that Trastuzumab and MMPs including MT1-MMP have been 
shown to influence the action of CD44 shedding, we probed the concentration of soluble 
CD44 (sCD44) in conditioned media to determine whether CD44 shedding could serve as 
a mechanistic cue to the observed changes in expression upon Trastuzumab, Mariamstat 
and siRNA treatments in BT-549 and BTHER cells.  As predicted from previous work, 
Marimastat, Trastuzumab, and MT1-MMP knockdown all were able to independently 
decrease sCD44 concentration (Figure 5.6B).  sCD44 has been shown to interfere with 
HER2 activation by preventing Hyaluronan (HA) binding and also plays a role in CD44 
expression, HER2 internalization, and the binding of Trastuzumab to HER2 [419,429].  
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Therefore one may inquire as to whether the expression level changes in the PI3K and 
ERK pathway seen in our data are a direct result of any changes in CD44 cleavage 
behavior, apart from the loss of CD44 expression upon MT1-MMP knockdown.  Our 
data, however, shows no change in the CD44 cleavage pattern between BT-549 (Figure 
5.6B, columns 1-8) and BTHER (Figure 5.6B, columns 9-16) cells.  As a result we 
hypothesize that while CD44 cleavage may play a role in the mechanistic underpinnings 
of the observed expression levels changes, a more likely culprit is the dramatic loss of 
CD44 expression (which in its own right also contributes to the loss of sCD44 
concentration) when MT1-MMP is knocked down. 
 
5.3.4 Summary 
 Analysis of the data has revealed several important observations regarding the 
function of MT1-MMP in HER2 positive breast cancer.  While Trastuzumab was able to 
effectively decrease proliferative capacity and activation of the PI3K and ERK pathways 
in ZR-75-30 cells, a different response was seen in both triple negative BT-549 cells and 
the HER2
+
/CD44
+
 BTHER line.  The BTHER cells in particular were not only resistant 
to Trastuzumab treatment, but were also expressed downregulation of the full form HER2 
as well as an increase in activity of the ERK pathway.  In addition, these cells showed 
differential sensitivity to Marimastat, which was able to increase MT1-MMP, HER2, and 
PI3K activity.  However, upon downregulation of MT1-MMP in these cells, the action of 
both Trastuzumab and Marimastat was abrogated, suggesting that MT1-MMP plays a 
role in these drug related mechanisms. In addition, loss of MT1-MMP decreased HER2 
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and CD44 content, while increasing ERK activity further.  From this we conclude that 
MT1-MMP is necessary for Trastuzumab and Marimastat induced activation of the PI3K 
and ERK pathways mediated by HER2 expression in HER2
+
/CD44
+
 breast cancer cells.  
We identify the loss of HER2 and CD44 expression as well as the increase in p-ERK 
expression in these cells as part of a possible mechanism that not only disrupts 
upregulation of p-ERK and p-Akt S308 in the presence of Trastuzumab and Marimastat 
but also protects from further decrease in proliferative potential. 
 Resistance to treatment in HER positive cells remains a prevalent problem in the 
treatment of breast cancer.  The mechanisms by which these cells avoid common 
treatments such as Trastuzumab continue to be studied, however, the interaction of this 
and other drugs on the less common HER2
+
/CD44
+
 cell type remain elusive.  Our work 
provides the initial observation that MT1-MMP is involved in expression level changes in 
response to both Trastuzumab as well as Marimastat, part of another class of anti-cancer 
drugs, in this cell type.  Clear future studies may be enacted to elucidate the mechanism 
by which MT1-MMP governs HER2, CD44 and p-ERK expression in these cells to 
overcome this highly resistant and invasive cell type. 
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5.4 Figures 
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Figure 5.1: Establishment of stably transfected BTHER cells and siRNA mediated 
knockdown of MT1-MMP.  MT1-MMP knockdown in control, scramble 
siRNA, and siRNA against MT1-MMP samples 48 hours post transfection 
(A).  HER2 expression in multiple isolated transfected clones (BTHER 
Clone 1,2,3), empty vector (EV) clones, untransfected BT-549 cells, and 
positive control sample ZR-75-30 (B).  
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Figure 5.2: Expression of HER2, CD44, MT1-MMP, and the Akt, and ERK pathways 
in BT-549 and ZR-75-30 cells for control cells and in response to 
Marimastat (10 µM, 72 hours), Trastuzumab (25 µg/mL, 72 hours) and a 
combination of both drugs (Marimastat 10 µM, Trastuzumab 25 µg/mL, 
72 hours) (B)  
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Figure 5.3: BT-549 and ZR-75-30 cellular behavior toward Marimastat and 
Trastuzumab.  Percent absorbance of control for BT-549 and ZR-75-30 
cells cultured with Trastuzumab at 25 µg/mL for 72 hours (A).  Percent 
absorbance of control for BT-549 and ZR-75-30 cells cultured with 
varying concentrations of Marimastat for 72 hours (B). The symbol ‘*’ 
corresponds to statistical significance between BT-549 and ZR-75-30 
samples as observed via two-tailed student’s t-test (p < 0.05).  
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Figure 5.4: Characterization of BTHER cells and the role of MT1-MMP in the HER2 
mediated PI3K pathway.  Expression of HER2, CD44, MT1-MMP, and 
the Akt, and ERK pathways in response to Marimastat (10 µM, 72 hours), 
Trastuzumab (25 µg/mL, 72 hours) and a combination of both drugs 
(Marimastat 10 µM, Trastuzumab 25 µg/mL, 72 hours) for HER2 positive 
transfected cells (BTHER), empty vector transfected cells also transfected 
with siRNA against MT1-MMP (EV-MT1), and BTHER cells also 
transfected with siRNA against MT1-MMP (BTHER-MT1).  
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Figure 5.5: Changes in expression for empty vector and HER2 positive cells in 
response to MT1-MMP knockdown.  Expression of HER2, CD44, MT1-
MMP, and the Akt, and ERK pathways for empty vector transfected cells 
(EV), EV cells transfected with siRNA against MT1-MMP (EV + siRNA), 
HER2 positive transfected cells (BTHER), and BTHER cells also 
transfected with siRNA against MT1-MMP (BTHER + siRNA).  
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Figure 5.6: Proliferative response and sCD44 content for cells cultured in various 
combinations of Marimastat, Trastuzumab, siRNA against MT1-MMP, 
and stably transfected HER2 positive vector.  Percent absorbance of 
control after culture for 72 hours for the following cell lines and 
conditions: (1) BT-549 + Marm; (2) BT-549 + Tras; (3) BT-549 + TM; (4) 
BT-549-MT1 + Marm; (5) BT-549-MT1 + Tras; (6) BT-549-MT1 + TM; 
(7) BTHER + Marm; (8) BTHER + Tras; (9) BTHER + TM; (10) 
BTHER-MT1 +Marm; (11) BTHER-MT1 + Tras; (12) BTHER-MT1 + 
TM; (-MT1 = transfected with siRNA against MT1-MMP, + Marm = 
culture with Marimastat at 10 µM, + Tras = culture with Trastuzumab at 
25 µg/mL, +TM = culture with both Marimastat at 10 µM and 
Trastuzumab at 25 µg/mL) (A).  Concentration of sCD44 in conditioned 
media after culture for 48 hours for the cell lines and conditions described 
previously for ‘A’ (B). 
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CHAPTER SIX: INTEGRIN β1 AND MT1-MMP GOVERN HT-1080 
MIGRATION IN 3D MATRICES 
 
6.1 Introduction 
The rise in individualized cancer treatment and targeted therapies has created an 
emphasis toward understanding how specific proteins interact to direct invasiveness and 
malignancy [412,430–432]. As a result, methods to curb cancer cell invasiveness have 
begun to focus on specific protein signaling pathways to comprehensively characterize 
how cells avoid therapeutic treatment based on cell type or a specific oncogenic defect.  
In addition to probing specific pathways involved with migration, model systems for in 
vitro analysis have begun to incorporate 3D matrices that better recapitulate native 
environments.  Coupling both 3D culture with specific pathway analysis allows for more 
intimate investigations into mechanistic pathways.  Of particular importance in the 
context of migration and invasion are integrin β1 and membrane type 1 matrix 
metalloproteinase (MT1-MMP) [433,434].  Both proteins have been implicated in 
processes such as ECM remodeling, migration, cytoskeletal stiffness, and the FAK/ERK 
pathway [435–438].   
Since their inception, research regarding and utilizing fibrosarcoma HT-1080 cells 
has been rampant and thorough.  Due to an N-Ras oncogene rendering the Ras pathway 
constitutively active, HT-1080 cells have been a useful model for both invasive cancer 
and for studying the action of the Ras pathway.  While HT-1080 cells have been studied 
extensively, the role of both integrin β1 and membrane type 1 matrix metalloproteinase 
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(MT1-MMP) in migration has not yet been completely understood, particularly when 
cultured in 3D matrices.  This is due to the fact that most work has been done on 2D 
substrates.   
Increasing evidence is showing that 3D culture systems develop cells that offer 
very different characteristics.  Not only is morphology clearly changed, but cells exhibit 
an increased resistance to apoptosis and decreased proliferation in 3D environments 
[333,421].  Several reports have indicated that signaling in 3D matrices may differ from 
2D substrates due to differences in spatial mechanical stress between the culture systems.  
These dissimilarities indicate that 2D assays may miss important aspects of how cells will 
respond in vivo [339,439–441]. In response, 3D platforms are beginning to become more 
common; however, the study of migration in 3D is often one-dimensional.  Assays 
monitoring end point displacement fail to capture more intimate migration characteristics 
such as instantaneous cell speed and persistence [442].   As HT-1080 cells are frequently 
chosen for works to study the invasive potential of cancer, it is imperative not only to 
solidify the roles of specific proteins in the migration cascade but also to parse out the 
contributions of these proteins toward instantaneous cell speed and directionality in 2D 
and 3D. 
The migration pathway has been studied extensively over the past two decades; 
however, the role of integrin β1 and MT1-MMP in HT-1080 cells, a widely used cellular 
invasion model is less understood.  How these proteins directly interact with the 
cytoskeleton and ERK signaling to influence cancer migration in 3D has also not been 
completely characterized.  In this chapter we aim to specifically probe how integrin β1 
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and MT1-MMP can influence migration in HT-1080 cells by controlling cytoskeletal 
activity and ERK pathway activation in 3D networks.  Our analysis of migration does not 
only encompass speed, but also how persistent the cell moves.  This rigorous approach to 
analyzing the roles of both proteins in both speed and persistence in 3D matrices has not 
yet been studied.  In addition to understanding how integrin β1 and MT1-MMP govern 
migration in 3D we hope to further characterize how cytoskeletal contractility and ERK 
activation themselves individually impact cell speed and persistence in this system.  
 
6.2 Materials and Methods 
 
6.2.1 Cell culture and preparation of culture substrates 
HT-1080 cells were obtained from American Type Cell Culture (ATCC, 
Manassas, VA) and propagated in Eagle’s Minimum Essential Media (EMEM). Culture 
conditions of interest to the presented studies include 2D collagen type I-coated 
polystyrene dishes and collagen type-I hydrogels. Briefly, high concentration rat tail 
collagen type I (BDBiosciences) was diluted to a concentration of 50 g/mL in 0.02N 
acetic acid. 1 mL of diluted collagen solution was plated per 35mm polystyrene dish, 
incubated at room temperature for 1 hour and rinsed liberally with PBS. HT-1080 cells 
were cultured within rat tail collagen type I gels as previously described [421]. Briefly, 
collagen type I stock solution was diluted to the experimental collagen concentration by 
mixing equal volumes of collagen stock solution with neutralizing buffer (100mM Hepes 
in 2x PBS, pH 7.3) with PBS. 1 mL of the collagen solution was pipetted into a 35mm 
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plate (MatTek, Ashland, MA) then placed in at 37°C to allow for complete 
polymerization. After polymerization, 2ml of media was added on top of the gels. 
 
6.2.2 siRNA transfection 
Sequences of siRNA targeting the RNA sense strands are as follows: MT1-MMP, 
5’-UCCAGGGUCUCAAAUGGCAACAUAA-3’ targeting nts 571-599, and integrin 1, 
5’- GAUGGGAAACUUGGUGGCAUUGUUU-3’ targeting nts 1080-1104. The 
nucleotide sequences were scrambled to generate control sequences for MT1-MMP: 5’- 
GGCGGGUGAGGAAUAACCAAGUGAU-3’ and Integrin 1: 5’- 
GAUAAAGGUUCGGUGUUACGGGUUU-3’, respectively. As described by the 
manufacturer, HT-1080 cells were transfected with siRNA oligonucleotides (100-150nM) 
and Lipofectamine 2000 (Invitrogen). Transfected HT-1080 cells were maintained in 
DMEM with 10% FBS, and no antibiotics and maintained for 36 hours post-transfection.  
 
6.2.3 RT-PCR Analysis 
siRNA mediated knockdown of MT1-MMP and integrin β1 were verified by RT-
PCR. Briefly, total RNA was isolated and purified using TRIzol Reagent and PureLink 
RNA Mini Kit (Life Technologies) as directed by the manufacturer. RT-PCR was 
performed with 75ng of purified RNA, 100nM of specific primers using one step SYBR 
Green RNA-to-CT 1-Step Kit (Applied Biosystems) and ABI 7300 Real-Time PCR 
System (Applied Biosystems). 
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6.2.4 Immunoblotting 
Immunoblotting experiments were performed to evaluate protein expression of 
HT-1080 cells on 2D collagen-coated polystyrene dishes and collagen matrices. Lysates 
from the above experiments were harvested using 1x cell lysis buffer (10mM Tris-HCl 
(pH 8.0), 100mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 10% Glycine, 
0.1% SDS, 0.5% DOC) supplemented with phosphatase and protease inhibitors. For cells 
cultured in 3D collagen gels, cells were liberated and harvested using Collagenase I 
treatment. Briefly, 48 hours post plating, cells were released from collagen gels via 
incubation with collagenase type I (100U/mg/ml, Gibco) at 37°C for one hour.  Liberated 
cell suspensions were normalized by cell count and lysed in lysis buffer. Protein lysates 
were analyzed via western blot as previously described [443].  Antibodies used in this 
study were anti-FAK Y925, anti-paxillin Y188, anti-ERK1/2, anti-ERK T202/Y204, anti-
Met (Cell Signaling Technology), anti-FAK (BD Transduction Laboratories), anti-MMP-
14 (Abcam), anti-Integrin 1, anti-P13K (p110) or anti-GAPDH (Santa Cruz 
Biotechnology) antibodies followed by either anti-Rabbit-HRP or anti-Mouse-HRP 
secondary antibody (Santa Cruz Biotechnology).  
 
6.2.5 Zymography 
Cells were incubated in serum free media for 24 hours and conditioned media 
harvested from the apical surface of cells or gels. Samples were concentrated via 
ultracentrifugation using a 10 kDa cutoff filter and subsequently mixed with 4x 
zymography loading buffer (0.25M Tris-HCl (pH 6.8), 40% Glycerol (v/v), 8% (w/v) 
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SDS and 0.02% (w/v) bromophenol blue) and allowed to incubate at room temperature 
for 10 minutes. Samples were analyzed via zymographic technique described previously 
[444]. 
 
6.2.6 Immunofluorescence 
2D cell cultures were fixed and stained atop collagen coated coverslips similarly 
as described for 3D samples. After plating, 3D cells culture atop 1 mL gels, were fixed 
and stained as previously described [445]. Briefly, gels were fixed with 4% 
paraformaldehyde in PBS and blocked with 1% BSA/1xPBST for 30 minutes at 37°C. 
Primary antibody incubation followed using either mouse anti-Integrin 1 (SCBT) or 
rabbit anti-MMP-14 (Millipore) diluted in 1% BSA/1xPBST for 1 hour at room 
temperature before incubation in secondary antibody rabbit anti-Ms AlexaFluor 555 or 
goat anti-Rb AlexaFluor 488 (Molecular Probes) for 1 hour at room temperature. 
Samples were mounted on coverslips with ProLong Gold antifade medium with DAPI 
(Molecular Probes). Images were visualized using a Leica Confocal Microscope, 
collected and deconvoluted using ImageJ software. 
 
6.2.7 Cell Migration and Shape 
Tracking of individual cells was performed first by labeling cells with 
CellTracker Orange CMRA (Invitrogen) and then either seeding on 12 well collagen 
coated plates (5250 cells/cm
2
), or embedded within 3 mg/ml collagen matrices (200,000 
cells/ml). Cells were allowed to attach 6 hours post cell seeding and then tracked using a 
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Leica DMI6000B confocal microscope paired with a Nipkow spinning disk (Yokogawa) 
and imaged with an ImagEM EM-CCD Camera (Hamamatsu).  Images from each well 
were taken every 15 minutes for 16 hours.  For 3D samples, small 1 μm fiduciary beads 
were embedded within gels to account for z-axis drift during the acquisition time span.  
All image stacks were analyzed using Imaris version 7.2.3 (Bitplane) under the spot-
tracking algorithm.  Autoregressive cell tracks were constructed and custom MATLAB 
scripts were used to calculate cell speeds and displacements from raw position data.  
Persistence time was determined via curve fitting data of average mean square 
displacement versus time to the following equation: 
𝑀𝑆𝐷 =  2𝑆𝑃2[𝑡 − 𝑃(1 −  𝑒−𝑡/𝑃)]  Equation 6.1 
where 𝑆 is the average speed of tracks, 𝑃 is the persistence time, and 𝑡 is the time lag.  
Cell Sphericity was determined using z-stacks of confocal images to produce a 3D 
volumetric rendering of cells using Imaris.  Quantitative values were obtained using the 
equation: 
Ψ =  
𝜋
1
3(6𝑉𝑝)
2
3
𝐴𝑝
     Equation 6.2 
Where 𝑉𝑝 and 𝐴𝑝 are the volume and surface area of the cell respectively.   
 
6.2.8 Statistical Analysis 
Statistical analysis of data was performed with a student’s two-tailed t-test for 
three independent experiments.   
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6.3 Results 
 
6.3.1 MT1-MMP, not Integrin β1 contributes to FAK/ERK signaling in HT-1080 cells 
The impact of MT1-MMP and integrin β1 on ERK pathway activation was 
observed via treatment of HT-1080 cells with siRNA.   Protein knockdown was verified 
via quantitative PCR (Figure 6.1,6.2), immunostaining of cells (Figure 6.4), and western 
blot (Figure 6.3). Further evidence of efficient MT1-MMP knockdown was provided via 
zymography on culture media, which showed that siRNA against MT1-MMP was able to 
decrease activation of MMP-2 (Figure 6.3).   
Upon siRNA treatment, Integrin β1 knockdown did not affect p-ERK and p-FAK 
Y925 expression in HT-1080 cells, contrary to previous work in other cell lines 
describing an intimate signaling connection between integrin β1, FAK and ERK [446–
448]. In contrast to integrin β1 siRNA samples, knockdown of MT1-MMP caused loss of 
ERK activation as well as an increase in FAK activity in 2D samples (Figure 6.5).  
 
6.3.2 Integrin β1 and MT1-MMP influence HT-1080 cytoskeletal organization and 
Rho/ROCK mediated signaling in 3D 
The role of integrin β1 and MT1-MMP on actin organization was studied via 
phalloidin staining. Phalloidin staining of cells embedded in 3D collagen matrices 
showed that both knockdown of integrin β1 and MT1-MMP results in a loss of actin 
distributed amongst the core of the cell, giving rise to only punctate regions near the cell 
membrane (Figure 6.7B). While both knockdown conditions affected the abundance of 
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actin in the cell, only loss of MT1-MMP protein conferred a change in cell shape as 
measured by a sphericity index (Figure 6.7A).    
Actin filaments are highly regulated by the Rho pathway and specifically Rho 
kinase (ROCK), which is capable of maintaining quantities of actin in the cell as well as 
controlling contractility through phosphorylation of the myosin light chain.  ROCK also 
targets a myriad of other pathways and has also been shown to stimulate PTEN activity 
and influence ERK activation, two proteins highly involved in both migration and 
invasiveness [449–451].  To test whether MT1-MMP and integrin β1 knockdown 
contributed to changes in ROCK mediated signaling, samples in 3D (3 mg/ml matrices) 
were either transfected alone or transfected and subsequently treated with Y27632.  Both 
transfected samples experienced a change in p-ERK expression when treated with drug 
(Figure 6.6).  Those samples transfected against integrin β1 showed initially no loss of p-
ERK activation (compared with control cells, Figure 6.5A, 3D), but after treatment with 
the ROCK inhibitor in 3D lost p-ERK expression (Figure 6.6).  The opposite is true in 
samples transfected with MT1-MMP, where an initial loss of p-ERK is counteracted by 
Y27632 to rescue p-ERK expression.  Treatment with Y27632 on control cells does not 
cause p-ERK expression to be altered; only when either protein is knocked down does 
Y27632 effect ERK activation (Figure 6.6).  
 
6.3.3 Integrin β1 and MT1-MMP influence HT-1080 migration speed and persistence in 
collagen networks. 
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The physical manifestation of changes in the FAK/ERK/ROCK pathway and 
cytoskeletal arrangement by knockdown of integrin β1 and MT1-MMP was studied 
through migration speeds and persistence.  Cell tracking revealed knockdown of both 
integrin β1 and MT1-MMP caused a monotonic decrease in cell speed in relation with 
control samples as 3D collagen density was increased (Figure 6.8A).  MT1-MMP 
knockdown resulted in a greater loss in cell speed than integrin β1 knockdown in both 3 
mg/ml and 5 mg/ml formats, presumably due to the dual nature of MT1-MMP 
contributing both as a signal transduction modifier as well as reducing matrix remodeling 
capabilities.  At high matrix densities, the speed of integrin β1 knockdown samples 
converged to that of the control cells and in 5 mg/ml settings the two samples show no 
significant difference (Figure 6.8A).  This suggests that at high matrix densities integrin 
β1 is not as crucial as MT1-MMP in producing migration speeds.  Cell speeds resulting 
from treatment with marimastat mimicked the results seen from MT1-MMP knockdown 
samples suggesting that matrix remodeling is the main bottleneck behind cell migration 
in 3D.   
In contrast to 3D samples, protein knockdown did not decrease cell speed in 2D 
(Figure 6.8A).  The decrease in speed from marimastat treated cells could be due to the 
fact that marimastat blocks a wide variety of proteases other than MT1-MMP.    
Although speed is an extremely useful metric for analyzing migration, of equal 
importance is the persistence at which migration occurs.  Cells with a high degree of 
persistence are able to coordinate movement toward a specific target, which is an inherent 
characteristic of invasive cells [452].  Through curve fitting the mean square 
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displacement of cell tracks the data indicate that persistence does not exhibit the same 
pattern between 2D and 3D samples as cell speed.  For all culture conditions, the 
persistence was lost when either integrin β1 or MT1-MMP was knocked down (Figure 
6.8B).  Integrin β1 and MT1-MMP therefore mediate migration in 3D through both cell 
speed and persistence, while 2D movement is dominated by losses of persistence only. 
 
6.3.4 ROCK mediated contractility is required for migration speed, but not persistence 
in 3D networks 
To further investigate the contributions of MT1-MMP and integrin β1 on 
migration behavior in HT-1080 cells via cytoskeletal interactions, cells were embedded in 
3D matrices and tracked in the presence or absence of siRNA treatment and ROCK 
inhibition.  Comparing migration speeds from the original set of migration experiments 
(Figure 6.8A, 3 mg/ml) to those cultured with ROCK inhibitor Y27632, a uniform 
decrease in cell speed is observed across all samples (Figure 6.9A). In contrast to the 
results of migration speed, migration persistence was not uniformly affected by the 
treatment of Y27632.  Persistent migration continued to exist in both control samples, 
and those transfected only with siRNA against MT1-MMP (Figure 6.9B).   
 
6.3.5 Integrin β1 and ERK activation are required for migration persistence, but not 
speed in 3D networks 
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The contribution of ERK activation in migration and persistence was investigated 
using control and transfected samples treated with MEK inhibitor U0216.  MEK lies 
directly upstream of ERK and is responsible for phosphorylating ERK. 
Curiously, inhibition of ERK activation via U0126 treatment did not reduce the 
speed of cells migrating in 3D (Figure 6.9A).  Persistence was reduced in all samples, 
which was not the case for those cells treated with Y27632 (Figure 6.9B).  Grouping 
migration data from both Y27632 and U0216 shows that persistent migration is 
coordinated with ERK expression, with the added caveat that integrin β1 must be present.  
In the case of MT1-MMP transfected cells, ERK is downregulated and therefore 
persistence is lowered.  However, in the presence of Y27632, ERK activity is rescued and 
persistence follows (Figure 6.6).  These cells now possess integrin β1 as well as ERK, 
and the persistence is restored, although speed continues to suffer due to the loss of MT1-
MMP activity.  While ERK has been shown to induce higher rates of invasion and 
migration in cells [453], to our knowledge the effect of ERK preferentially modulating 
persistence in HT-1080 cells cultured in 3D networks has not yet been published.  
Integrin β1 does not seem to play a direct signaling role in this cell line, therefore further 
work is required to fully understand the mechanistic reasons for why expression of both 
integrin β1 and p-ERK is necessary for persistent migration. 
 
6.4 Discussion 
The lethal nature of cancer metastatsis puts emphasis on understanding in great 
detail how cancer cells migrate.  HT-1080 cells, due to their invasive nature have been 
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widely included in works to elucidate both mechanistic and behavioral aspects of 
migration.  However, the specific nature of how integrin β1 and MT1-MMP contribute to 
cancer cell speed and persistence in 3D matrices in HT-1080 cells is not yet completely 
understood.    To date, there have been many studies performed both on integrin β1 and 
MMPs in regards to motility [454,455] however, great proportions of migration 
experiments are either performed on 2D substrates, or ignore how cellular persistence 
plays into the overall translation of cell movement.  Reports of decreased invasiveness 
using migration apparatuses such as transwell assays are unable to decipher whether 
speed, persistence or both have been affected.  While this may be a sufficient result in 
many cases, the loss of persistence does not guarantee a loss of motility.  Our work has 
described further how both integrin β1 and MT1-MMP contribute to both persistence and 
speed in HT-1080 3D migration via cytoskeletal alterations and their involvement in 
ROCK mediated ERK signaling.    
  The connection between both integrin β1 and MT1-MMP to cytoskeletal 
processes suggests that they both may govern the migratory process via alterations in 
cytoskeletal based signaling [433,436–438].  In this chapter we show that both integrin 
β1 and MT1-MMP alter cytoskeletal organization in HT-1080 cells through spatial 
changes in actin fibers.  In addition to disrupting actin, both proteins in 3D also affect 
speed as well as persistence.  The data here show that knockdown of MT1-MMP and 
integrin β1 do not affect speed and persistence in the same way across culture conditions.  
In 2D speed is not altered with the omission of either protein, but persistence is 
completely ablated.  In contrast 3D cultures see a decrease in both speed and persistence, 
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with MT1-MMP producing a much larger decrease in speed especially in dense matrices. 
This further highlights the importance of conducting experiments both in more native 
environments while also studying all aspects of motility.  Loss of integrin β1 and MT1-
MMP activity has been shown to reduce migration previously; however our work 
additionally highlights the importance of understanding both persistence and speed, and 
performing migration assays in 3D to completely characterize motility.  
Using knockdown of integrin β1 and MT1-MMP as a basis for studying speed and 
persistence in ROCK contractility based migration, the data show that cytoskeletal 
contractions are necessary for cell speed, but not for persistence in HT-1080 cells.  
Despite the loss of contractile force, ROCK activity is not necessary for the cell to 
polarize, suggested by the high level of persistence that is maintained in those cells that 
contain both integrin β1 expression and ERK activation.  Careful analysis suggests that 
the requirement for persistent migration for HT-1080 cells in 3D networks is adequate 
integrin β1 expression and ERK activation.  To our knowledge, the expression of integrin 
β1 and p-ERK in 3D as requirements for persistent migration has not yet been reported in 
any cell line.   
Pathway analysis concluded that integrin β1 does not alter ERK signaling through 
FAK, a report that is incongruent with many studies on integrin β1 signaling in other cell 
lines.  Instead, MT1-MMP governs ERK and FAK activity in HT-1080 cells.  FAK is 
normally a precursor to ERK activation and phosphorylation at Y925 has been shown to 
induce ERK activation [456,457]. Here we note that our results agree with previous 
reports about integrin signaling in our cell line, which contains a Ras oncogene [458,459] 
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which HT-1080 cells possess.  It is possible that oncogenic Ras marginalizes the effect of 
integrin in protein signaling, an important aspect to consider when utilizing a cell line for 
migration studies or as a model for cancer.  MT1-MMP however, does contribute to ERK 
and FAK activated states as evidenced by the increase in p-FAK activity and decrease of 
p-ERK activity upon knockdown of MT1-MMP. Phosphorylation of FAK at Y925 by 
Src, a regulator of both migration and focal adhesion structure, contributes to focal 
adhesion turnover and is associated with the Rho pathway, which informs cytoskeletal 
activity. MT1-MMP has been shown to interact with Src mediated signaling and perhaps 
downregulation of MT1-MMP confers a loss in Y925 activity via modification of Src 
mediated signaling [460–462].  In this way MT1-MMP may alter oncogenic Ras 
signaling, which has been shown to decrease FAK phosphorylation, as far upstream as 
Src [160].   
The absence of FAK Y925 in 3D has been previously reported and seen again in 
our data.  This could be explained by a pervading theory that focal adhesions are not only 
smaller but offer different signaling than those in 2D [463,464].  It is possible that focal 
adhesion proteins such as FAK Y925 are much more transient, making them difficult to 
detect or that fundamental pathways relating matrix proteins such as MT1-MMP to ERK 
signaling are altered completely.  Another possibility is that this absence of FAK Y925 
contributes to, or is a product of the differential behavior displayed between cells in 2D 
and 3D with regards to cell persistence and speed. 
Despite the fact that only MT1-MMP shows an effect on the FAK/ERK pathway 
knockdown of both proteins changed their effect on pathway activity in response to the 
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ROCK inhibitor Y27632 in HT-1080 cells.  Only when either protein was knocked down 
was Y27632 shown to alter ERK activation.  No change was seen between control cells 
and their Y27632 counterpart.  This suggests interplay between both integrin β1 and 
MT1-MMP and ROCK mediated signaling.  While the extent of how ROCK, MT1-
MMP, and integrin β1 interact is specifically unknown, here we show that interaction 
between all three influence HT-1080 cytoskeletal organization and in turn migration.   
The change in ERK activation after administration of Y27632 in integrin β1 and 
MT1-MMP knockdown samples could potentially be explained by treating ROCK 
activity as a switch in the cell, determining whether the cell will adopt a mensenchymal 
integrin sensitive state or an amoeboid Ras dependent state.  ROCK inhibition has 
previously been proposed to act as a switch in HT-1080 cells, alternating the cell from an 
amoeboid state to mesenchymal migration, making the cell more dependent on integrin 
β1 expression and FAK activation [465,466].  It is possible that HT-1080 cells in 3D 
collagen natively prefer an amoeboid like state rather than the default mesnenchymal 
migratory mechanisms and following treatment with Y27632 adopt a more mesenchymal 
state.  By utilizing amoeboid machinery as a default mechanism, cells would therefore be 
generally indifferent to the signaling effects of integrin, which is what we have observed 
in this current cell line.    
Our work adds to the potential role of ROCK as a switch in HT-1080 cells that 
governs the state of the cell and the ERK pathway.  Under this hypothesis, ROCK 
inhibition would produce a switch from Ras dependent to integrin dependent migration, 
causing the cell to change from a Ras dominated signaling mechanism to an integrin 
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dominated mechanism. The potential change from integrin resistant to integrin sensitive 
signaling agrees with p-ERK expression data between control and ROCK inhibited 
sample sets.  Under normal conditions, knockdown of MT1-MMP and potential 
disruption of the Ras pathway results in p-ERK modulation while the cell is insensitive to 
integrin β1 knockdown.  After the supposed ROCK inhibition mediated swtich toward 
the mesenchymal integrin sensitive state, knockdown of integrin β1 and not MT1-MMP 
results in p-ERK modulation.   A schematic of the hypothetical action of ROCK 
inhibition on the relationship between integrin β1, MT1-MMP and ERK activation is 
displayed in figure 6.10.  
All of this would suggest that perhaps integrin β1 and MT1-MMP oppose one 
another with respect to ROCK activity, with MT1-MMP governing ERK activity in 
regimes of high ROCK activity, while integrin is the main regulator when ROCK activity 
is significantly reduced. The idea that integrin β1 and MT1-MMP oppose one another via 
cytoskeletal contractility is also supported by the upregulation of MMP-2 activation seen 
through 2D zymography and a slight increase in MT1-MMP protein expression when 
integrin β1 is knocked down (Figure 6.3).  It has been shown that loss of integrin activity 
can lead to decreased cytoskeletal contractility, which correlates with higher MT1-MMP 
expression [467,468]. Other work has also established that loss of contractility 
contributes to increases in both MT1-MMP and MMP-2 [469,470].  While this evidence 
that MT1-MMP and integrin β1 may act in an opposing fashion with respect to 
contractility and ROCK activity is compelling, further work must be done to fully 
understand how these two proteins contribute to cytoskeletal mediated signaling, and 
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whether they exhibit direct crosstalk.  The implications of this have the potential to be 
profound, since most works assume that migration proceeds through the default 
mesenchymal method.   
Our research concludes that both integrin β1 and MT1-MMP play vital roles in 
HT-1080 migration in both 2D and 3D settings and that cell migration behaviors stand to 
differentiate between the two common culture methods.  We also show that this 
migration behavior governed by integrin β1 and MT1-MMP is due in part to changes in 
the cytoskeletal network of cells and signal transduction of FAK and ERK in 3D.  
Through control of protein expression of MT1-MMP and integrin β1 we observe that 
persistent migration is dependent on both integrin β1 expression and ERK activation, 
while cell speed is mainly controlled by cytoskeletal contractility via ROCK.  Finally, we 
postulate that our work contributes to the hypothesis that ROCK acts as a switch in HT-
1080 cells, altering the mode of migration from a Ras dominant to an integrin dominant 
pathway.  Our findings add to the growing knowledge base regarding the mechanistic 
understanding of migration in 3D and in the HT-1080 cell line.  Future work on this 
subject shows potential to completely characterize the roles of both MT1-MMP and 
integrin β1, with aims to improve current in vitro cancer based assays. 
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6.6 Figures 
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Figure 6.1: siRNA mediated knockdown of integrin β1 and MT1-MMP.  Quantitative 
rtPCR performed on cells cultured on 2D collagen coated plates.  siRNA 
induced knockdown is able to silence >85% targeted mRNA  
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Figure 6.2: siRNA mediated knockdown of integrin β1 and MT1-MMP.  Quantitative 
rtPCR performed on cells cultured in 3D collagen matrices at 3 mg/ml.  
siRNA induced knockdown is able to silence >85% targeted mRNA.  
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Figure 6.3 Western blot analysis and zymography of MMP-2 activity under siRNA 
knockdown conditions.  siRNA against integrin-β1 and MT1-MMP are 
able to significantly knock down target compared to scrambled control.  
Samples treated with siRNA against MT1-MMP also show reduced MMP-
2 activity via zymographic analysis.  
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Figure 6.4: Immunostaining of cells either on 2D collagen coated plates or embedded 
in 3D collagen gels.  siRNA treatment is able to effectively reduce 
integrin-β1 or MT1-MMP expression.  Integrin β1 (red), MT1-MMP 
(green), DAPI nucleus. Scale bar = 10 μm 
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Figure 6.5: Integrin β1 and MT1-MMP contribute to Rho pathway signaling (A) 
Western blot analysis of cells transfected with siRNA against Integrin β1 
or MT1-MMP.  In 2D culture only, MT1-MMP causes alterations in p-
ERK and p-FAK signaling.  In 3D MT1-MMP is still able to alter p-ERK 
while showing undetectable levels of p-FAK.  (B) Densitometry analysis 
of ERK and FAK blots as visualized in ‘A’.  Y-axis indicates the ratio of 
phosphorylated to total protein for a given sample.  ‘*’ indicates statistical 
significance with respect to experimental group control as verified via 
students t-test (p < 0.05). 
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Figure 6.6 Western blot analysis of cells transfected with either siRNA against 
integrin-β1 or MT1-MMP, embedded in 3 mg/ml collagen matrices, and 
subsequently treated with 10 µM Y27632 for 1 hour.  Drug treatment is 
able to alter the response of cells to siRNA treatment in the form of p-
ERK expression compared to the non-drug treated cells.  
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Figure 6.7: (A) Cell shape in 3D as quantified from volumetric rendering of confocal 
images and measured by a sphericity index.  Only loss of MT1-MMP 
expression confers a change in cell shape, adopting a less rounded 
morphology.  (B) Phalloidin staining of cells transfected with either 
siRNA against integrin β1 or MT1-MMP.  Both transfected samples show 
bunching of actin to punctate regions on the cell membrane. ‘*’ indicates 
statistical significance with respect to experimental group control as 
verified via students t-test (p < 0.05). 
  
190 
  
191 
Figure 6.8: Migration and persistence of cells tracked via confocal microscopy.  (A) 
Cell speeds measured at varying collagen densities.  Cells are either 
untreated (control), transfected with siRNA against integrin-β1 or MT1-
MMP, or treated with Marimastat.  (B) Persistence of cell tracks from ‘A’.  
‘*’ indicates statistical significance with respect to experimental group 
control as verified via students t-test (p < 0.05).   
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Figure 6.9: (A) Cell speeds at 3 mg/ml collagen density for samples in 3 different 
cohorts: Control, treated with 10 µM Y27632, or treated with 10 µM 
U0216.  In each cohort samples can either be untransfected, or transfected 
against either integrin-β1 or MT1-MMP (B) Persistence of cell tracks 
from ‘A’.  ‘#’ indicates statistical significance with respect to 
correspondingly transfected (or not transfected) cell population in the non-
drug treated control cohort (i.e. non-transfected control paired with non-
transfected control + Y27632, integrin siRNA transfected paired with 
integrin siRNA transfected + Y27632, etc.) as verified via students t-test 
(p < 0.05).  ‘*’ indicates statistical significance with respect to 
experimental control within a cohort (i.e. 3mg/ml control paired with 
3mg/ml + Integrin siRNA, 3mg/ml + Y27632 paired with 3 mg/ml + 
Y27632 + Integrin siRNA) as verified via students t-test (p < 0.05).  
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Figure 6.10: Schematic describing potential roles of integrin β1 and MT1-MMP in 
migration signaling in which ROCK acts as a migratory switch.  In the 
unperturbed cell, Ras inhibits FAK phosphorylation through Src, which 
prevents inhibition of ERK phosphorylation by Rho GTPases.  siRNA 
against MT1-MMP, by disrupting Ras signaling upstream of FAK as 
indicated by the arrow, increases FAK signaling leading to a loss of ERK 
activity.  Integrin β1 knockdown does not produce changes in ERK 
signaling due to the availability of Ras to dominate and continue to inhibit 
FAK activation.  Decrease in ROCK activity via administration of Y27632 
(red arrow) changes the relationship between Rho GTPase activity and 
ERK (inhibitory to excitatory).  Cells under this inhibition still exhibit 
ERK activation due to stimulation of FAK from integrin β1 (which now 
dominates over Ras signaling).  Knockdown of MT1-MMP, by allowing 
FAK activation, now leads to ERK activation instead of suppression.  In 
contrast, siRNA against integrin β1 decreases FAK activity, causing ERK 
activation to decrease. 
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CHAPTER SEVEN: COMBINATIVE IN VITRO STUDIES AND 
COMPUTATIONAL MODEL TO PREDICT 3D CELL MIGRATION RESPONSE 
TO DRUG INSULT 
 
7.1 Introduction 
Cell migration plays a vital role in several key biological processes including 
development, wound healing, and disease progression [471].  The migration process has 
also been the target of drug development in treating inflammatory diseases and cancer 
[311].  It is therefore paramount to understand how certain drugs influence migration on 
the cellular and sub-cellular level.  Unfortunately, while migration has been studied 
extensively for several decades, there remains an incomplete picture of the process of 
drug action.  This is because migration is seldom predictable, often differing between cell 
types and microenvironmental conditions [472,473].  To meet these challenges, a 
multitude of in vitro, in vivo, and computational approaches have been designed to assay 
cellular response to changes in extracellular matrix (ECM) content, drug insult, or 
signaling pathway modulations.  However, to truly understand the process, and ultimately 
predict how drugs will influence this process, multifaceted platforms need to be created 
that are able to combine the various interdependent aspects that govern migration. 
The most commonly studied modulators of migration are protein signaling 
pathways.  However, migration is controlled not only by protein signaling, but the 
surrounding ECM as well.  Even a simple change from planar two-dimensional (2D) 
culture to three-dimensional (3D) matrices can substantially alter cell behavior [474,475].  
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The interplay between cell and ECM, especially in 3D matrices, is mediated by matrix 
metalloproteinases (MMPs) enzymes that are responsible for cleaving matrix fibers 
[254].  While the general function of MMPs suggests that their role is exclusively in 
proteolysis, they are also involved in several signaling cascades including the 
Extracellular signal-related kinase (ERK) pathway, especially MT1-MMP a 
transmembrane bound MMP [388].  The involvement of MT1-MMP in the ERK pathway 
has suggested that MMPs may contribute more to migration than simply cleaving matrix 
fibers, however, the role of this and other MMPs in migration is not fully understood.  
Intertwined between the ECM, the ERK pathway, and MT1-MMP are β1 integrins, the 
primary adhesive integrin to collagen [476].  These transmembrane proteins mediate a 
plethora of signaling responses including ERK activation, act as mechano-sensors to 
guide contractility, and co-localize with MT1-MMP at the leading edge of migrating cells 
[328,477].  The relationship between 3D culture, proteolytic processors such as MMPs, 
integrin mediated adhesions, and the signaling pathways they modulate, represents a clear 
example of the complexity of migration and the need for platforms to encompass all of 
these facets simultaneously.  The goal for such an approach is to understand and 
ultimately predict how cells behave in different environments or in the presence of 
certain drugs.  While meeting these challenges may be accomplished through in vitro 
studies, these assays can be very time consuming, expensive, and limited to current 
culturing techniques.  Fortunately, computational models represent a robust and efficient 
means to inform in vitro techniques. 
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 Migration models represent a wide array of computational techniques to describe 
specific processes such as cell protrusion, up to the movement of entire cell sheets.  
Currently, many models have focused on the physical process of migration, studying the 
actin network, cell protrusions, and adhesion characteristics [370–372].  Models have 
even begun to address the role of 3D culture, the cell-ECM network, and proteolysis in 
migration [478].  However, there is a lack of robust and scalable models that can connect 
proteolysis, protein signaling, integrin adhesions, and the 3D ECM network together to 
ultimately predict migration in response to drug insult.  In addition to this, many models 
are based on a phenomenological framework and are not directly relatable to any tangible 
in vitro system.  These deficiencies can lead to limited capacities of the models in 
capturing complex in vivo behavior [479,480].  Here we aim to formulate a model, 
symbiotically with in vitro experimental work, to serve as a multifaceted platform for 
predicting migration while incorporating all of MMPs, the ERK signaling pathway and 
3D matrix architecture. 
 Our approach provides a simple methodology to synergistically predict cell 
migration in 3D matrices in response to drug insult using both in vitro results and a 
computational model.  While previous models exist to predict responses to cancer 
therapeutics [481,482], there have been almost no attempts to study migration speed and 
persistence on the single cell level in response to drug insult.  The integrative approach 
described here is able to predict migration behavior in a variety of matrix densities and 
drug insults, with direct applicability to corresponding in vitro data.  Our results 
contribute further to the knowledge base of how matrix density, MMP activity, integrin 
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adhesions, and p-ERK expression all independently influence migration, specifically 
speed and persistence.  We also describe how this system is capable of providing insight 
into drug development by using the model to perform predictions of drug combinations to 
more effectively ablate speed and persistence in 3D.  Finally, we highlight how our 
model is capable of providing basic knowledge of the phenomenological mechanisms of 
migration.  This represents an integrative and customizable methodology that can directly 
compliment and inform future in vitro assays in drug development. 
   
7.2 Results 
 
7.2.1 Matrix density, proteolytic activity, p-ERK expression all interdependently drive 
migration in 3D collagen matrices 
In vitro experimental data was collected to serve as the basis for model 
assumptions.  3D experiments with cells cultured in collagen matrices demonstrated that 
increasing matrix concentration decreased both cell speed and persistence in 3D collagen.  
Migration speed and persistence was also decreased from the blocking of proteolytic 
activity via Marimastat and knockdown of MT1-MMP (Figure 7.1).  MT1-MMP 
knockdown was confirmed via western blot and RT-PCR analysis.  Zymograms on 
conditioned media treated with siRNA showed that knockdown of the protein also led to 
a decrease in MMP-2 activation (Figure 7.4).  Since MT1-MMP is a known activator of 
MMP-2, this provides further evidence toward efficient MT1-MMP knockdown.   
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Decreases in speed due to Marimastat or MT1-MMP knockdown were very 
similar.  However, Marimastat treatment, while depressing persistence to a lower value in 
the 1.75 and 3 mg/ml matrix densities, did not abolish persistence to the extent of MT1-
MMP knockdown (Figure 7.1B).  Unlike Marimastat, MT1-MMP siRNA was also 
responsible for knockdown of p-ERK activity (Figure 7.3A).   
p-ERK expression was also effected by the drugs U0126 and Y27632.  U0126 
decreased p-ERK expression (Figure 7.3C) and was able to ablate persistent movement in 
3mg/ml samples while leaving cell speed intact (Figure 7.2A,B).  This relationship was 
observed in control cells as well as those cells cultured with siRNA to MT1-MMP.  
Interestingly, the loss of persistent movement via treatment with siRNA to MT1-MMP 
was rescued upon treatment of Y27632 (Figure 7.2B).  This rise in persistence was 
accompanied by the re-emergence of p-ERK expression (Figure 7.3B).  In addition to 
rescuing persistent motion, Y27632 decreased cell speed at 3mg/ml, (Figure 7.2A).  
These results were later used to make assumptions and optimize the model. 
 
7.2.2 Optimized model faithfully followed trends observed in in vitro experiments 
The model was created and optimized based on assumptions established from the 
data as described in the methods.  It was then validated to ensure it was able to recreate 
these relationships.  The effects of several model inputs on p-ERK expression or the 
driving variables were tested.  Each model parameter was found to have successfully 
altered their intended variables in a linear fashion as outlined by the model assumptions 
(Figures 7.5-7.9).   
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Next, the different relationships between the input variables and output speed and 
persistence were examined.  The results showed that the model followed the general 
trends displayed by the data in figure 7.1 and figure 7.2.  Marimastat was able to decrease 
speed along with MT1-MMP knockdown.  While MT1-MMP knockdown was also able 
to significantly decrease persistence, Marimastat did not exhibit as strong of a response 
(Figure 7.10-7.11).  Changes in drug concentrations through the model also followed 
trends displayed by the data.  While an increase in the concentration of Y27632 led to a 
decreased cell speed, the effect of U0126 on speed was negligible (Figure 7.12A, Figure 
7.13A).  Increases in concentration for both drugs were able to control persistence.  
Y27632 was able to rescue persistence from MT1-MMP siRNA treated samples (Figure 
7.12B).  Finally, U0126 was able to ablate persistence with increasing concentration 
(Figure 7.13B).   
After all model relationships were expressed appropriately by the model, initial 
tests were performed to confirm its general action.  Both speed and persistence were 
probed as a function of lattice spacing and azimuthal angle.  Since neither of these terms 
is expressed in the terms of equation 7.3 for cell speed they should not perturb speed 
output from the model.  In contrast, the azimuthal angle as well as lattice spacing (which 
like azimuthal angle also contributes to the allowable range of lamellipodial contacts) 
should directly influence the directionality of movement.  As anticipated, both angle and 
lattice spacing have no effect on cell speed but influence the persistence (Figure 7.14).  
As the allowable angle is decreased cells follow a more directed path and persistence 
increases.  Similarly, as lattice spacing is increased cells are given fewer adhesion options 
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within the allowable azimuthal angle projection and therefore stochastic variability is 
lessened leading to a more direct and persistent motion.  Cell tracks are also able to 
visually depict the difference in control and MT1-MMP samples to show the model is 
performing and intended.  Control tracks exhibit much more persistent movement as 
displayed through the increased displacement after 3 hours (Figure 7.15).  The adherence 
of these principle relationships stemming from variable optimization allowed next for the 
testing of the model in its ability to recapitulate migration responses as well as test its 
predictive capacity. 
Optimization of variable relationships allowed the model to match the previous 
migration data in 3 matrix densities under conditions of siRNA and Marimastat 
treatment.  Both speed and persistence of the optimized model closely mimicked the 
experimental results with minimal error (Figure 7.1).  The model was also able to match 
the results from migration experiments for samples treated with drugs Y27632 and 
U0126 in 3 mg/ml for both control and siRNA treated samples.  (Figure 7.2). 
 
7.2.3 Model accurately predicted speed and persistence in response to drugs in 3D 
The model was then used to predict migration in other scenarios without changing 
any model parameter relationships.  Migration predicted by the model for control and 
siRNA treated cells in the presence of Y27632 or U0126 at a new matrix density of 1.75 
mg/ml was performed and validated via experimental procedures.  The same was done 
for the predictions made at 1.75 mg/ml and 3 mg/ml for cells treated with both 
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Marimastat and U0126.  The predicted speed and persistence matched our values 
recorded from cells migrating under those conditions in vitro (Figure 7.16,7.17).   
To ensure that predictions at the 1.75 mg/ml density were valid protein expression 
was also observed.  The protein expression patterns of p-ERK under the predicted 
conditions remained consistent with initial observations depicted in figure 7.3.  
Marimastat, MT1-MMP knockdown, Y27632 and U0126 all retained their effects on p-
ERK as observed at 3 mg/ml.  This confirmed that the relationships and assumptions 
based on signaling data were still applicable in the predicted scenarios and that no 
significant signaling changes would contribute to major alterations in behavior when 
progressing from 3 mg/ml to 1.75 mg/ml cell culture (Figure 7.18). 
 
7.2.4 Integrin-ECM adhesions do not solely govern migration of HT-1080 cells in 3D 
collagen 
  To model the behavior of cells under the influence of integrin inhibitor 4B4, the 
concentration of integrins and p-ERK content were reduced significantly as informed 
from previous works discussed in the methods.  As expected, predictions of speed and 
persistence from the model dropped well below control values for unperturbed cells at 3 
mg/ml.  The prediction of persistence due to 4B4 treatment matched well with 
experimental techniques (Figure 7.20B).  As predicted from a phenomenological 
standpoint, this corresponded with a decrease in p-ERK activity in the presence of 4B4 
(Figure 7.19C).  However, experimental data revealed that 4B4 treatment did not 
decrease cell speeds to the extent predicted in the model (Figure 7.20A).  In order to 
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further bolster the in vitro migration data obtained via 4B4 treatment, migration of cells 
was also tested after siRNA knockdown of β1 integrins (Figure 7.19A,B, Figure 7.20A).  
While the speed for integrin knockdown samples did not exactly match that of the 4B4 
group, the two experimental data sets both showed that blocking of integrins did not 
decrease speed as the model predicts.  Additionally, it was observed that integrin 
knockdown and blocking did not decrease speed to the lowest values seen during data 
collection.  The lowest values of speed belonged to those cells treated with both siRNA 
against MT1-MMP and Y27632 in which proteolysis and integrin mediated contractility 
were inhibited.  These data along with the predicted results from the model invite 
discussion as to the role of integrin-ligand interactions and motility.   
 
7.3 Discussion 
Understanding and predicting how drugs will influence migration is vital to the 
development of treatments against disease.  While in vitro studies are commonly used to 
screen for drug efficacy, these results can be greatly augmented using computational 
techniques.  Unfortunately, computational approaches to study and predict migration fail 
to incorporate simultaneously the roles of the prominent migration effectors proteolytic 
activity, 3D matrices, integrin adhesions, and protein signaling.  Our results bridge this 
gap in our understanding and present a methodology for the prediction of migration 
response to drugs using both in vitro and computational techniques.  Our model 
accomplishes this while also addressing the role of signaling proteins, the proteolytic 
drivers MMPs, integrin-ligand interactions, and the influence of matrix density. 
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Our approach resulted in the accurate prediction of migration response to drug 
from different matrix concentrations and alterations to protein signaling pathways.  
Sufficient data was collected to measure the accuracy of predictions via statistical 
analysis between in vitro and computational results; however, these tests were not 
performed.  This is because we are more concerned with the ability of the model to 
recreate trends seen between different in vitro samples than its capacity to output any 
particular numerical value within significance.  In addition, our observed results in our 
estimation did not merit the use of any given statistical test due to the fact that the 
differences seen between any two in vitro or model data sets, while displaying the 
potential to be technically statistically significant, were not practically significant in the 
context of migration speeds or persistences.  In such cases the lack of overlap shown 
between reported confidence intervals may be due to very large sample sizes.  The 
differences between in vitro and model data uncovered through these large data sets may 
be valuable toward evaluating the weaknesses of the model; however, they are not 
necessary in the assessment of the model to predict bulk level processes.   
The results from both arms of the study also provided additional knowledge into 
how matrix density, proteolytic activity, integrin adhesions and p-ERK influence speed 
and persistence.  Specifically, our experimental and computational results showed that p-
ERK expression is required for persistent migration in HT-1080 cells in 3D matrices, 
however, downregulation of this protein alone does not affect speed.  We also conclude 
that matrix density can alter both speed and persistence of cells, and drugs that alter the 
proteolytic processing of the matrix such as Marimastat can alter speed and persistence 
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without inhibiting p-ERK.  This suggests that while p-ERK is a direct modulator of 
persistence, cellular directionality is also inherently a function of matrix architecture.  
Not only is this result observable via in vitro experiments but recapitulated in our model 
in which adhesion lattice spacing had a direct effect on persistent migration.  Changes in 
proteolytic activity that disrupt matrix remodeling therefore harness potential to ablate 
persistence without influencing any signaling of p-ERK.  In this way, cell migration is 
tunable through both physical interactions with the matrix as well as signal processing.  It 
is this duality between cell-ECM interactions that cannot be ignored, and is addressed by 
our platform, when exploring how cells migrate.  
Results from our experimental and modeling data also suggest that matrix 
adhesions mediated via β1 integrins do not fully govern motility in 3D.  Our model was 
able to capture this result while predicting speed and persistence of cells in the presence 
of an integrin β1 inhibitor.  While our model was able to correctly describe the trend in 
cell speed during integrin inhibition, the predicted speed was much lower than our 
experimental data.  If migration was in fact solely dependent on integrin-collagen ligand 
based contractility, our experimental data would match what our model produced.  
However, our results indicate that extensive blocking, and knockdown of integrins 
reaching in excess of 90% depletion of the coding mRNA, are still incapable of fully 
depressing cell speed.  This conclusion must however be met with skepticism regarding 
the actual amount of integrin inhibition and knockdown that is present during the entirety 
of our collection of cell movements.  Indeed, it is very possible that integrin recycling 
could potentially decrease the load of 4B4 inhibition of integrins [483].  The transient 
207 
nature of integrin knockdown events also breeds caution when speculating the actual 
numbers of integrin-ligand interactions that are present at any given time.  It is entirely 
possible that our model can and will predict accurate speeds in response to integrin 
inhibition given the exact extent to which inhibition occurs in vitro. 
Nevertheless, our data confirms that lower migration speeds for these cells are 
possible when both contractile force mediated by integrins and proteolytic capacity are 
hindered together.  This suggests that in 3D both of these cellular processes play an 
additive role in motility.  Neither is fully responsible for motility.  Indeed, during periods 
of amoeboid migration, in which cells primarily utilize actin-myosin contractile forces in 
order to progress, cells are thought to rely less upon integrins and in extreme cases of 
amoeboid motion adopt a form of integrin-independent migration [262,484].  It is by 
these mechanisms that the cells observed in this study may continue to migrate despite 
integrin blocking and downregulation.  This suggests that other factors must be included 
outside the realm of a simple integrin driven contractile force mechanism (perhaps an 
integrin indepdent actin-myosin contractility upon loss of integrin expression) when 
attempting to fully characterize cellular motility.  
Our conclusions on this subject are validated through other work observing cells 
migrating in 3D networks in the presence of integrin inhibitors.  Wolf et. al. has shown 
that while speeds of cells decrease in 3D upon integrin inhibition, further losses in speed 
can also be seen when MMP activity is also abrogated [406].  Furthermore, Zaman and 
colleagues has reported that integrin inhibition potentiates a preference for softer matrices 
in order to achieve maximal migration speed, suggesting that proteolysis becomes ever 
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more important in the absence of optimally acting integrins in 3D [399].  Stemming from 
this observation we conclude that our model, while performing more accurately using 
parameters previously optimized is still capable of producing phenomenologically 
relevant migration trends without prior knowledge of a drug’s effect on the current 
system.  In this regard we are able to use the information collected from our model to 
make inferences about how cells migrate in 3D.  
From a computational perspective we showed that cell migration can faithfully be 
recapitulated using a force based system as we describe while treating both speed and 
persistence as independent entities.  In the formulation of the model, there exists no direct 
relationship between the two and our simulations support this notion.  Whether cellular 
pathways also treat these two important entities as fully independent of one another is 
highly unlikely given the interdependent nature of biological signaling processes.  
However their relative detachment may prove to be a significant characteristic that 
requires further research and remains an important observation rendered possible by the 
model.  
The independence of speed and persistence may arise in our model as a result of 
portraying the matrix as a set of discrete adhesion points rather than a heterogeneous 
assortment of fibers and therefore modeling the influence of the matrix on migration as 
primarily a result of ECM viscosity.  Modeling the matrix as a set of identical adhesion 
points ensures that during each motile event the forces upon the cell due to attachment to 
the matrix are only felt at the site of lamellipodial extension.  In reality, cells adhere at 
multiple locations resulting in several force vectors acting upon the cell body.  Within a 
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network of individual fibers expressing multiple adhesion opportunities, cellular speed 
and directionality would both be influenced by the necessity to detach various unique rear 
adhesions during each migration event.  Each adhesion experienced by the cell may also 
express differential force generation due to the heterogeneity of fiber stiffness felt by the 
cell leading to further modulation of both speed and persistence.  In this way the 
abundance and local stiffness heterogeneity of matrix fibers would govern speed as well 
as persistence.  Inclusion of a matrix with fibers of heterogeneous stiffness and adhesion 
opportunities in our model (presumably represented similarly to elastic springs with 
spring constants dependent on local matrix stiffness) would therefore most likely not 
result in a complete decoupling of speed and persistence.  This setup would also allow for 
specific migration behaviors such as durotaxis and would account for the natural variance 
in migration speeds, a characteristic that was introduced in the model artificially.  
Perhaps more importantly our predicted results, validated via time lapse 
migration, show that while U0126 is only able to ablate cell persistence, the combination 
with Marimastat can produce a state in which both speed and persistence are decreased 
significantly.  Targeted ERK inhibition remains an active chemotherapeutic strategy 
[485].  Our model shows that the particular inhibitor U0126 does not affect migration 
speed, but the combination with MMP inhibitor Marimastat can help augment this 
treatment.  This type of prediction represents the potential this model can bring to drug 
discovery. 
Limitations of the model may stem from variations within cell lines, and other 
culture conditions.  While the model was made to predict drug response at varying matrix 
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densities, more complex matrices with an unclear compositional structure (e.g.  Matrigel) 
may show deviation from the model.  Nonetheless, this model provides a novel approach 
to characterize and predict migration behavior in a non-generalized manner.  An 
additional limitation of the model stems from the structural framework regarding the 
relationship between the contractile migration force and matrix rigidity.  Previous 
research has established that cells utilize integrins to act as mechano-sensors and as such 
are able to match contractile force upon matrix fibers with the inherent stiffness of the 
ECM [467].  The relationship between cell contractile force and ECM stiffness has also 
been shown to be logarithmic in nature, with traction forces reaching an asymptotic 
maximum upon very stiff substrates [486].  This behavior of cells has been incorporated 
into several models of migration and particular for cells in 3D matrices [382,486,487].  
The underlying characteristics that a variable contractile force imparts are that of a 
bidirectional relationship between substrate stiffness and motility.  At low substrate 
stiffness, the contractile force is insufficient to propel cell migration.  As the stiffness of 
the ECM increases, cells are then able to utilize myosin-actin machinery to increase 
speeds and contractile force.  However, in the regime of high substrate stiffness 
contractile force no longer increases with the stiffness and migration speeds decrease.  
The hypothesis for this behavior is that stagnant contractile forces can no longer compete 
with the opposing forces of an increasing viscous force in higher density gel 
environments, and the inability to release rear adhesions due to large focal adhesion size 
and strength.   
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Models that include this relationship between contractility and matrix stiffness are 
able to capture the biphasic nature of motility in regard to substrate rigidity.  Several 
models that include contractility of cells as an ECM dependent quantity have shown that 
intermediate substrates offer the optimal environment for motility [382,399,486–488].  In 
contrast, our model simplifies the relationship between contractility and matrix 
environment by allowing it to remain a static quantity and consider viscosity and lattice 
spacing as the main influences of the ECM on cell migration.  The result of such 
assumptions is the loss of the biphasic response to ECM stiffness, with softer substrates 
always offering less resistance and therefore a greater cell speed.  However, this 
simplification allows our model to more easily develop a relationship between the drug 
Y27632 and contractility by allowing it to remain a constant force in the model.  
Moreover, the current form of the model does not necessitate biphasic behaviors as 
suggested by the data.  Indeed, for our purposes simplifying the role of ECM in migration 
to lattice spacing and viscosity was sufficient to recreate the behaviors and trends 
displayed in the data suggesting that in this instance varying contractility with matrix 
rigidity was not necessary to fulfill our goal.  Future iterations of this or other models 
using our framework could, however, include this behavior during optimization and be 
better equipped to scan a greater range of matrix stiffness.  Such an example of the ability 
for one to include a variable contractile force to achieve the biphasic migration response 
to matrix stiffness is seen in Figure 7.21. 
In an effort to simplify our approach, further assumptions were made outside of 
those addressed and justified in the methods section.  These mainly revolve around the 
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structure of the model space including the surrounding matrix and the cell itself.  For our 
purposes the matrix was defined as a homogenous lattice of discretized adhesion points.  
In reality the matrix is composed of a network of cross-linked and bundled fibers.  Other 
models have incorporated these intricacies in 3D networks and therefore achieve 
migration directions dependent on the orientation and remodeling of these fibers instead 
of stochastic migration events [489–491].  Cellular based assumptions include static 
uniform adhesion distributions, constant cell shape, and a lack of viscoelasticity 
expressed from the cell body.  Models that include the dynamic nature of adhesions are 
able to describe cell polarization, directionality, and the biphasic response of migration to 
adhesion-ligand concentrations [382,488].  Meanwhile other models have incorporated 
the non-uniform shape and mechanical properties of the cell to allow for mechano-
sensing during migration to recreate haptotaxic tendencies [486,487,491].  While such 
specific cellular and matrix components are absent in our model, our data shows that the 
simplifications taken do not impact the ability for recapitulation of behavioral tendencies 
or the accuracy of migration prediction.  In fact, the interdisciplinary approach described 
here highlights how migration predictions are possible without incorporation of detailed 
mechanisms when relevant in vitro data is used to optimize the system.  However, this 
also does not prevent any future iterations of this approach to consider and integrate such 
detailed cellular and matrix components to increase the relevancy to any specific 
application.   
Recent work continues to reveal an increasingly interconnected relationship 
between cells and the extracellular matrix [294,492], it is therefore important to develop 
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tools to probe cell behavior in a high throughput manner.  Current computational 
approaches perform admirably however; they often neglect multiple facets of the 
migration process.  Models that are constructed from phenomenological systems may 
also have little applicability and predictability in real in vitro settings.  The overarching 
benefit of this platform stems from its ability to incorporate cell signaling, changes in the 
ECM, integrin adhesions, and proteolytic activity governed by MMPs to predict 
migration response to drug in 3D.  This structure allows for prediction in a wide variety 
of drug concentrations, siRNA treatments, and matrix concentrations, that work 
synergistically with and are directly applicable to an in vitro data set. 
As our knowledge of migration becomes increasingly complex, our platforms to 
study it must also adapt and evolve.  The framework described here represents a step 
toward systems to study migration as set of connected, interdependent processes.  To our 
knowledge, a model to allow for prediction of migration in 3D matrices using signaling 
data together with attention to MMPs, integrin adhesions and proteolysis has not yet been 
undertaken.  Future iterations of this model may be adopted to predict migration response 
to drugs to probe for patterns worthy of further in vitro analyses. 
 
7.4 Conclusions 
 We have presented an integrated technological method combining both in vitro 
and computational approaches in a simple manner to predict migration response to drug 
in 3D matrices.  Our platform is able for the first time to incorporate 3D culture along 
with the action of proteases as well as signaling pathway function.  The results show that 
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matrix density and proteolytic blocking are capable of influencing migration speed and 
persistence.  We also have pinpointed p-ERK as an exclusive modulator of migration 
persistence, unable to affect the speed of HT-1080 cells in 3D.  By integrating both in 
vitro and computational approaches, the formulated model was then able to provide 
further knowledge to the action of anti-migratory drugs by predicting the ablation of both 
speed and persistence through the combination of Marimastat and U0126.  In this case 
our prediction was able to inform us of the added benefit of adding Mariamstat to U0126 
treated cells to induce a drop in speed, which U0126 alone is incapable of inhibiting.  The 
ability of the model to predict at several matrix densities also showed that this affect was 
achievable in both 1.75 and 3 mg/ml matrices.  Finally, our model was able to test 
phenomenological trends produced via integrin inhibition.  Our results indicated that 
integrin mediated contractility was not solely responsible for migration speed in 3D.  
When applied appropriately this integrative, innovative method has potential to greatly 
increase throughput for studying migration response to changing matrix and drug 
conditions.   
 
7.5 Methods 
 
7.5.1 Cell culture, and preparation of 3D matrices and reagents 
HT-1080 cells were obtained from American Type Cell Culture (ATCC) and 
propagated in Eagle’s Minimum Essential Media (EMEM).  For culture in 3D collagen 
gels, cells were cultured within matrices formed from rat tail collagen type I as 
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previously described [421].  Briefly, collagen gels were formulated via a mixture of 
collagen derived from rat tail and maintained in acetic acid (BD Biosciences), 
neutralizing buffer (100mM Hepes in 2x PBS, pH 7.3) and complete media containing 
cells.  Collagen was added to gel mixtures in an appropriate volume as to achieve desired 
concentrations and an equal volume of neutralizing solution was added to offset the 
acidity of the collagen and maintain pH balance.  The remaining volume needed to reach 
desired collagen concentrations within gels was supplied via complete media and a 
corresponding cell population to achieve 200,000 cells/mL.  The solution was then cast in 
well plates and incubated at 37°C to allow for polymerization for 1 hour.  After gelation, 
an equal volume of media was added to the apical surface of gels. 
Proteolytic activity was inhibited using the broad based MMP inhibitor 
Marimastat (10µM).  Expression of p-ERK and its effect on migration was probed using 
the MEK inhibitor U0126 (10µM) and p160ROCK inhibitor Y27632 (10µM).  Integrin 
β1 inhibition was accomplished using the 4B4 anti-CD29 antibody clone (10 µg/mL). 
 
7.5.2 siRNA transfection 
 Sequences of siRNA targeting the RNA sense strands are as follows: MT1-MMP, 
5’-UCCAGGGUCUCAAAUGGCAACAUAA-3’ targeting nts 571-599, and integrin 1, 
5’- GAUGGGAAACUUGGUGGCAUUGUUU-3’ targeting nts 1080-1104. The 
nucleotide sequences were scrambled to generate control sequences for MT1-MMP: 5’- 
GGCGGGUGAGGAAUAACCAAGUGAU-3’ and Integrin 1: 5’- 
GAUAAAGGUUCGGUGUUACGGGUUU-3’, respectively.  Cells were transfected 
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using Lipofectamine 2000 after having been embedded in gels overnight according to 
manufacturer protocol. 
 
7.5.3 Quantification of cell migration 
Cells were tracked using the cytoplasmic dye CellTracker Orange CMRA and 
embedding the stained cell population within collagen matrices as previously described.  
Cells were allowed to attach for 6 hours before imaging.  In order to test migration in the 
presence of drugs media on the apical surface of gels was changed an hour prior to 
imaging to contain either Marimastat (10µM), MEK inhibitor U0126 (10µM), or 
p160ROCK inhibitor Y27632 (10µM).  Cells were then tracked using a Leica DMI6000B 
confocal microscope and imaged with an ImagEM EM-CCD Camera (Hamamatsu).  
Images from each well were taken every 15 minutes for 16 hours.  All image stacks were 
analyzed using Imaris version 7.2.3 (Bitplane).  Cell speeds and displacements from raw 
position data were obtained from recorded cell tracks using MATLAB.  Speed was 
calculated as the mean displacement over time between each time step.  Persistence time 
was determined via curve fitting data of average mean square displacement versus time to 
the following equation: 
𝑀𝑆𝐷 = 2𝑆2𝑃(𝑡 − 𝑃 [1 − 𝑒(
−𝑡
𝑃
)])  Equation 7.1 
Where 𝑀𝑆𝐷 is the average mean square displacement of all cell tracks, 𝑆 is the average 
speed of tracks, 𝑃 is the persistence time, and 𝑡 is the time lag [365]. 
 
7.5.4 Immunoblotting  
217 
In order to assess changes in protein expression, cells were analyzed via western 
blot as previously described [421].  All samples treated with siRNA were cultured within 
transfection media containing lipofectamine and siRNA mixture for 24 hours before 
changing media.  At this juncture media was changed to either complete media or 
complete media containing one of Marimastat (10µM), U0126 (10µM) or Y27632 
(10µM) and allowed to incubate for 24 more hours before lysis and sample collection.  
Samples not treated with siRNA were cultured for 24 hours post seeding using complete 
media without transfection materials.  Media was then changed identically to those 
samples treated with siRNA and allowed to incubate for another 24 hours before lysis. 
Immunoblotting of samples treated with 4B4 integrin inhibitor were processed 
separately.  These cells required pretreatment with 4B4 antibody prior to being embedded 
into collagen gels.  Therefore, these cells were either transfected or not transfected on 
collagen coated flasks for 24 hours.  They were then trypsinized and suspended in control 
media or media containing 10 µg/mL 4B4 antibody for 45 min before being embedded 
within collagen matrices.  Cells were then harvested at the appropriate time interval 
identically to all other samples. 
 
7.5.5 RT-PCR Analysis 
siRNA mediated knockdown of MT1-MMP and integrin β1 was verified by RT-
PCR.  Briefly, total RNA was isolated and purified using TRIzol Reagent and PureLink 
RNA Mini Kit (Life Technologies).  RT-PCR was performed using one step SYBR 
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Green RNA-to-CT 1-Step Kit (Applied Biosystems) and ABI 7300 Real-Time PCR 
System (Applied Biosystems). 
 
7.5.6 Zymography 
Cells were incubated in serum free media for 24 hours and conditioned media 
harvested from the apical surface of cells or gels.  Samples were concentrated via 
ultracentrifugation using a 10 kDa cutoff filter and subsequently mixed with 4x 
zymography loading buffer before being analyzed via zymographic technique described 
previously [444]. 
 
7.5.7 Model Formulation 
Cell migration speeds and persistences were simulated using a force based model 
based on the work of Zaman et.  al.  2006 [399], and implemented using MATLAB 
v7.10.0 (MathWorks).  Spheres with radius R  approximated single cells, and their 
centroid placed within a 3D lattice of discrete equidistant points.  Distance of lamellipod 
extension was generated using an exponential random variable with the mean set in the 
range of previously established values [493–495].  Direction of the extension was a semi-
random process in which direction was chosen in the y and z axis at random.  The x 
direction was a bounded random variable, controlled by input parameters affecting the 
azimuthal angle at which the protrusion vector can deviate from the x-axis (𝜃).  After a 
lamellipodial vector was determined, it attached to the nearest lattice point in the matrix 
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within the allowable angle 𝜃.  If no point existed, the lamellipod did not attach and the 
cell did not migrate during that time iteration.   
Cell motility was calculated using a set of force equations incorporating the force 
of the contraction by the cell, 𝐹𝐶 and the viscous force applied on the cell by the matrix, 
𝐹𝑣.  Summing the forces acting on the cell and assuming the shape of a cell to be a sphere 
in a low Reynolds number setting at constant velocity gave the equation:  
∑ 𝐹 =
𝐴[𝐿]𝑠𝑎[𝐼]𝐶
𝐾𝑑
− 6𝜋𝜂𝑅𝑣 = 0 
Equation 7.2
 
where 𝐴 is avogadro’s number, [𝐿] is the concentration of matrix ligand at the site of the 
focal adhesion, 𝑠𝑎 is the surface area of the focal adhesion, [𝐼] is the concentration of 
integrins at the site of the focal adhesion, 𝐶 is the contractile force imparted on the matrix 
by a single integrin-actin connection, 𝐾𝑑 is the integrin-collagen dissociation constant, 𝜂 
is the viscosity of the matrix, 𝑅 is the radius of the cell and 𝑣 is the instantaneous 
velocity.  The first term in the equation is representative of the contractile force 𝐹𝐶, while 
the second term is the viscous force, 𝐹𝑣.  Solving the equation for 𝑣 allowed for the 
determination of the instantaneous velocity for the migration step. 
𝑣 =
𝐴[𝐿]𝑠𝑎[𝐼]𝐶
𝐾𝑑6𝜋𝜂𝑅
     Equation 7.3 
Values for the constants in the equation that remain unaltered, [𝐿] , [𝐼], 𝑠𝑎, 𝐾𝑑, and 𝑅 , 
were estimated from previous publications [262,496–500].  The value of 𝜂 for each 
matrix density was also estimated via previous work [501].  Velocity was the result of a 
stochastic Gaussian process where 𝑣 was the mean and 0.4𝑣 was the standard deviation 
220 
to match the variance seen in experiments.  The cell was then displaced in the direction of 
the lamellipod at a distance equal to the velocity times the change in time.   
At each time step, which corresponded to 15 minutes to match with our 
experimental techniques, cell positions were tracked.  Instantaneous speed was calculated 
by taking the vector magnitude and dividing it by the time interval.  An average speed 
was then determined for each cell track and repeated for 1000 cell tracks to obtain the 
total average speed.  For determining persistence, first the mean square displacement 
from position data was calculated via the equation: 
𝑀𝑆𝐷(𝑡) =
∑ 𝑟𝑖
2(𝑡−𝜏)𝑖
𝑁
   Equation 7.4 
where  𝑟2 = 𝑥2 + 𝑦2 + 𝑧2, 𝑡 is the time, 𝜏 is the time lag and 𝑁 is the total number of 
displacement vectors for that time interval.  Tracks were simulated for the equivalent of 3 
hours (16 time points) and the total number of tracks for any given time point 𝑁 was 
1000.  The persistence was then calculated via fitting to equation 7.1.  This method for 
measuring persistence was repeated 10 times and the average from 10 curve fitting 
algorithms was taken. 
 
7.5.8 Model Optimization and Predictions 
The model was constructed to describe and reproduce the acquired data in which 
the only input variables would be matrix density, MT1-MMP concentration, and 
concentration of drugs Marimastat, U0126 and Y27632.  To allow these variables to 
influence the speed and persistence of the model, they were related to the variables in the 
model that drive speed and persistence, termed the driving variables.  The driving 
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variables of the model were the angle 𝜃, matrix viscosity 𝜂, contractile force 𝐶, and 
lattice spacing.  By establishing relationships between the input variables and the driving 
variables, the input variables were then able to control the output speed and persistence.  
To relate the input variables to the driving variables of the model, linear relationships 
were constructed between the two sets based on assumptions from the data and other 
works.   
 
7.5.8.1 Model assumptions based on interpretation of experimental data 
From our data we recorded observations and that informed our model.  These 
interpretations, while preliminarily backed by data, are not absolute claims but rather 
informal relationships we will use to manufacture the model.  These assumptions are 
summed in Table 7.1.   
The data showed that increasing matrix concentration decreased cell speed and 
persistence.  The properties of the matrix that influence speed and persistence most likely 
stem from matrix fiber density, which has the potential to influence both the apparent 
viscosity as well as the pore size [444,501].  This hypothesis is supported by the drop in 
speed and persistence seen when proteases were inhibited via Marimastat which reduces 
proteolytic matrix remodeling and can affect matrix pore size and fiber density [444].  
Therefore we assume that increasing matrix density decreases speed by increasing the 
viscosity of the matrix and decreases persistence by decreasing lattice spacing.   
Results for cells cultured with Marimastat showed that it decreased speed and 
persistence of cells.  From our previous assumption that matrix density can affect speed 
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and persistence through its viscosity and fiber density, we hypothesize that Marimastat 
influences speed and persistence in a similar way, by controlling fiber density and 
viscosity by blocking proteolytic activity and disrupting matrix remodeling.  In a way, 
adding Marimastat translates to moving from a lower to higher density matrix.  From this, 
the assumption is made that Marimastat decreases speed and persistence by increasing the 
viscosity of the matrix and decreasing the lattice spacing, similar to the action of moving 
from a sparse to dense matrix.   
The knockdown of MT1-MMP via siRNA showed a similar, but different result 
than treatment with Marimastat.  siRNA decreased MMP-2 activity (Figure 7.4B), 
reducing total proteolysis similar to Marimastat.  However while speed values for cells 
cultured with Marimastat and siRNA MT1-MMP were similar, the persistence values 
were much lower for those cells with MT1-MMP knockdown.  Cells treated with siRNA 
against MT1-MMP also showed reduced p-ERK expression.  In order to fully understand 
out how MT1-MMP knockdown effects migration, the changes in p-ERK expression and 
proteolytic blocking due to siRNA against MT1-MMP need to be examined separately.  
The drugs U0126 and Y27632 shed insight into the relationship between MT1-MMP 
knockdown, p-ERK expression, and proteolysis in speed and migration. 
 In siRNA treated cells, Y27632 rescued p-ERK expression and persistence to the 
level of control cells.  From this data we observe that MT1-MMP knockdown cells 
cannot decrease cell persistence without decreasing p-ERK.  They can however continue 
to decrease speed.  Cells cultured with siRNA MT1-MMP and treated with Y27632 still 
decreased speed compared to control cells treated with Y27632 alone.  These data 
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contribute to the assumption that p-ERK correlates with persistence.  When p-ERK is 
knocked down, persistence falls, however in samples when this protein is preserved, the 
migration is persistent.  This is further supported by the decrease in persistence seen 
when treated with U0126 a potent MEK inhibitor which prevents p-ERK expression.  
Changes in p-ERK do not, however, lead to changes in speed.  These trends are observed 
in control and siRNA treated samples.  From this we assume that MT1-MMP knockdown 
cells reduce persistence by reducing p-ERK expression.   
How then does MT1-MMP knockdown lead to changes in cell speed? Changes in 
proteolytic processing and matrix remodeling are the likely culprit.  This is supported by 
the fact that MT1-MMP knockdown cells that express p-ERK due to Y27632 treatment 
still have lower cell speed compared to control cells treated with Y27632.  Since this 
decrease in speed cannot be due to any changes in p-ERK expression, we therefore make 
the assumption that siRNA against MT1-MMP decreases speed by increasing the 
viscosity of the matrix.  We also assume that while Marimastat is able to affect lattice 
spacing by blocking proteolysis, MT1-MMP knockdown cannot match this effect 
because MT1-MMP is bound to the membrane, and does not block as many MMPs as 
Mariamstat.  For the basis of our model only we therefore conclude that siRNA 
knockdown of MT1-MMP does not affect lattice spacing. 
Our final model assumption is that Y27632 decreases cell speed by decreasing 
cell contractility.  The main function of this drug is the selective inhibition of p160ROCK 
which mediates cell polarity, actin organization, and stress fiber formation.  Addition of 
this drug decreased speed at 3 mg/ml and in other works has been described to directly 
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ablate contractile force [502].  With these assumptions, we were able to create the 
framework for the model. 
 
7.5.8.2 Establishing relationships between input and driving variables 
Establishing the relationships between input and driving variables was done by 
finding the values of the driving variables such that the model output fit the experimental 
data for each condition (matrix concentration, drug concentration, etc).  First, a set of 
values for the driving variables were established such that the model data fit experimental 
data for control cells in 3mg/ml gels.  The condition was then varied (i.e. matrix 
concentration changed, drug added etc.) and the appropriate driving variable or variables 
were scanned until a value(s) was found that minimized the error between the model 
output and the data.  Which driving variable was scanned as the conditions were altered 
was based on the assumptions of the model.  Using the optimized values for the driving 
variables in each scenario together with the known values for the input variables (known 
from experiments), linear relationships between the input variables and the driving 
variables they influence were constructed (Figures 7.5-7.9).  An example is described 
below.  Optimization revealed that matrix density was not linearly related to lattice 
spacing and 𝜂, therefore a second order polynomial was used to approximate the 
relationships.  Since some inputs influence the driving forces indirectly through p-ERK 
expression, the linear relationship between p-ERK and the driving variable of the angle 𝜃 
was first constructed for all conditions.  Linear relationships were then appropriately 
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defined between the input values and p-ERK to achieve the desired control of the driving 
variables and outputs. 
Example of linear optimization between input and driving variables 
1) Set of driving variables to reproduce model output at 3 mg/ml established 
2) Condition changed: Marimastat introduced at 10µM 
3) From assumption 1 in Table 7.1, Marimastat is related to both lattice spacing and 
η. 
4) From equation 7.3 in methods, η influences speed.  From model simulations 
described in Figure 7.14B, lattice spacing influences persistence.   
5) Both η and lattice spacing are scanned until the speed and persistence from the 
model matches that from experimental data. 
6) The original values for η and lattice spacing correspond to 0uM Marimastat.  The 
new values for η and lattice spacing correspond to 10uM Marimastat.   
7) Linear relationship is constructed between Marimastat and lattice spacing and 
Marimastat and η.  This is seen in Figure 7.5A,B. 
 
 
7.5.8.3 Model Predictions 
After optimizing the linear relationships between input and driving variables, 
prediction was then performed for cells in the presence of Y27632 or U0126 
administration at a matrix density of 1.75 mg/ml.  A second prediction was also made at 
both 3 mg/ml and 1.75 mg/ml matrices in which the drugs Marimastat and U0126 were 
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used in combination.  A final prediction was then performed to test the predictive 
capacity of the model to a foreign drug not introduced to the model during the 
optimization period.  This study was performed to show that the model is also able to 
make inferences about the phenomenological aspect of migration after sufficient 
optimization with in vitro data sets.   
In this prediction, the model was manipulated to address the effect of decreasing 
concentration of available integrin on the cell surface due to the integrin β1 blocking 
antibody 4B4.  Due to the fact that β1 integrins comprise the majority of integrin subunit 
combinations that adhere to collagen, we assumed that this antibody effectively blocks all 
integrins associated with migration that are present in the model.  Previous research has 
indicated that concentrations of this antibody at 10 µg/mL correspond to approximately 
95% blocking of β1 integrins [399].  In our model we therefore decreased the 
concentration of integrin to 5% of its initial value upon treatment with 4B4.  Integrin β1, 
the primary subunit for collagen binding, has also been implicated in the ERK pathway 
with integrin-collagen binding leading to increases in p-ERK activity [503].  We 
therefore, upon insult with the antibody 4B4 decrease our value of p-ERK to 5% of its 
original value.  After these changes, our model was made to predict the outcome of speed 
and persistence in the presence of 4B4 treatment.  This simulation was performed at 3 
mg/ml collagen density.  Subsequent experiments were then performed as outlined 
previously to validate all model predictions.  Migration data was collected to compare to 
the predicted results from the model.  In addition, protein expression data in each of the 
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prediction cases was obtained to ensure that the signaling patters used to develop the 
model still held under the predicted conditions. 
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7.7 Figures 
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Figure 7.1: Cell speed and persistence as observed from experiments and model 
simulations.  Experimental data shows a decrease in cell speed and 
persistence as matrix density increases.  Further losses in cell speed are 
evident during MT1-MMP knockdown and treatment with MMP blocker 
Marimastat (A).  While depressing speed similarly, MT1-MMP 
knockdown was also able to decrease persistence with greater significance 
than Marimastat (B).  Model optimization allowed for the recreation of 
trends seen from experiments at different matrix concentrations for speed 
and persistence.  Error bars represent standard deviation. 
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Figure 7.2: Cell speed and persistence as observed from experiments and model 
simulations.  Treatment with Y27632 showed a concatenate decrease in 
speed in both control and MT1-MMP knockdown samples.  This is in 
direct contrast to the effect of U0126, which had no effect on cell speed 
(A).  Both drugs also contributed differently to persistence in 3 mg/ml.  
Y27632 was able to rescue persistence from MT1-MMP knockdown 
samples while leaving control samples unaffected.  Meanwhile, drug 
treatment with U0126 ubiquitously decreased persistence in both control 
and MT1-MMP samples (B). Optimization of the model was able to 
capture the changes in speed and persistence when cells are treated with 
either U0126 or Y27632 at 3 mg/ml.  Error bars represent standard 
deviation. 
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Figure 7.3: Western blot analysis of p-ERK expression at 3 mg/ml.  Western blot 
results combined with migration data suggested that p-ERK expression is 
directly correlated to persistence in 3D.  While both MT1-MMP and 
Marimastat were shown to influence the speed and persistence of cells at 3 
mg/ml, only knockdown of MT1-MMP depressed p-ERK expression (A).  
When treated with Y27632, samples treated with siRNA recovered their p-
ERK expression (B), which correlated with a recovery in persistence as 
well.  U0126 was able to ablate p-ERK expression similarly to MT1-MMP 
knockdown (C), causing decreases in persistence as shown earlier. 
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Figure 7.4: Quantification of siRNA mediated MT1-MMP knockdown using RT-
PCR, western blotting, and gelatin zymography.  Target siRNA was able 
to induce >85% knockdown in MT1-MMP RNA as normalized to 18s 
rRNA (A).  MT1-MMP expression was significantly reduced compared to 
control samples and those cultured with a scramble siRNA.  In addition, 
knockdown of MT1-MMP led to a decrease in the active form of MMP-2 
during zymographic analysis (B). 
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Figure 7.5: Relationships between Marimastat concentration and matrix lattice 
spacing and viscosity formulated through parameter optimization to 
experimental data.  An increase in Marimastat concentration resulted in an 
increase in matrix viscosity (A), and a decrease in matrix lattice spacing 
(B).  Error bars represent standard deviation. 
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Figure 7.6: Relationships between MT1-MMP concentration and percent p-ERK 
expression and matrix viscosity formulated through parameter 
optimization to experimental data.  An increase in MT1-MMP 
concentration (decrease in siRNA against MT1-MMP) resulted in a 
decrease in viscosity (A) and an increase in p-ERK expression (B).  Error 
bars represent standard deviation. 
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Figure 7.7: Relationships between Y27632 concentration and contractile force and 
percent p-ERK expression formulated through parameter optimization to 
experimental data.  Y27632 was able to rescue p-ERK expression in 
samples with low MT1-MMP expression.  It does not have an effect for 
those samples in which p-ERK is natively expressed and MT1-MMP 
concentration is not altered via siRNA (A).  Increasing amounts of the 
drug Y27632 resulted in a decrease in contractility (B).  Error bars 
represent standard deviation. 
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Figure 7.8: Relationship between U0126 concentrations and percent p-ERK 
expression formulated through parameter optimization to experimental 
data.  An increase in U0126 resulted in a decrease in p-ERK expression, as 
seen in the data.  Error bars represent standard deviation. 
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Figure 7.9: Relationships between contractile force and cell speed and persistence 
time formulated through parameter optimization to experimental data.  
Increasing amounts of the drug Y27632 resulted in a decrease in 
contractility (Figure 7.7B), which lead to a decrease in speed (A), as 
modeled theoretically in equation 7.3 and outputted here.  According to 
the phenomenological framework of the model, contractility should have 
no bearing on persistence time, which is reproduced from the model as 
well (B).  Error bars represent standard deviation. 
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Figure 7.10: Relationships between MT1-MMP concentrations and the output speed 
and persistence from model simulations.  MT1-MMP concentration 
showed a positive correlation with both speed (A) and persistence (B), 
matching the trends seen in vitro.  Error bars represent standard deviation. 
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Figure 7.11: Relationships between Marimastat concentration and the output speed and 
persistence from model simulations.  An increasing Marimastat 
concentration led to a minor decrease in persistence (B) and a much more 
dramatic decrease in speed (A); matching the trends seen in vitro.  Error 
bars represent standard deviation. 
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Figure 7.12: Relationships between Y27632 concentration and the output speed and 
persistence from model simulations.  Increasing Y27632 concentration 
was able decrease cell speed (A).  Y27632 was also able to rescue 
persistence in samples treated with siRNA (B); matching the trends seen 
in vitro.  Error bars represent standard deviation. 
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Figure 7.13: Relationships between U0126 concentration and the output speed and 
persistence from model simulations.  Increasing U0126 concentration was 
unable decrease cell speed (A), but did lead to decreases in persistence 
(B); matching the trends observed in vitro.  Error bars represent standard 
deviation. 
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Figure 7.14: Speed and persistence output to assess the performance of the model after 
optimization.  Model persistence was intended to be governed by the 
azimuthal angle and lattice spacing, while speed should be indifferent to 
these variables (Speed is controlled by the terms in equation 7.3).  Model 
output confirmed that speed was largely unaffected by either spacing or 
the azimuthal angle (A) while persistence dependent on the degree of the 
angle, and lattice spacing (B).   
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Figure 7.15: Position output to assess the performance of the model after optimization.  
Cell tracks representing a control cell (A) and one treated with siRNA 
against MT1-MMP (B) produced expected results with the control cells 
following a much more persistent path and with larger displacement. 
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Figure 7.16: Speed and persistence predictions from the optimized model, validated via 
experimental techniques.  Predictions were made for the administration of 
drugs Y27632 and U0126 at the untested matrix density of 1.75 mg/ml for 
speed (A) and persistence (B).  Data from subsequent in vitro experiments 
validate the accuracy of these predictions.  Error bars represent standard 
deviation. 
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Figure 7.17: Speed and persistence predictions from the optimized model, validated via 
experimental techniques. Prediction at both 1.75 mg/ml and 3 mg/ml was 
performed for the combination of drugs Marimastat and U0126.  The 
model results of speed (A) and persistence (B) match extremely well to 
experiments.  Error bars represent the standard deviation. 
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Figure 7.18: Western blot analysis of p-ERK expression at 1.75 mg/ml.  Expression of 
p-ERK was tested to confirm that the relationships between p-ERK and its 
effectors were maintained at the lower matrix density of 1.75 mg/ml.  
Marimastat and MT1-MMP (A), Y27632 (B), and U0126 (C), offered the 
same relationships with p-ERK as previously described, outlined in the 
model, and seen at 3 mg/ml in Figure 7.2.  The combination of Marimastat 
and U0126 did not change the relationship with either drug to p-ERK 
expression.  Marimastat was still unable to affect p-ERK, while U0126 
decreased its expression.  When combined, U0126 was able to depress p-
ERK (D). 
  
264 
  
265 
Figure 7.19: Changes in protein expression in the presence of integrin β1 inhibitor 4B4.  
Knockdown of integrin β1 via siRNA is confirmed to reduce mRNA 
content >90% (A) and results in substantial loss of protein expression at 3 
mg/ml (B) as compared to scramble sequence.  As predicted from 
phenomenological models of integrin signaling, treatment with 4B4 at 10 
µg/mL was able to decrease p-ERK expression in cells within 3 mg/ml 
collagen gels (C). 
  
266 
  
267 
Figure 7.20: Comparison of experimental and model speed and persistence in the 
absence of integrin-β1 mediated collagen adhesion.  Decreasing the 
concentration of integrins in the model almost completely abrogated 
speed, however this was not seen experimentally in 4B4 treated and 
integrin β1 knockdown samples which maintained significant cell speeds 
(A).  The persistence time predicted by the model, which is hypothesized 
to be reliant upon p-ERK expression, matched well with experimental data 
(B).  Error bars represent standard deviation. 
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Figure 7.21: Biphasic response of cellular speed as a result of matrix stiffness.  As 
other models have reported, contractile force may be treated as a variable 
entity due to the mechano-sensing ability of integrins.  When this behavior 
incorporated into migration models, a biphasic migration response to 
matrix stiffness is observed.  In order to prove that our model is capable of 
this addition and increase its relevancy in future studies, we have designed 
the contractile force to vary with the matrix concentration using the 
sigmoidal function: 𝐶 =
1
(1+𝑒−𝑚𝑎𝑡𝑟𝑖𝑥)
, where 𝐶 is the contractile force and 
𝑚𝑎𝑡𝑟𝑖𝑥 represents the concentration of the collagen gel.  This function 
allows for the contractility to increase with increasing matrix density until 
reaching an asymptotic limit as commonly described.  When applying this 
relationship to the model we observe the characteristic biphasic response 
of migration speed with respect to matrix concentration and inherently 
matrix stiffness.  By augmenting the model with a varying contractile 
force one may be able to probe different cell and matrix types where the 
biphasic effect is much more prevalent.   
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7.8 Tables 
Variable Assumption References 
Matrix Density Inversely proportional to 
lattice spacing and directly 
proportional to 𝜂 
[444,501] 
p-ERK Expression Proportional to the angle 𝜃, 
or in other words 
persistence 
Figure 7.2B, Figure 7.3C 
MT1-MMP Expression Proportional to p-ERK 
expression and inversely 
proportional to 𝜂 
[387,388,399,504,505] 
Marimastat Concentration Inversely proportional to 
lattice spacing and directly 
proportional to 𝜂 
[433,444] 
Y27632 Concentration Directly proportional to 𝐶 [506–508] 
U0126 Concentration Inversely proportional to p-
ERK expression 
[509] 
 
Table 7.1: Summary of assumptions based on experimental data used to formulate 
the basic underlying relationships of the model. 
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CHAPTER EIGHT: CONCLUSIONS AND FUTURE WORK 
 
 Despite decades of research, in 2012 cancer represented the leading cause of 
disease worldwide and in the United States alone more than 1.5 million new cases are 
estimated to be diagnosed in 2014, accompanied by over 500,000 deaths [1,510].  While 
the risk of mortality continues to decline for most cancer types, the non-uniform nature of 
the disease continues to demand more sophisticated treatments to account for resistance 
to chemotherapy and radiation treatment [511].  Newer therapeutic strategies are also 
needed to decrease the debilitating side effects of many treatments in an effort to improve 
the quality of life of those diagnosed with a terminal disease.  This dissertation has 
described several measures founded in basic research that serve to augment the current 
knowledge base, as well as pave the way for new avenues of research to better inform the 
development of future cancer treatments.  By probing intimate relationships between 
MMPs, the ECM, and the underlying signaling networks that govern cellular behavior, 
this work lends insight into the various mechanisms by which this family of proteases 
enact specific cellular processes related to migration, cell survival, and response drug 
induced inhibitions. 
 
8.1 Crosstalk between MMPs and the ECM 
While treatments for cancer primarily focus on methods to disrupt or slow the 
development and metastasis of tumor cells, cancer development also heavily relies on the 
surrounding microenvironment.  Inflammatory chemokines may recruit several cell types 
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such as macrophages and lymphocytes to the surrounding ECM of fledgling tumor cells 
[71,127].  These cells may either aid in transforming somatic cells into a malignant 
phenotype, or become recruited by the existing tumor mass to produce an abundance of 
growth factors or supply nutriment [27,73].  Such changes to the tumor 
microenvironment may be in part influenced by alterations in the mechanical and 
structural properties of the ECM imparted by MMPs [403].  Disregulation of MMPs may 
cause changes in matrix stiffness, cell signaling and enhance migration, all hallmarks of 
cancerous lesions in tissue [255,437,455].  In turn, several characteristics of the ECM 
such as fiber stiffness and ligand density have been shown to govern MMP production 
[266,328]. 
   
8.1.1 Scientific Contributions 
 In this dissertation we have quantitatively described a concrete link suggesting a 
bidirectional relationship between the ECM and MMPs.  Quantitative analysis of ECM 
structure via CRM and image analysis has shown that not only do different cell types 
remodel their local ECM in unique ways, but that MMPs are necessary for this action to 
occur.  Significant changes in both the pore size and fiber density imply that MMP 
restructuring has great potential to alter the mechanical properties of the ECM as well.  
Conversely, by stiffening matrices with tTG crosslinker the data here shows that the 
interaction between the ECM and MMPs is not a one way street.  Changes in crosslinking 
were able to alter the expression and activity of several MMPs, a function that was 
dependent on adhesion via integrin β1.  Not only was MMP activity and expression 
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dependent on crosslinking, but the relationship was bidirectional in nature, implying that 
a delicate balance is maintained between the structural components of the ECM and the 
MMPs that maintain it. 
 
8.1.2 Future Investigations 
 The results presented here serve as a jumping off point for several potential future 
studies.  While CRM was effectively able to allow for quantification of collagen 
restructuring, developing a method to also visualize fibers parallel to the incident light 
will enable users to fully define changes in the matrix.  The assays and methods presented 
here could also be extended to include matrices of differing protein composition as well 
as testing for heterogeneity and alignment of fibers, which lied outside the scope of this 
current study.  Probing a wider set of matrix types and densities would expand the 
knowledge base to include how different cell types react in a variety of settings.  Such 
analyses of matrix characteristics could also be coupled with a variety of molecular 
studies, including not just MMPs but other proteins, pathways, and signaling effectors 
that could potentially be responsible for specific alterations in matrix fibers or pore sizes.  
Finally, further investigations may take place to uncover in more detail the mechanism by 
which changes in matrix architecture, such as crosslinking, influences the production of 
matrix remodeling proteins in order to fully understand how the cell-ECM crosstalk 
develops at a cellular level or in the case of cancer and other ECM related diseases. 
 
8.2 Role of MMPs in HER2 positive breast cancer 
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 With approximately 25% of all breast cancers over expressing the growth factor 
HER2, a high degree of importance has been placed on understanding this specific sub-
type of breast cancer, resulting in several current therapeutic options [409,423].  The 
monoclonal antibody Trastuzumab, developed to block the dimerization of the HER2 
receptor and thus stunt the cell cycle in HER2 positive cancers, has developed into one of 
the single most important drug discoveries for breast cancer.  Unfortunately, the 
effectiveness of Trastuzumab has been constantly met with either acquired or nascent 
resistance [203].  Some research has debated that resistance to Trastuzumab is a result of 
HER2 downregulation and internalization or site specific steric blocking through CD44 
and its ligand hyaluronan [412,413,423].  Co-expression of HER2 and CD44 while rare 
among common immortal cell lines, has been shown to develop in response to 
radiotherapy and represents a highly invasive cell type potentially harnessing the 
chemoresistive properties of CSCs [415,416,419].   A portion of this dissertation has been 
dedicated to helping uncover the mystery behind the action of HER2 signaling, the main 
target of Trastuzumab, in the highly invasive HER2
+
/CD44
+
 cell type.  Specifically, this 
dissertation sought to determine how MMPs may play a role in the HER2 pathway of 
HER2
+
/CD44
+
 cells. 
 
8.2.1 Scientific Contributions 
 The data presented here has unveiled several important characteristics of the 
HER2
+
/CD44
+
 cell type.  Initial observations from experiments with proteolytic blocking 
and treatment with Trastuzumab revealed that pathway signaling in HER2
+
/CD44
+
 cells 
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differs greatly compared to HER2
-
/CD44
+
  and HER2
+
/CD44
-
  cell types, suggesting that 
the co-expression of both proteins results in a unique relationship between MMPs, HER2 
and both the PI3K and the ERK pathway.  Perhaps more interestingly, the data provided 
here shows that changes in the PI3K and ERK pathway as a result of Marimastat and 
Trastuzumab treatment are dependent on expression of the cell surface bound MMP, 
MT1-MMP.  Knockdown of MT1-MMP was able to abrogate any increase in pathway 
activity from proteolytic or HER2 blocking, suggesting that it may serve as an agent for 
any potential compensation mechanisms undertaken by cells to avoid cell death.  MT1-
MMP knockdown also decreased expression of both HER2 and CD44, suggesting that 
there may be expressional interplay between HER2, CD44, and MT1-MMP leading to a 
dependency of upon one another. 
 
8.2.2 Future Investigations 
 The results presented on this subject provide great potential to further understand 
not only the HER2
+
/CD44
+ 
subtype, but HER2 signaling as a whole.  Future work may 
consider the mechanism by which HER2 and CD44 expression is tied to that of MT1-
MMP, and how each protein may play a role in the PI3K and ERK pathways.  A clearer 
picture may be achieved by probing even more cell subtypes that vary in their expression 
of MT1-MMP and other MMPs as well.  A similar effect could also be accomplished by 
performing a systematic genetic profiling of many cancer types in response to 
Trastuzumab and/or Marimastat to ascertain potential expression level patterns that 
correlate with survival.  Further into the future, a firm understanding of such questions 
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could inform future drug development projects, or better equip clinicians in formulating 
more efficacious treatment schedules. 
 
8.3 MMP mediated proteolysis and integrin β1 expression in migration 
 Due to the fact that metastatic lesions, not the primary tumor, account for the 
majority of cancer related deaths; cell migration has, and continues to be an important 
area of research [343,344].  However, until recently most studies on migration were 
performed on 2D culture plates, which lack important molecular cues and ultimately lead 
to differences in cell signaling, focal adhesion formation and behavior when compared to 
culture in 3D matrices [333,475].  As a result, 3D culture has become a growing trend in 
in vitro studies.  Unfortunately, a dearth of knowledge exists regarding the extent by 
which 2D and 3D culture differs in the way of protein signaling and cell migration.  Of 
particular importance is the action of both integrins and MMPs; specifically β1 integrins, 
the primary adhesion receptors for collagen, and MT1-MMP an MMP that has been 
shown to associate with β1 integrins on the cell surface as well as participate in collagen 
degradation and the activation of other MMPs [328,455].  In this dissertation the role of 
both such proteins in the ERK pathway, FAK pathway and migration has been described, 
and provides a detailed observation into how integrin β1 and MT1-MMP influence both 
uniquely in HT-1080 cells. 
 
8.3.1 Scientific Contributions 
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 Careful analysis of data revealed several interesting observations regarding the 
role of MT1-MMP and β1 integrins in migration and signaling in both 2D and 3D culture 
conditions.  Through knockdown of both proteins via siRNA treatment, it was observed 
that cell migration in 2D is less sensitive to loss of either protein than in 3D.  In addition, 
signaling patterns were altered in 3D, with those cells showing less activity in the FAK 
pathway.  Equally important was the distinction made between the role of integrin β1 and 
MT1-MMP in signaling and migration in 3D.  The data showed that persistent migration 
necessitates both intact integrin β1 expression and activation of the ERK pathway while 
cell speed depends more readily on MMP activity and ROCK mediated contractility.  A 
final stated hypothesis was that inhibition of ROCK may switch the migratory mode of 
the cell from a Ras dominant to integrin dominant state, shifting the importance of 
integrin β1 expression in migration upon drug treatment.  
 
8.3.2 Future Investigations 
 This portion of the dissertation contributes much potential for future work in 
studying MT1-MMP and integrin β1 and their relationship with cell migration 
particularly in cell types such as HT-1080 where integrin mediated signaling may be 
subservient to other growth factor pathways.  The exact mechanism as to how MT1-
MMP expression influences both FAK and ERK signaling is an interesting topic of future 
study, given that it shows no potential for traditional signal transduction in its 
cytoplasmic domain.  How a loss of an MMP such as MT1-MMP can so heavily affect 
oncogenic signaling should be probed further to parse out a potentially vital connection 
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between this protein and Ras signaling.  In addition, the role of ERK as an exclusive 
modulator of persistence and ROCK as an exclusive modulator of speed needs to be 
studied further.  The potential for cell speed and persistence act truly independently of 
one another is intriguing and provides potential for future exhibitions is controlling 
aberrant cell migration.  
 
8.4 Modeling cell migration to predict response to drug 
 The development of drugs to counter diseases related to cell migration has 
resulted in a multi-billion dollar endeavor.  Unfortunately, few drugs have emerged from 
this effort highlighting the need for new methods to enhance assays to study, analyze and 
control cell migration [311].  In response to this complex process, computational models 
have emerged as potent tools to describe migration providing a high throughput and low 
cost method.  However, most models are unable to predict migration response to drug 
with direct application to in vitro experiments.  In addition to this, no model to date has 
attempted to describe migration in response to drugs while incorporating simultaneously 
protein signaling, proteolytic activity, and 3D culture.  This dissertation describes an 
integrated computational approach, in conjunction with in vitro observations, to serve as 
a platform to accurately predict migration in 3D matrices incorporating the function of 
matrix metalloproteinases (MMPs) and their interaction with the Extracellular signal-
related kinase (ERK) signaling pathway. 
 
8.4.1 Scientific Contributions 
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 Described in this dissertation is a methodology to combine cell migration trends 
obtained from in vitro experiments with a computationally derived force based model of 
cell motility to accurately predict migration response to drugs in previously untested 
scenarios.  The model system uniquely is able to incorporate the effect of a changing 
matrix density, ERK pathway signaling, MT1-MMP expression, and the effect of the 
drugs Marimastat, U0126, Y27632, and the monoclonal antibody 4B4 integrin blocker.  
Due to the fact that the model was built using relevant in vitro data, the results are 
directly applicable to the system in question, rather than relying on phenomenological 
trends that may not hold true for any one cell line or matrix type.  Using this method, one 
may predict the effect of any given drug in a previously untested matrix density, or assay 
the effect of drug combinations.  In the latter case, the model was able to predict a drug 
combination in which both cell speed and persistence was more effectively reduced.  This 
prediction was subsequently validated experimentally, highlighting the potential of this 
model toward determining more effective drug treatments on the cellular level.  In 
addition to providing results directly applicable to the system upon which it was founded, 
the model, like other more traditionally constructed approaches, is also able to perform 
predictions on previously untested relationships based on its phenomenological 
framework.  In this dissertation the model was made to predict the response to integrin 
blocking and faithfully recreated the trend toward decreasing speed and persistence, 
despite this observation never being input into the initial model framework.  Finally, 
through this prediction it was postulated that cell migration does not rely solely on 
integrin mediated adhesions. This highlights the capability of the model to not only 
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provide extremely accurate predictions relevant to the current in vitro system upon which 
it was built, but also provide information on phenomenological mechanisms of migration. 
 
8.4.2 Future Investigations  
 The methodology described in this portion of the dissertation holds significant 
potential in cell based research.  Future models may be similarly constructed to aid in the 
interpretation of other cell lines or culture conditions.  Information garnered from these 
models may include migration predictions in matrix densities or stiffness that are 
unattainable using in vitro culture methods.  The flexibility of the model also invites 
future users to incorporate new signaling pathways, drugs, and phenomenological 
relationships such as integrin mediated mechanosensing, adhesion turnover, or cell 
membrane viscoelasticity.  Newer more complex versions of this approach would 
represent a more robust system with predictions that are applicable to a more diverse set 
of conditions.  Perhaps the most obvious future direction of this methodology is to 
examine drug interactions with a known influence on a given signaling pathway to 
determine how this would translate to changes in migration in 3D. 
 
8.5 Closing Remarks 
 In this dissertation, a thorough investigation of MMPs and their role in cancer cell 
signaling, migration, and interplay with the ECM has been performed.  As cancer 
treatments continue to evolve toward cell-type and disease specific regimens, 
understanding the action of MMPs in these important mechanisms is paramount.  Future 
281 
studies building upon this work and others promises to advance the knowledge base of 
how cancer cells operate on a molecular and cellular level.    
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Automation Engineer Intern Jun. 2009 – Aug. 2009 
 Integrated picoliter scale low volume liquid handler technology 
 Developed custom software protocols for assay development 
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Rutgers University New Brunswick, NJ 
Aresty Research Fellow 2007 – 2009 
 Probed the role of Ephrin-A5 in the retinal development of chick embryos 
 Studied neuronal outgrowth in response to genetic expression modification 
 Constructed custom image processing algorithm to quantify axon growth 
 
New Jersey Commission on Cancer Research (NJCCR) Fellow Jun. 2007 – Aug. 2007 
 Assessed protein expression of CD44 in different mouse breast cancer cell lines 
 Performed general laboratory duties to increase efficiency of other lab member 
activities 
 
Research Assistant 2006 – 2007 
 Established qualitatively the mechanical properties of murine dura mater 
 Analyzed large data sets using SPSS software 
 Created custom Microsoft Excel macro programs to increase efficiency of data 
analysis 
 
 
TECHNICAL EXPERIENCE 
Cell Culture: Bacterial, Mammalian breast/prostate/lung cancer, 3D single cell, 3D 
spheroid 
Molecular Biology: DNA/Protein gel electrophoresis, Western blot, 
Immunoprecipitation, Immunocytochemistry, DNA/RNA lipofection, DNA 
electroporation transfection, Plasmid engineering, DNA ligation/digestion/gel extraction, 
Bacterial/Mammalian cell molecular cloning, RT-PCR/PCR, FACS, ELISA 
Animal Models: Embryonic chick, Rat, Tissue extraction from retina, spinal cord, brain 
dura. Tissue sectioning/staining, Slide preparation 
Microscopy: Inverted light microscopy, Confocal, Polarized light, Phase contrast, 
Differential interference contrast, Fluorescence 
Computer Skills: MATLAB, Microsoft Excel, ImageJ, Imaris, 
 
 
TEACHING AND OUTREACH 
Boston University Boston, MA 
Teaching Assistant, Fluid Mechanics Sep. 2011 – Dec. 2011; Jan. 2012 – May 2012 
 Conducted recitation sessions to support reinforcement of subject material 
 Graded and proctored exams 
 Instructed students on difficult concepts during office hours 
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Honors College Assistant Instructor Jan. 2012 – Mar. 2012 
 Developed, managed, and oversaw experiments for students from various 
academic backgrounds to foster an understanding of the scientific method 
 Instructed on concepts of biomedical science such as cellular culture and 
microscopy 
 Provided guidance for students interested in pursuing careers in science 
 
RISE (Research Internship in Science and Engineering) Mentor Jun. 2011 – Aug. 2011 
 Designed model projects and experiments to encourage lifetime learning  
 Introduced and instructed concepts of academic research and project formulation 
 Trained students to perform cell culture, ELISA, and western blot experiments 
 
 
HONORS AND AWARDS 
 Trainee, NIH Quantitative Biology and Physiology Grant  Sep. 2010  
 Recipient, BU Biomedical Engineering Fellowship Sep. 2009 
 Recipient, New Jersey Commission on Cancer Research Fellowship  Jun. 2008 
 2x Recipient, Aresty Research  Grant Oct. 2008, Oct. 2009 
 Secretary, Alpha Eta Mu Beta BME Honors Society Apr. 2008 – May 2009 
 Member, Tau Beta Pi BME Honors Society Mar. 2007 - Present 
 1st Place, Undergraduate Research Presentation Competition Apr. 2007 
 Member, Rutgers BME Honors Academy Sep. 2007 – May 2009 
 Member, National Society of Collegiate Scholars May 2005 - Present 
 Engineering Honors Program Member, Rutgers University Sep. 2005 
 Recipient, Rutgers University Scholarship Sep. 2005 
 Dean’s List (All semesters) 2005 – 2009 
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